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Zusammenfassung 
Das nichtkleinzellige Lungenkarzinom (‚non-small cell lung cancer‗, NSCLC) ist die 
tödlichste Form des Lungenkrebses mit schlechter Prognose aufgrund hoher 
Metastasierungsneigung. Metastasierung ist eine der häufigsten Todesursachen bei 
Krebspatienten. Trotz ihrer klinischen Bedeutung sind die zellulären und 
molekularen Mechanismen der Entstehung, Etablierung und Progression von 
Metastasen weiterhin unklar. Darüberhinaus basiert das bisherige Wissen über den 
Metastasierungsprozess überwiegend auf Zellen, die entweder in vitro kultiviert oder 
manipuliert und danach in immundefiziente Mäuse rückübertragen wurden.In der 
vorliegenden Studie wurde ein Mausmodell mit erblichem Fluoreszenzmarker 
(DsRed) zur spontanen Metastasierung bei NSCLC entwickelt, der durch den CAG-
Promotor (‚combination of cytomegalovirus early enhancing element and chicken 
beta actin‗) in alveolären Typ II-Zellen (SpC-rtTA/TetO-Cre/LSL-DsRed) exprimiert 
wird. Aufgrund des Reprogrammierungscharakters des Myc-Onkogens war dieser 
Ansatz essentiell (Rapp et al, 2009). Die Markierung der Zellpopulation auf 
genetischem Weg erlaubte uns zum einen, die molekularen und zellulären 
Veränderungen während der Bildung des Primärtumors zu verfolgen, zum anderen 
konnte so die Entwicklung von Sekundärtumoren unterschiedlicher Stadien in 
entfernten Organen identifiziert werden. Bei kombinierter Expression von 
onkogenem C Raf-BXB und c-Myc (MYC-BXB-DsRed) in Lungenalveolar-
Epithelzellen vom Typ II entstanden makroskopische Tumore in der Lunge, die auf 
zellulärer Ebene sowohl kuboidalen als auch kolumnaren Charakter aufwiesen und 
Metastasen, vorwiegend in der Leber, ausbildeten. Durch C Raf-BXB (CRAF-
DsRed) induzierte Tumore erschienen morphologisch als kuboidal ohne 
Metastasierungsneigung. Überraschenderweise exprimierten zystische Läsionen in 
der Leber, obwohl negativ für SpC (‚surfactant protein C‗) und CCSP (‚Clara cell 
secretory protein‗), als Kennzeichen für deren Ursprung aus Lungenalveolarzellen 
Typ II stark das DsRed-Protein. Darüberhinaus sind in den frühen zystischen 
Läsionen Marker für frühe Lungenvorläuferzellen wie GATA4 (‚GATA-binding protein 
Zusammenfassung 
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4‗) und TTF1 (‚thyroid transcription factor 1‗) weiterhin exprimiert, was auf den 
Metastasierungsprozess als gestörte Rekapitulation der Ontogenese hindeutet 
(Rapp et al, 2008). Metastatische Tumore und Mischformen zu zystischen Läsionen 
enthielten DsRed- und SpC-positive Zellpopulationen. Diese Ergebnisse weisen in 
Sekundärtumoren den Übergang von zystischer Läsion zur Mischform mit 
zystischem Anteil und zur malignen Transformation nach.Unsere Resultate werfen 
ein neues Licht auf Reprogrammierungsprozesse metastasierender Zellen bei der 
Bildung von Sekundärtumoren. Das vorgestellte fluoreszenzmarkierte und 
metastasenbildende Mausmodell kann zum einen zur Untersuchung der 
Migrationsfähigkeit metastasierender Krebszellen in unterschiedliche Organe 
verwendet werden. Darüberhinaus  ermöglicht dieses Mausmodell die Untersuchung 
des Differenzierungspotenzials markierter Zellen in andere Zelltypen wie Blutgefäße 
oder Stromazellen im Primärtumor.  
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Summary 
Non-small cell lung cancer (NSCLC) is the deadliest form of lung cancer and has a 
poor prognosis due to its high rate of metastasis. Notably, metastasis is one of the 
leading causes of death among cancer patients. Despite the clinical importance, the 
cellular and molecular mechanisms that govern the initiation, establishment and 
progression of metastasis remain unclear. Moreover, knowledge gained on 
metastatic process was largely based on cultured or in vitro manipulated cells that 
were reintroduced into immune-compromised recipient mice.  
In the present study, a spontaneous metastasis mouse model for NSCLC was 
generated with a heritable fluorescent tag (DsRed) driven by CAG (combination of 
cytomegalovirus early enhancing element and chicken beta actin) promoter in 
alveolar type II cells (SpC-rtTA/TetO-Cre/LSL-DsRed). This approach is essential, 
keeping in mind the reprogramming nature of Myc oncogene (Rapp et al, 2009). 
Such genetic lineage tracing approach not only allowed us to monitor molecular and 
cellular changes during development of primary tumor but also led us to identify the 
different stages of secondary tumor development in distant organs. Upon combined 
expression of oncogenic C Raf-BXB and c-Myc (MYC-BXB-DsRed) in lung alveolar 
type II epithelial cells, macroscopic lung tumors arose comprising of both cuboidal 
and columnal cellular features. C Raf-BXB induced tumors (CRAF-DsRed) exhibit 
cuboidal morphology and is non-metastatic whereas Myc-BXB induced lung tumors 
(Myc-BXB-DsRed) present cuboidal-columnar cellular features and is able to 
undergo metastasis mainly in liver. Surprisingly, cystic lesions which were negative 
for SpC (Surfactant protein C) and CCSP (Clara cell secretory protein), strongly 
expressed DsRed proteins indicating its origin from lung alveolar type II cells. 
Moreover, early lung progenitor markers such as GATA4 (GATA-binding protein 4) 
and TTF1 (Thyroid Transcription Factor 1) were still expressed in these early cystic 
lesions suggesting metastasis as a faulty recapitulation of ontogeny (Rapp et al, 
2008). Interestingly, mixed cystic lesions and metastatic tumors contained DsRed 
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and SpC positive cells. These results demonstrate secondary tumor progression 
from cystic, mixed cystic to malignant transformation.  
Our results shed tremendous light on reprogramming of metastasizing cells during 
secondary tumor development. Moreover, such fluorescent tagged metastatic mice 
model can also be used to track the migration ability of metastatic cancer cell to 
different organs and its potential to differentiate into other cell types such as blood 
vessel or stromal cell within the primary tumor. 
Introduction 
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1 Introduction 
Lung cancer is the leading cause of cancer related deaths throughout the world. 
(Landis et al, 1999). There are two types of lung cancer based on histology; Small-
cell lung carcinoma (SCLC) (Schiller, 2001) and Non-small cell lung carcinoma 
(NSCLC) (van Zandwijk et al., 1995). NSCLC is the most prevalent type of human 
lung cancer and has a poor prognosis due to its high rate of metastasis. Metastasis 
is a process by which cancer cells learn to form satellite tumors in distant organs 
and represents the principle cause of patient‘s death with solid tumors (Langley & 
Fidler, 2007). Metastasis of cancer may cause as many deaths as cancer itself. 
Amongst other reasons, this is because it is very difficult to know where the new 
tumour is going to develop. Moreover, the mechanisms of metastasis are still not 
well understood, although a lot of research into it is taking place and advances are 
being made. In view of this, the current work is an attempt focused on unraveling the 
identity of cell type responsible for metastasizing into secondary organs in a murine 
lung adenocarcimona model. 
1.1 Non small cell lung cancer (NSCLC) 
Lung cancer has become the leading cause of cancer deaths in the world, 
accounting for even more solid tumor deaths than breast, pancreatic, prostate, and 
colorectal combined (Landis et al, 1999). More than 170,000 new cases are being 
diagnosed each year in the United States alone, of whom ∼160,000 will eventually 
die, representing 28% of all cancer deaths (Jemal et al, 2004). Lung cancer can be 
divided into two major histopathological groups: non-small-cell lung cancer (NSCLC) 
(van Zandwijk et al, 1995) and small-cell lung cancer (SCLC) (Schiller, 2001). About 
80% of lung cancers are NSCLC, and they are subdivided into adenocarcinomas, 
squamous cell, bronchioalveolar, and large-cell carcinomas (Travis, 2011). 
Squamous cell carcinomas and adenocarcinomas are the most prominent. The 
remaining 20% of lung cancers show properties of neuroendocrine cells. These 
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neuroendocrine lung tumors can be further sub-divided into four subgroups based 
upon their morphological characteristics. 
 
 
Type Frequency 
5-Year Survival Rate (All 
stages) 
Small cell: 18% 5% 
Non-small cell:       
Squamous or epidermoid 
carcinoma 
29% 15% 
Adenocarcinoma 32% 17% 
Large cell carcinoma 9% 11% 
 
 
Table 1 Types of Lung cancer with their surveillance rates {Adapted from Dennis (Kaspar et 
al, 2002)} 
1.1.1 The mitogenic cascade and Ras/Raf signaling  
In a variety of human tumors, one can find a deregulation of the mitogenic cascade 
on different levels. Going through the list of hallmarks of cancer defined by Hanahan 
and Weinberg in 2000 (Hanahan & Weinberg, 2000) the Ras/Raf signaling can 
contribute to any individual of these criteria (Table 2).The growth factor receptor that 
triggers the consecutive signaling pathway, the EGF-receptor (EGFR), was found to 
be mutated in various epithelial tumors (Gschwind et al, 2004) and in 20% of NSCLC 
a mutation in the EGFR can be observed (Meuwissen & Berns, 2005). Furthermore, 
the Ras proteins, the transceiver of the receptor signals, are also popular targets for 
mutations in approx. 30% of human cancers (Karreth & Tuveson, 2009), as for e.g. 
in 15 to 20% of NSCLC activating KRas mutations are found (Meuwissen & Berns, 
2005). Other important targets for mutations in the mitogenic cascade are the Raf-
Introduction 
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kinases, which are central players of the MAPKinase signaling pathway, for e.g. B 
Raf is mutated in 66% of the melanoma patients (Schreck & Rapp, 2006). 
 
Hallmarks of a cancer cell 
Corresponding effect of the Ras/Raf 
signaling pathway 
Immortalization Telomerase Induction 
Growth-factor-independent growth Cell cycle activation 
Insensitivity to growth-inhibitory signals Inactivation of tumor suppressors 
Ability to invade and metastasize 
Stimulation of motility and extracellular 
remodelling 
Ability to secure nutrients by 
stimulating angiogenesis 
Stimulation of the production of pro-
angiogenic factors 
Avoidance of apoptosis BAD inactivation; Caspase inhibition 
Resistance to therapeutic measures 
Induction of radiation resistance; 
induction of the multidrug resistance 
protein MDR 1 
 
Table 2 The Ras/Raf signaling impacts on the hallmarks of cancer defined by Hanahan and 
Weinberg {Modified from (Kolch et al, 2002)} 
1.1.1.1 Ras/Raf signaling 
RAF proteins are part of a highly conserved signaling module, the mitogenic 
cascade, which transduces signals from the cell surface to the nucleus (Fig 1) The 
upstream regulators of the Raf proteins are members of the Ras-family of small G-
proteins (Robbins et al, 1994). Ras is activated by extracellular ligands such as 
growth factors, cytokines or hormones binding to their receptor leading to the 
exchange of GDP with GTP, which converts Ras into its active conformation 
(Boguski & McCormick, 1993). Activated Ras directly interacts with high affinity with 
Raf and recruits it to the cytoplasmic membrane, where Raf activation via 
phosphorylation takes place (Avruch et al, 1994). Activated Raf phosphorylates and 
this triggers the subsequent activation of the kinases MEK1 and MEK 2 on two 
serine residues on their activation segment. These kinases phosphorylate and 
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further activate the mitogen activated protein kinases (MAPK) ERK 1 and ERK 2 
(extracellular signaling related kinase) on threonine and tyrosine residues within their 
activation segment. ERK1/2 have both cytosolic (kinases and cytoskeletal proteins) 
and nuclear (transcription factors) substrates (Flory et al, 1996) and (Marshall, 
1999). The activation of this cascade leads to transcriptional activation of proteins 
possessing cell stimulating, pro-survival and anti-apoptotic properties (Troppmair & 
Rapp, 2003). In addition to the Raf-kinases, Ras also regulates other proteins , for 
example the phosphatidylinositol-3 (PI3)kinases, which activates the 
serine/threonine-specific protein kinase Akt (PKK) via phosphorylation leading to 
phosphorylation and inactivation of the pro apoptotic protein BAD (Downward, 
1998). Raf kinases not only phorphorylate and activates MEK1/2 , but also interact 
with the anti apoptotic protein Bcl-2 and by this blocks the mitochondrial  apoptotic 
pathway. Furthermore they phosphorylate and thereby inactivate the pro apoptotic 
Bcl-2 family protein BAD (Troppmair & Rapp, 2003). 
 
Fig 1 RAF signaling pathway regulating cell growth, differentiation, proliferation and survival 
{modified from (Troppmair & Rapp, 2003)}. 
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1.2 Molecular abnormalities found in human lung cancer 
Cancer is fundamentally a disease of failure of regulation of tissue growth. This 
comprises the involvement of genes that turn awry and involves aberrant cell 
signaling. A brief account on some of the major/frequent aberrations found in human 
NSCLC and their relevant murine models has been summarized below. 
Mitogen Activated Protein Kinase (MAPK) cascade is a key signaling pathway 
involved in the regulation of normal cell proliferation, survival and differentiation. 
There is a frequent involvement of the members of the mitogenic cascade in the 
pathogenesis of NSCLC. More than 50% of human NSCLC carry mutations in genes 
that encode activators of the mitogenic cascade (RAS-RAF-MEK-ERK) (Fig 2). 
 
 
Fig 2 Mitogen Activated Protein Kinase cascade (in green) and its relationship with other 
signaling pathways. Raf and Myc oncogenes highlighted in red circles. (adapted from 
http://en.wikipedia.org/wiki/C-Raf)   
 
In addition to MAPK members, there are also other molecules that are shown to be 
de-regulated in Human NSCLC (Table 3). 
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                     Molecular abnormality in Human Lung Cancer                          
 
Table 3 Prominent bio-molecules that are de-regulated in human lung cancer; adapted from 
(Meuwissen & Berns, 2005). 
 
1.2.1 Raf protein  
Raf protein serine/threonine kinases are effectors of Ras signaling and therefore, are 
likely involved at least in those 30% of lung cancers in which mutated ras is detected 
(Salgia & Skarin, 1998) and (Forgacs et al, 2001). Among Raf proteins; C-Raf has 
been found to be overexpressed in a large fraction of human lung cancers (Rapp et 
al, 1988). The basis for increased CRaf protein content in lung tumor cells 
presumably is translational rather than transcriptional up-regulation (Rapp et al, 
1988). Lung targeted expression of normal CRaf kinase in transgenic mice induced 
development of adenomas at high frequency. Oncogenically activated CRAF (CRAF 
BXB) caused the same histological type of adenoma to occur more rapidly in 100% 
of mice (Kerkhoff et al, 2000). CRAFis today a validated target for treatment of a 
variety of solid tumors (Hotte & Hirte, 2002). 
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1.2.2 The RAS genes 
The Ras genes (HRAS, KRAS, and NRAS) encode GTPase proteins that play a role 
in transducing growth promoting and survival signals from membrane-bound RTKs. 
Hydrolysis of bound GTP to GDP abrogates RAS signaling, but oncogenic mutations 
in RAS impair GTP hydrolysis, causing persistent signaling. The RAS oncogenes 
acquire their transforming capacity by point mutations that are detected in 20%–30% 
of lung adenocarcinomas and ∼20% of all NSCLCs (Slebos et al, 1990) . Most point 
mutations are G–T transversions and are correlated with smoking (Slebos et al, 
1990). KRAS accounts for 90% of RAS mutations in lung adenocarcinomas, and 
approximately 97% of KRAS mutations in NSCLC involve codons 12 or 13 (Forbes 
et al, 2006). Mouse tumour models carrying oncogenic alleles of K-ras that can be 
activated only on a spontaneous recombination event in the whole animal has been 
previously described where the mice harbouring these mutations were highly 
predisposed to a range of tumour types, predominantly early onset lung 
cancer(Johnson et al, 2001). More recently  reports demonstrated an improved 
mouse lung tumor model that harbours  a loxP-Stop-loxP KrasG12D knockin allele and 
both alleles of p53 flanked by loxP sites (KrasLSL-G12D/+;p53flox/flox mice). Upon 
intratracheal administration of lentiviral vectors that express Cre-recombinase (Lenti-
Cre)10.,these animals developed between 5 and 20 lung tumors, lived 8–14 months 
after tumor initiation and developed macroscopic metastases to the draining lymph 
nodes, pleura, kidneys, heart, adrenal glands and liver (Winslow et al, 2011). 
 
1.2.3 The MYC proto-oncogenes  
MYCL, MYCN, and CMYC, encode transcription factors that regulate the expression 
of genes involved in DNA synthesis, RNA metabolism, and cell cycle regulation). 
The family of myc proto-oncogenes encodes basic helix–loop–helix transcription 
factors (c-, N-, and L-Myc) that regulate cell growth and proliferation and are 
involved in the etiology of diverse cancers (Oster et al, 2002). Activation of MYC 
genes occurs by amplification or loss of transcriptional control, which results in MYC 
protein overexpression. MYC amplification occurs in 15%–30% SCLCs and 5%– 
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10% NSCLCs (Richardson & Johnson, 1993). Hence MYC amplification is an 
indicative for poor prognosis (Johnson et al, 1996). Over-expression of myc genes is 
also strongly associated with the genesis of diverse cancers in many species (Lutz 
et al, 2002). 
 
1.2.4 Tumor suppressor genes  
Tumor suppressor genes are frequently inactivated in lung cancer.  One of the most 
commonly found aberrations is mutation or deletion of Tp53. p53 is critical for 
maintaining genomic integrity after DNA damage inflicted by gamma and UV 
irradiation or carcinogen exposure(Hanawalt et al, 2003; Khanna & Jackson, 2001). 
Cellular stress such  as DNA damage or hypoxia causes up-regulation of p53, which 
then acts as a sequence-specific transcription factor driving expression of a range of 
genes such as p21, controlling G1/S cell cycle transition, or GADD4, involved in the 
G2/M DNA damage checkpoint. Finally apoptosis is induced through p53 by 
activating BAX, PERP (Ihrie et al, 2003), and other genes (Mori et al, 2004). Loss of 
p53 function in lung cancer often occurs through missense mutations and rarely by 
deletions and is found in 75% and ∼50% of SCLCs and NSCLCs, respectively 
(Toyooka et al, 2003). The Tp53 mutations in lung tumors, mostly G–T 
transversions, carry the hallmark of smoking (Lewis & Parry, 2004). Normally, 
expression levels of p53 are kept low through an autoregulatory feedback loop with 
MDM2, which itself is transcriptionally controlled by p53. MDM2–p53 binding 
enhances the proteasome-dependent degradation and therefore keeps p53 levels in 
check. Overexpression of MDM2 is found in 25% of NSCLCs (Higashiyama et al, 
1997). 
1.3 Metastasis 
The spread of cancer from one part of the body to another is called metastasis. 
Tumors formed from cells that have spread are called "secondary tumors" and 
contain cells that are like those in the original primary tumors. Tumors are called 
"malignant" because they have the ability to invade normal tissues (replacing healthy 
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cells with cancer cells) and to metastasize (spread) to other parts of the body. Death 
from cancer often comes not from the primary site but from the metastases. It is a 
multistep process in which metastatic cancer cells invades the surrounding stroma, 
intravasate, survive in the circulation, arrest, extravasate, invade the matrix, and 
finally grow in the target organ (Talmadge & Fidler, 2010), Fig 3). The persistence of 
tumorigenic and migrating cancer progenitor cells in locally invasive and metastatic 
cancer to current clinical treatments is responsible for the relapse of the disease 
(Brabletz et al, 2005). NSCLC accounts for about 80% of lung cancers, is the most 
prevalent, lethal and has poor prognosis due to its high rate of metastasis.  
 
 Fig 3 Metastatic progression adapted from (Dorsam & Gutkind, 2007) 
1.3.1 Collective migration  
Cell migration and invasion are critical parameters in the metastatic dissemination of 
cancer cells resulting in the formation of metastasis; which represent the major 
cause of death in cancer patients. Different types of cancer cell migration seem to 
exist, including single-cell mesenchymal or amoeboid migration and collective cell 
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migration.  Although solitary migrating epithelial cancer cells have mostly undergone 
epithelial-to-mesenchymal transition (mesenchymal migration), and sometimes even 
lose their cell-matrix adhesion (amoeboid migration), collective migration of cancer 
cells in cell sheets, clusters, or streams is also frequently observed (Yilmaz & 
Christofori, 2010). It is known that collectively migrating cells maintain their cell-cell 
junctions and migrate in sheets, strands, tubes, and clusters, either still in 
connection with their originating tissue or as separated, independently migrating 
clusters (Friedl et al, 2004). There is increasing evidence that collective cell 
migration is common during invasion and metastasis of malignant tumors 
(Deisboeck & Couzin, 2009). Hence understanding the biological mechanisms 
driving cancer cell migration and designing anti-migratory drugs to combat them thus 
constitute current needs in oncology (Decaestecker et al, 2007). 
1.4 Cellular architecture of the lung 
Mouse lung development involves four histological stages (Cardoso & Lu, 2006). 
During the pseudoglandular stage [embryonic day (E) 10.5-16.5] (Au et al, 2004), 
the bronchiolar tree is laid down by branching morphogenesis (Metzger et al, 2008) 
and the epithelium begins to differentiate into secretory (Clara), neuroendocrine 
(NE), or ciliated cells. During the canalicular stage (E16.5-17.5), the undifferentiated 
distal epithelium continues to branch and gives rise to terminal sacs. These increase 
in number during the terminal sac stage E17.5- postnatal day (P) 5, and type I and II 
alveolar epithelial cells begin to differentiate. During the alveolar stage (P5-30), the 
terminal sacs develop into mature alveoli. 
The respiratory system originates from the foregut endoderm, differentiating into 
many kinds of specialized epithelial cells which include pseudostratified epithelium, 
columnar epithelium and the alveolar epithelium. The lung develops during 
embryogenesis from two primary buds that arise in the ventral foregut. These buds 
undergo extensive branching morphogenesis, directed by reciprocal signaling 
between the epithelial endoderm and the surrounding mesoderm. During this 
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branching stage it is thought that the terminal buds contain a population of 
multipotent epithelial progenitors (Okubo et al, 2005). 
The adult lung is composed of two major anatomically distinct regions—the 
conducting airways and gasexchanging airspaces. It is functionally and structurally 
divided into three epithelial domains: the proximal cartilaginous airway (trachea and 
bronchi), distal bronchioles (bronchioles, terminal bronchioles, and respiratory 
bronchioles) and gas-exchanging airspaces (alveoli). The conducting airways 
(including the trachea, bronchi, and bronchioles) constitute a minority of the surface 
area in the human lung, amounting to approx. 0.25 sq.m whereas the alveolar 
regions of the lung make up approx. 100 sq.m.  In the murine proximal conducting 
airway and major bronchi; basal, Clara, and ciliated cells are predominant cell types, 
although less frequent pulmonary neuroendocrine cells (PNECs) also reside in this 
domain. 
In the adult mouse trachea and primary bronchi (cartilaginous airways), the luminal 
epithelium contains two main columnar cell types: ciliated cells and Clara-like cells. 
The nonciliated, columnar Clara cells comprise the majority of the distal bronchiolar 
epithelium in mice. It produces secretoglobins, the most abundant of which is 
Scgb1a1 (also known as CCSP or CC10). A small number of innervated 
neuroendocrine (NE) cells are also present.  
The alveolar epithelium is lined by squamous alveolar type I pneumocytes (AEC I) 
and cuboidal type II pneumocytes (AEC II). type I cells have a highly flattened 
morphology , provided with  a  thin-walled gas exchange surface and are less 
differentiated, whereas cuboidal type II cells serve as progenitor cells for type I cells. 
These alveolar type II cells are important in synthesizing and secreting pulmonary 
surfactant proteins, a complex mixture of proteins and phospholipids which lower 
surface tension (Creuwels et al, 1997).They contain numerous secretory vesicles 
(lamellar bodies) filled with surfactant material, including surfactant-associated 
protein C or Sftpc. SpC is expressed in the distal epithelium during early lung 
development, and becomes restricted to alveolar type II cells late in gestation and 
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postnatally. Apart from SpC, there is also an existence of Nk2 homeobox1 (NKX2.1) 
(also Thyroid transcription factor 1 (TTF-1), one of the earliest known marker 
associated with commitment of endodermal cells to pulmonary and thyroid cell 
lineages and appears  before the definitive lung formation (Maeda et al, 2007). 
During fetal lung development, the level of NKX2.1 decreases with advancing age. 
At first it is expressed in all pulmonary epithelial cells, later it becomes restricted to 
distal alveolar type II cells and proximal Clara Cells (Yuan et al, 2000).  
1.4.1 Cell populations involved in the homeostasis and 
injury repair of the distal lung 
In a normal steady state airway, epithelial cell proliferation in the adult lung is much 
lower compared with highly proliferative compartments in the gut, skin, and 
hematopoietic system (Liu et al, 2006). It shows both slow turnover and rapid repair. 
Since the cell turnover in the lung is normally very low, so a conveyor belt type 
mechanism for constantly and rapidly renewing the epithelium is not required. 
However, when injury to the epithelium of the lung does occur it has to be repaired 
as quickly as possible. In this case, a situation in which multiple cell types can 
proliferate and function as progenitors for repair is probably the only scenario.  
Over the years, several experimental protocols have been developed in mice that 
mimic the injuries and rapid repair processes elicited in the lung by environmental 
challenges. The picture that is emerging from these models is that different regions 
of the respiratory system – the trachea and large airways, and the distal bronchioles 
and alveoli – use different kinds of stem cells and strategies for maintenance and 
repair. 
 
According to their position within the pulmonary tree, several cell types in the lung 
(Fig 4) have been suggested to act as stem/progenitor cells in response to injury, 
and to serve to effect local repair (Emura, 2002; Engelhardt, 2001; Otto, 2002). Lung 
injury modeling in rodents has suggested that adult lung stem or progenitor cells 
exist, yet there has been a paucity of lineage relationship analysis in the pulmonary 
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system and little demonstration that lung cells exhibit stem cell properties (Rawlins & 
Hogan, 2006), (Sutherland & Berns, 2010).  
 
Basal cells, Clara cells, and cells that reside in submucosal glands have been 
shown to function as progenitors or stem cells in the conducting airway of mice 
(Borges et al, 1997; Borthwick et al, 2001; Engelhardt, 2001; Engelhardt et al, 1995; 
Hong et al, 2004a). In the proximal airways, columnar epithelial cells give rise to 
basal cells (McDowell et al, 1985). Once formed, basal cells can self-renew and 
contribute to other lineages, but differentiated ciliated cells do not appear to divide 
(Otani et al, 1986). 
 
Bronchiolar progenitor cells are thought to be Clara cells, particularly the ones 
residing within neuroepithelial bodies or bronchoalveolar duct junctions (Hong et al, 
2001). In addition, a subset of variant Clara cells residing within neuroepithelial 
bodies (NEBs) (Hong et al, 2001; Peake et al, 2000; Reynolds et al, 2000) or 
bronchoalveolar duct junctions (Giangreco et al, 2002; Kim et al, 2005) has been 
considered stem cells in bronchioles. More recent studies have also found, in 
another region in the terminal bronchioles, that is, the bronchioalveolar duct 
junctions, bronchioalveolar stem cells (BASCs) that accumulate label-retaining cells. 
BASCs were previously termed DPCs (double-positive cells that express both SpC 
and CCSP) (Giangreco et al, 2002; Kim et al, 2005). These cells appear to be 
resistant to bronchiolar and alveolar damage, proliferate during epithelial cell 
renewal in vivo, and are thought to function to maintain the bronchiolar Clara cell 
and alveolar cell populations of the distal lung. BASCs also possess characteristics 
of regional stem cells, such as self-renewal and multipotency in clonal assays. More 
recently investigators reported a model in which the trachea, bronchioles, and alveoli 
are maintained by distinct populations of epithelial progenitor cells (Rawlins et al, 
2009b) 
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Pulmonary neuroendocrine cells and bodies (PNECs/NEBs) have been suggested to 
be capable of dividing, although further research is needed to confirm this notion 
(Giangreco et al, 2002). 
 
In the gas-exchanging regions of the lung, alveolar type II cells have been 
considered the stem/progenitor cell of the alveolar epithelium, based on their ability 
to repopulate/replenish both type II and terminally differentiated type I cells after 
injury (Giangreco et al, 2002; Kim et al, 2005). Studies using a rat lung injury model 
have suggested that there may be four alveolar type II groups, based on their 
expression of markers. The subpopulation of alveolar type II that is E-cadherin 
negative, proliferative, and expresses high levels of telomerase activity was 
considered a stem cell candidate for alveolar epithelium (Reddy et al, 2004). 
 
In the adult lung, candidate stem cell populations have been identified that are 
restricted to the tracheal submucosal gland ducts, neuroepithelial bodies (NEBs) of 
the bronchi and bronchioles, and bronchoalveolar duct junction (BADJ) of the 
terminal bronchioles, suggesting distinct regional stem cell niches in the adult lung 
(Borthwick et al, 2001; Engelhardt, 2001; Engelhardt et al, 1995; Giangreco et al, 
2002; Hong et al, 2001; Kim et al, 2005). 
 
Stem cells can produce daughter cells or transient-amplifying (TA) cells, which often 
have a limited proliferation capacity and a distinct marker profile before they enter a 
terminal differentiation state. Clara and alveolar type II cells meet this TA cell 
phenotype since both do proliferate but finally differentiate into ciliated and alveolar 
type I cells, respectively.  At this moment one cannot fully rule out that transient 
amplifying cells like Clara and alveolar type II cells are the precursors of lung tumors 
although these cells, unlike the multipotent pulmonary stem cells, do not have the 
ability to trans-differentiate. Identification of lung tumor precursor cells will ultimately 
not only be of great use for understanding basic lung tumor biology but will also 
enable the characterization of the consecutive steps early in SCLC and NSCLC 
development. 
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Fig 4 Cell populations involved in the Homeostasis and Injury repair of the distal lung 
1.5 Genetic lineage tracing  
1.5.1 What is lineage tracing? 
Clonal marking methods represent one of the most powerful tools available for 
identifying stem/progenitor cells and analyzing their function. Ideally, a single cell is 
marked in such a manner that the mark is faithfully transmitted to all daughters of the 
initial cell, resulting in a labeled clone. By analyzing the number, location and 
phenotype of clonally derived cells at increasingly greater times after marking, the 
types of cells generated by the progenitor, their movements and their lifetimes can 
all be deduced. Moreover, a cell's clonal profile reveals information about its state of 
differentiation. This methodology is widely accepted by investigators across the 
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globe and has contributed to outstanding findings. (Hoffman, 2005; Rock et al, 
2009). 
1.5.2 Need of lineage tracing strategy in   
pulmonary/oncology research 
Because cellular turnover in airways is relatively slow, methods for analysis of stem 
cells or progenitor cells in vivo have required prior injury to the lung. In contrast, ex 
vivo and in vitro models for analysis of airway stem cells have used genetic markers 
to track lineage relationships together with reconstitution systems that mimic airway 
biology. One way to follow cell fate during lung development, homeostasis, and 
repair is to use genetic lineage-labeling techniques to indelibly mark the 
descendants of specific cell types. In this way, the daughter cells express the 
lineage marker whatever phenotype they acquire. There are at least five distinct 
epithelial cell types in the lung that all derive from a common progenitor in the 
foregut endoderm. In contrast with our detailed understanding of cell lineage 
relationships in the hematopoietic system, the number of lineages and the 
relationship of cell types within a lineage of lung epithelial cells are poorly 
understood. Earlier studies were carried out to circumvent the limitations of cell 
enrichment approaches; retrovirus-mediated gene transfer has been used to 
genetically tag epithelial stem/ progenitor cells and to follow lineage relationships, 
using histochemical markers (Engelhardt et al, 1995; Engelhardt et al, 1992). 
Histochemical staining for marker transgenes such as β-galactosidase and/or 
alkaline phosphatase or other reporter proteins can then be used to visualize clonal 
expansion of stem/progenitor cells in the reconstituted airway epithelium. 
This genetic lineage labeling approach can serve an important advantage as well. It 
can be used to isolate progenitor cells and their daughters for gene expression 
analysis to investigate the mechanisms of cell fate specification and differentiation, 
and they can be exploited for functional studies based on gene inactivation and 
overexpression. Such tools have so far only been applied in a very limited way to the 
lung. Moreover, they have sometimes been used in the absence of a completely cell 
type-specific promoter, making interpretation difficult (Belteki et al, 2005; Hong et al, 
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2004b; Kim et al, 2006; Perl et al, 2002b). Therefore a long-term goal in this field is 
thus to engineer mice for efficient lineage labeling of each of the different airway 
epithelial cell types.  
1.5.3 Reporter molecules employed for lineage labeling 
experiments 
1.5.3.1 Fluorescent reporter proteins 
Non-invasive auto-fluorescent reporters have revolutionized lineage labeling in an 
array of different organisms. Naturally occurring fluorescent proteins have 
revolutionized biology by enabling what was fomerly invisible to be seen clearly. 
These proteins have allowed the researchers to visualize, in real time, cancer 
dynamics in living animals, including tumor growth, metastasis, cell mobility, invasion 
and angiogenesis. Visualization of many aspects of cancer initiation and progression 
in vivo are now possible, even at the subcellular level, with fluorescent proteins. 
(Yamamoto et al, 2003). In recent years green fluorescent protein (GFP) from the 
bioluminescent jellyfish Aequoria Victoria has gained popularity in mouse transgenic 
and gene targeting regimes (Chalfie et al, 1994). In murine system, enhanced green 
(EGFP) (Okabe et al, 1997), yellow (EYFP) (Hadjantonakis & Nagy, 2000) and cyan 
(ECFP) (Srinivas et al, 2001)fluorescent proteins have served as invaluable tools. 
1.5.3.2 Advantage of fluorescent reporters over conventional marking systems 
The application of fluorescent proteins as expression markers and protein fusion 
partners has proved immensely valuable for resolving the organization of biological 
events in living cells, tissues, and organisms (Hadjantonakis et al, 2003; Lippincott-
Schwartz & Patterson, 2003; Verkhusha & Lukyanov, 2004). One area of recent 
progress concerns the development of optical marking methods used to differentially 
highlight cells, organelles, and fusion proteins for tracking purposes. Such methods 
have found utility for studying organelle dynamics, protein trafficking, and cell 
lineage, as well as for selective retrieval of marked cells from within a population. It 
offers several advantages over conventional gene-based reporters, such as lacZ 
and alkaline phosphatase, in that its visualization does not require a chromogenic 
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substrate and can be realized in vivo. Fluorescence can be monitored in real-time in 
vivo and in situ, and has the added advantage in that it can be quantified.      
The development of new models of human and animal cancer by transfer of the 
fluorescent protein gene to tumor cells enables visualization of fluorescent tumors 
and metastases. Fluorescent labels have proven to be a highly versatile means with 
which to image tumors in mice, as in addition to providing an opportunity to observe 
tumor biology in vivo, labeled cells are particularly well suited to ex vivo analyses (eg 
fluorescence microscopy or FACS analysis) once experimental end-points have 
been reached (Schmitt et al, 2002). 
1.5.3.3 Red Fluorescent protein (DsRed) 
DsRed, a red-emitting fluorescent protein (RFP) is a 25.7-kDa protein and a variant 
of naturally occurring chromoproteins found in colored body parts of corals and 
anemones; Discosoma sp. (Mizuno et al, 2001), with the excitation and emission 
maxima at 558 and 583 nm, respectively (Matz et al, 1999). DsRed is homologous to 
green fluorescent protein (GFP), which forms an 11-strand b barrel and a 
chromophore embedded inside the barrel (Wall et al, 2000). It has a much higher 
extinction coefficient and fluorescent quantum yield compared to GFP, and it quite 
resists to photo bleaching with a wider pH tolerance range.The protein exhibits a 
bright red, autocatalytic fluorescence emission easily separable from of residual 
green emission (Terskikh et al, 2002; Verkhusha et al, 2001). These advantages 
attracted tremendous interests for applications in live-cell imaging (Matz et al, 1999). 
The longer wavelength of the emitted light minimizes problems associated with light 
scattering and autofluorescence of the cells (Tsien). The long-wavelength emission 
of RFP enables high sensitivity and resolution of microscopic tumor growth using 
appropriate imaging techniques. DsRed provides an opportunity to generate useful 
Imaging tools. The serendipitous discovery that multiphoton excitation  760 nm) 
rapidly bleaches the red species, dequenching the intrinsic FRET to result in a red-
to-green color change, allows exploitation of DsRed as an optical highlighter to track 
cell lineage and fusion protein dynamics or to retrieve marked cells from a larger 
population (Marchant et al, 2001). DsRed has shown to be very enabling for whole-
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body imaging and has been used to non-invasively follow cancer metastasis in real 
time (Katz et al, 2003) in nude mice as well as whole-body image dual-color models 
of tumors expressing DsRed-2 growing in transgenic GFP nude mice as hosts (Yang 
et al, 2003). 
Higher wavelength emissions (such as red) are preferred due to the lower 
background- autofluorescence in tissues (Miyawaki et al, 2003). Red fluorescent 
wavelength has a superior tissue penetrance compared with spectral variants of 
lower wavelength. 
1.6 In vivo imaging  
Significant progress has been made recently in the variety of ways that cancer can 
be noninvasively imaged in murine tumor models. Other tumor imaging strategies 
have been developed that rely upon the detection of reporter transgene expression 
in vivo, and these too have made a significant impact on both the versatility and the 
specificity of tumor imaging in living mice. The use of fluorescent proteins for 
imaging is revolutionizing in vivo biology (Hoffman, 2005; Hoffman, 2008). 
Fluorescent protein imaging has been particularly useful to study tumor progression 
(Hoffman, 2005). Whole-body imaging with fluorescent proteins has been shown to 
be able to quantitatively track tumor growth and metastasis, gene expression, 
angiogenesis, and bacterial infection (Hoffman, 2005; Zhao et al, 2001). 
Recent developments in the field of small animal imaging have advanced our 
understanding of in vivo tumor biology. The technology comprises of magnetic 
resonance imaging (MRI), positron emission tomography (PET), single photon 
emission computed tomography (SPECT), bioluminescence imaging (BLI), and 
fluorescence imaging and these approaches have had the most significant impact on 
mouse tumor model research. 
Tumors in mice can be imaged in vivo by fluorescence imaging techniques when 
labeled with fluorescent proteins, dyes or nano sized photonic crystals termed 
‗quantum dots‘. Light emission from labeled cells first requires excitation of the 
fluorescent marker with relatively shorter wavelengths of light. The imaging 
sensitivity of far-red and near-infrared materials is further enhanced by the fact that 
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their excitation results in significantly reduced levels of autofluorescence from 
normal non-labeled tissues. Populations of tumor cells labeled with either GFP or 
RFP have also been imaged together to investigate the clonal nature of metastasis 
(Yamamoto et al, 2003). 
A major advantage of fluorescent proteins expressing tumor cells is that imaging 
requires no preparative procedures, substrate, or contrast agents and is, therefore, 
uniquely suited for visualizing cells and tissues in vivo. The very bright fluorescence 
enables internal tumors and metastases to be externally observed in critical organs 
such as colon, liver, bone, brain, pancreas, breast, lymph nodes, prostate, etc. 
1.7 Mouse models for studying tumor progression and 
metastasis 
One of the most frequent malignancies in humans is lung adenocarcinoma. To 
develop novel diagnostic and therapeutic approaches for the management of this 
disease, animal models are required. With the possibility to introduce genetic insults 
(mutations, abnormalities) identical to those commonly found in human cancer into 
the endogenous murine gene locus; has served as a valuable tool not only for 
understanding the basics of tumor biology but also for the development and 
validation of new tumor intervention strategies as well as for the identification of 
markers for early diagnosis. 
For over two decades, transgenic mice have permitted the study of biological 
functions of numerous genes during normal organogenesis. In addition, the first 
generation of transgenic mice that were purposely made to induce neoplasia in a 
variety of tissues provided valuable insight into cellular processes that are crucial for 
the initiation of cancer (Brinster et al, 1984; Stewart et al, 1984). Hence, mouse 
models have provided an essential means with which to elucidate the involvement 
and in vivo effects of various genetic lesions in tumorigenesis, tumor progression, 
and metastasis. Here I briefly describe the two important and basic strategy of 
conditional gene activation exploited in the current research work. 
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1.7.1 Tetracycline-controlled transcriptional activation 
The scientific challenge of determining whether a multistage cancer process is 
reversible fueled the development of mouse models that overexpress oncogenes in 
a temporally and spatially controlled manner. One of the most powerful transgenic 
approaches that have been developed is the tetracycline (Tet)–dependent system, 
which permits temporal as well as tissue-specific control of transgene expression 
(Furth et al, 1994; Gossen & Bujard, 1992). 
Tetracycline-Controlled Transcriptional Activation is a method of inducible 
expression where transcription is reversibly turned on or off in the presence of the 
antibiotic tetracycline or one of its derivatives (e.g. doxycycline). In nature, the Ptet 
promoter expresses TetR, the repressor, and TetA, the protein that pumps 
tetracycline antibiotic out of the cell.  
The two most commonly used inducible expression systems for research of 
eukaryote cell biology are named Tet-Off and Tet-On. This system consists of a 
fusion of the Tet repressor and a VP16 activation domain to create a transcriptional 
activator protein (transactivator) rather than a repressor. Gene expression is 
activated as a result of binding of the Tet-Off or Tet-On protein to tetracycline 
response elements (TREs) located within an inducible promoter. The difference 
between Tet-On and Tet-Off is not whether the transactivator turns a gene on or off 
as the name might suggest; rather, both proteins activate expression. The difference 
relates to their respective response to doxycycline (Dox, a more stable tetracycline 
analogue); Tet-Off activates expression in the absence of Dox, whereas Tet-On 
activates in the presence of Dox. 
1.7.1.1 Tet Off 
The Tet-Off system for controlling expression of genes of interest in mammalian 
cells was developed by Professors Hermann Bujard and Manfred Gossen at the 
University of Heidelberg (1992). This system makes use of the tetracycline 
transactivator (tTA) protein created by fusing one protein, TetR (tetracycline 
repressor), found in Escherichia coli bacteria with another protein, VP16, produced 
by the Herpes Simplex Virus. The tTA protein binds on DNA at a 'tet'O operator. 
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Once bound the 'tet'O operator will activate a promoter coupled to the 'tet'O 
operator, activating the transcription of nearby gene. Tetracycline derivatives bind 
tTA and render it incapable of binding to TRE sequences, thereby preventing 
transactivation of target genes. This expression system is also used in generation of 
transgenic mice, which conditionally express gene of interest. 
1.7.1.2 Tet On 
The Tet-On system works in the opposite fashion. In this system, the rtTA protein is 
capable of binding the operator only when bound by doxycycline. Thus, the 
introduction of doxycyline to the system initiates the transcription of the genetic 
product. The Tet-On system is sometimes preferred for the faster responsiveness.  
 
Fig 5 Reverse Tetracycline controlled transactivator (tTA) dependent Tet System for 
conditional gene activation 
 
Recent advances in the development of mouse strains that express the reverse 
tetracycline-responsive transactivator (rtTA, Tet-ON) under the ubiquitously active 
Rosa26 locus are very valuable for studying the full spectrum of functions of 
particular genes in many cell types (Yu et al, 2005) and (Belteki et al, 2005). A tissue 
specific expression of the rtTA as well as the Tet controlled activation of transgenes 
can be achieved in these strains through Cre-mediated deletion of a selectable 
marker cassette that acts as a transcriptional Stop sequence located between the 
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Rosa26 promoter and the rtTA coding sequence. A sustained activation of the TetO-
driven transgenes requires a constant administration of doxycycline. Freshly 
prepared Dox in drinking water appears to be the safest and most effective way to 
activate transgenes. In contrast, feeding commercially available chow containing 
Dox is less expensive in the long-term. The rtTA-mediated transactivation of Tet 
operator-driven responder genes can be rapidly and completely blocked by 
withdrawing the doxycycline, and administration of the ligand lifts the transcriptional 
block from the Tet-regulatable promoter. 
1.7.2 The Cre-loxP technology 
One approach for inducing tightly restricted gene modification in mice is with the 
Cre/loxP system (Sauer & Henderson, 1988).The Cre-lox technology is a binary 
system, where the Cre recombinase catalyzes the deletion of a DNA fragment 
between two directly orientated loxP sites (Hoess & Abremski, 1984). LoxP 
recognition sites are inserted around the regions to be deleted using homologous 
recombination, thus creating an allele, which is flanked by loxP sites (a floxed allele). 
The temporal and spatial excision of the floxed allele is achieved by expressing the 
Cre enzyme under a tissue-specific promoter in the same mouse (Nagy, 2000). The 
details of this technology have been elaborated below. 
The Cre-lox system is used as a genetic tool to control site-specific recombination 
events in genomic DNA. This system has allowed researchers to manipulate a 
variety of genetically modified organisms to control gene expression, delete 
undesired DNA sequences and modify chromosome architecture. Cre-Lox 
recombination is a special type of site-specific recombination developed by Dr. Brian 
Sauer initially for use in activating gene expression in mammalian cell lines and 
transgenic mice (Sauer & Henderson, 1988). The Cre protein is a site-specific DNA 
recombinase, and can catalyse the recombination of DNA between specific sites in a 
DNA molecule. These sites, known as loxP sequences, contain specific binding sites 
for Cre that surround a directional core sequence where recombination can occur. 
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Lox P (locus of X-over P1) is a site on the Bacteriophage P1 consisting of 34 bp. 
There exists an asymmetric 8 bp sequence in between with two sets of palindromic, 
13 bp sequences flanking it. The detailed structure is given below (Fig 6a) 
13bp 8bp 13bp 
ATAACTTCGTATA - GCATACAT - TATACGAAGTTAT 
 Fig 6a Lox P sequence 
  
When cells that have loxP sites in their genome express Cre, a recombination event 
can occur between the loxP sites. The double stranded DNA is cut at both loxP sites 
by the Cre protein. The strands are then rejoined with DNA ligase in a quick and 
efficient process. The result of recombination depends on the orientation of the loxP 
sites. 
 
                            Fig 6b Cre Lox P system for gene expression  
LoxP sites can be inserted into the mouse genome such that they flank important 
coding sequences of a particular gene of interest (gene ―floxing‖). Genes modified to 
contain loxP sites within introns function normally in the absence of Cre, but are 
rendered nonfunctional in the presence of Cre due to excision of the floxed segment 
(Sauer & Henderson, 1988). Since the floxed gene is found in every cell of the 
mouse, the specificity of the gene excision arises from tissue- or cell-selective 
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delivery of Cre recombinase (Fig 6b). This can be accomplished through breeding of 
the mouse containing the floxed allele with a second transgenic mouse that 
expresses Cre only in the cells/tissue of interest through the use of a highly specific 
promoter (Kilby et al, 1993). However, in cases where such promoters are not 
available, recombinant viral vectors provide an important alternative for selective 
delivery of Cre (Brooks et al, 2000; Kaspar et al, 2002; Stec et al, 1999). 
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2 Experimental design and goals of the project 
 
The research work is focused on studying Non-small cell lung cancer (NSCLC) 
metastasis by genetic lineage tracing approach.  
In the primary neoplasm, the tumor initiation at host distant tissues/organs may 
result from the division of the tumorigenic and migrating cancer progenitor cells or 
their early progeny from primary neoplasm that give rise to further differentiated cell 
subpopulations. Non small-cell lung cancer is lethal due to its high rate of 
metastasis. Identifying the cell type that is capable of metastasizing to secondary 
tissues is of great importance which would help us in developing therapeutics 
targeting the identified cell type. Lack of suitable animal model has so far hampered 
the analysis of metastatic progression. Recently investigators have generated the 
first conditional model for metastasis of NSCLC and have declared the ability of c 
Myc in successfully executing metastasis in a C-RAF driven mouse model for 
NSCLC (Rapp et al, 2009). In view of this, the present study aims at incorporating a 
heritable tag to the alveolar type II cells and following its fate invivo during the 
process of tumor progression culminating into metastasis thereby investigating the 
contribution of type II cells in metastasis. The advantage of genetic lineage labeling 
of type II cells with a marker will eventually reflect the record of the previous status 
acquired by the type II cells. Thereafter during the course of tumorigenesis and 
metastatic progression; loss of differentiation markers (SpC in this case), will no 
longer pose a threat in identifying the previous fate of the cell type, since the lineage 
tag would still retain in the current status of the cell type once it has been initially 
marked by the reporter molecule; inspite of whatever phenotype a cell aquires during 
the later stages in the process of neoplastic transformation and in malignant 
progression. 
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2.1 Goals of the project 
1. Generation of transgenic mouse model to label alveolar type II cells 
with the reporter gene, driven by a combination of oncogenes. 
2. To investigate whether we can follow the track of the labeled cells and 
detect them in the metastatic sites. 
3. To unravel the identity of the cell type responsible for initiating 
metastasis in the NSCLC murine model. 
2.2 Transgenic mice used for the study 
1. DsRed transgenic reporter mouse (Tg(CAG-Bgeo,-DsRed*MST)1Nagy/J) 
These Lac Z/RED transgenic mice express beta-galactosidase (lacZ) under the 
control of the chicken beta actin promoter coupled with the cytomegalovirus (CMV) 
immediate early enhancer (Nagy, 2000). When crossed with a Cre recombinase-
expressing strain, lacZ expression is replaced with red fluorescent protein 
(DsRed*MST) expression in tissues expressing Cre recombinase. This double 
reporter system makes it possible to distinguish a lack of reporter expression from a 
lack of Cre recombinase expression while providing a means to assess Cre excision 
activity in live animals and cells. A transgenic construct containing a Red 
Fluorescent Protein variant (DsRed.MST) gene under the control of the a chicken 
beta actin promoter coupled with the cytomegalovirus (CMV) immediate early 
enhancer upstream of a loxP site flanked beta-geo gene, was introduced into 
129S6B6F1 derived G4 embryonic stem (ES) cells. ES cell clone containing one 
copy of the transgene and expressing LacZ was aggregated with ICR outbred 
tetraploid embryos to generate chimeric mice. The resulting chimeric male animal 
was bred with an ICR outbred female. Progeny from this cross, that were 
hemizygous for the transgene, were bred to ICR outbred mice. While mice 
hemizygous for this Z/RED transgene are reported to be viable and fertile, but 
hemizygous animals are often smaller than littermates and subject to postnatal 
mortality. Delayed weaning greatly enhances the survival. Although homozygous 
animals are born, animals have not survived past five weeks of age (Fig 7).  
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Fig 7 Lac Z (Floxed) /DsRed mouse 
2. SP-C-rtTA mice 
This mouse line was obtained from Dr. Whitsett Lab.  
This mouse line is being used to target alveolar type II cells of the lung in a 
conditional manner. Crossing these mice with other transgenic mice that have the 
Tet-regulated genes will lead to type II cell specific expression.  
Plasmid construction: The rtTA construct was a gift of Dr. Herman Bujard (ZMBH, 
Heidelberg). The 1 kb rtTA coding sequence was placed under the control of the 3.7 
kb human SP-C promoter (Glasser et al., 1991) or the 2.3 kb rat CCSP promoter 
(Stripp et al., 1992) that direct expression of transgenes in respiratory epithelial cells 
of the lung. Polyadenylation sequences from SV40 (SP-C-rtTA) and the human 
growth hormone gene (CCSP-rtTA) were used to ensure transcript termination (Perl 
et al, 2002a).  
3. Tet O Cre (LC-1) 
This mouse line was obtained from other Dr. Bujard Lab.  
This is a conditional transgenic mouse system in which Cre will be expressed in 
desired organs only when these mice are crossed with another transgenic mouse 
line (inducer line).  The purpose of using these mice is to employ them to inactivate 
specific genes in certain cell types in an inducible manner. The bidirectional 
transcripton unit encoding the cre and the luciferase (luc) gene under the control of 
the promoter Ptetbi-1 was derived as described previously. The PLAP rtTA2s-S2 
transcription unit was obtained by first replacing the SV40 poly (A) site in pUHrT61-1 
by the β-globin intron/poly (A) sequence. Subsequently, the PCMV sequence was 
exchanged for the sequence encoding the promoter of the liver enriched activator 
protein derived from plasmid pUHG15-30. LC transgenic mice were obtained by 
pronuclear injection of a purified 6.8 kb NotI fragment  containing the bidirectional 
transcription unit into fertilized F2 (C57Bl/6X BALB/c) eggs.  Similary, rTALAP mice 
were generated by transferring the 5.1 kb XmnI–AsnI fragment of p UHrT61-30 into 
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fertilized F2 (C57Bl/6X DBA) eggs, following standard techniques (Schonig et al, 
2002).  
4. Tet-O C-RAF BXB  
  This mouse was generated in Ulf R.Rapp‘s Lab.  
To generate mice conditionally expressing C-RAF BXB, Tet-O C-RAF ha-BXB 
fragment (6.0 kb) was isolated by gel electrophoresis and injected into the 
pronucleus of fertilized mouse eggs. To generate mice conditionally expressing C-
RAF BXB, pcDNA3 plasmid harboring ha-tagged oncogenic C-RAF, here after C-
RAF ha-BxB, was digested with Hind III and Xba I and cloned into pTS4 vector. The 
resulting pTS4-C-RAF ha-BxB plasmid was subsequently cut with Sma I and Xba I 
to clone a 1.3 kb C-RAF ha-BxB fragment into pBI5 vector (containing a tet operator) 
using Pvu II (compatible with Sma I site) and Xba I sites. The final PBI5 C-RAF ha-
BxB plasmid was cut with Ase I to remove the vector backbone and the Tet-O C-
RAF ha-BxB fragment (6.0 kb) was isolated by gel electrophoresis and injected into 
the pronucleus of fertilized mouse eggs. Eight potential founders were generated 
and five of them showed germ line transmission after PCR genotyping. All positive 
founders were mated with either SP-C rtTA or CCSP rtTA transgenic activator lines 
to obtain double transgenic progeny. These compound mice were induced with 
doxycycline (DOX) (Sigma) containing food (500 mg/kg, Sniff) for different periods 
and analyzed for phenotypes of lung pathology. All mice were kept on FVB/n 
background.  
5. SPC c Myc  
  This mouse line was obtained from Dr. Halter‘s Lab.  
This mouse line express the murine oncogene c-myc under the control of lung-
specific surfactant protein C promoter, to study the bronchiolo-alveolar 
adenocarcinomas derived from alveolar type II pneumocytes. The transgenic mice 
were produced as follows:  The ApaI-HindIII mouse c-myc DNA fragment from the 
plasmid pTG2948 (Dalemans et al, 1990) was subcloned into the corresponding 
restriction sites in pBSKS II (+/–) (Stratagene). ApaI was converted into a SalI 
restriction site. The 2.7 kb SalI/EcoRI c-myc DNA fragment was ligated to the 
SalI/EcoRI site of the vector pUC18/3.7SP-C downstream of the human SP-C 
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promoter 5¢-flanking region (Wikenheiser et al, 1992). The BamHI site of the 
BamHI–SalI IgEGF fragment (nucleotides 0 to 360, including the Ig signal sequence 
and a synthetic EGF gene) derived from the plasmid alb-DS4 (Tönjes et al, 1995) 
was converted to a SalI restriction site. The new IgEGF SalI fragment was cloned 
into the SalI restriction site 3¢ of the promoter of the human SP-C gene of 
pUC18/3.7SP-C. Both gene constructs were cleaved with NdeI and NotI and the 
fusion gene fragments were purified by the Qiagen gel extraction kit and 
microinjected into male pronuclei of fertilized oocytes from hybrid CD2/F1 (DBA/2 ´ 
Balb/C) mice (Hogan et al, 1994). Viable oocytes were transferred into the oviduct of 
pseudopregnant CD2F1 recipient mice. Transgenic founder mice were mated with 
CD2F1 for propagation as hemizygous transgenics (Ehrhardt et al, 2001).  
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3 Materials  
3.1 Instruments         
Hardware/General materials                                                           Manufacturer
Autoclave            Webeco 
Blotting Chamber                                                               Bio-Rad
Bacterial shaker                                                                   New Brunswick Scientific innova 4330 
Cell Culture Hood                                                                Heraeus Instruments 
Cell culture Incubator                                                                          Heraeus Instruments
Cell culture dish (6, 12, 24, 96 well)                                                  Nunc Brand Products
Cell culture dish (6, 10 cm)                                                                Corning 
100/40/20 um cell strainer                                BD Falcon 
Conical tubes (15, 50 ml)                                                                    BD Falcon
Cover slips                                                                                             Menzel-Glaser 
Cooling centrifuge                                                                                                                                        OMNILAB
Cryo Microtome                                                                 Leica
Dissection Microscope                                                        Leica 
Desktop centrifuge                                                              OMNILAB/EPPENDORF 
Electrophoresis power supply                                           Bio-Rad
Electrophoresis unit, small                                                 Bio-Rad Mini-Protean II 
Embedding cassettes                                                                           Simport
Exposure cassettes                                                              Dr.Gross-Suprema 
Electrophoresis unit for Agarose Gels                           BioRad
Electrophoresis unit for Agarose Gels                              BioRad
Earmarks                                                                                     Harlan
Flourescence Microscope (CCD)                                         Leica 
FACS Calibur                                                                        Becton Dickinson 
Filter paper                                                                           Schleicher & Schuell 
Freezer -20 degree                                                              Liebherr
Freezer -80 degree                                                              Liebherr
Fridge 4degree                                                                     Nunc
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FUJI Medical X –Ray films                                                       Hartenstein
Glass plates for SDS gels                                                          BioRad
Glass coverslips                                                                         Leica
Heating block                                                                        Gebr.Liebisch
Heating Block with shaker                                                                                  GFL 1083, Amersham-Buchler 
Homogenizer                                                                            Ultra-Turrax 
Inverted Microscope                                                           Olympus 
Incubator            Heraeus Instruments 
Ice Machine                                                                          Scotsman 
Microtome                                                                               Leitz,Wetzlar
Microscope slides                                                                Super frost ®Plus 
MicroAmp® Fast Optical 96-Well 
Reaction Plate         
Applied Biosystems 
Nanodrop Thermo Scientific 
Neubauer chamber                                                                 Hartenstein 
PCR Machine                                                                         Bio-Metra 
Ph meter                                                                                Inolab
Pipettes                                                                                 Eppendorf Research  
Power supply                                                                      Bio-Rad 
Parafilm‖M‖ ®                                                                     Verschlußfolie Josef Peske GmbH & 
Co.KG 
Scale                                                                                       A.Hartenstein
Shakers                                                   BellcoBiot, Heidolph,Unimax 2010 
Spectrophotometer                                                            Ultraspec 3000, Pharmacia Biotech 
Sonicator                                                                                   Sono Plus HD
Scalpel                                                                                         Hartenstein 
Triple-Timer weiß 100 stunden                                             Hartenstein 
Thermocycler                                                                       PE 9600, Perkin Elmer; T3, Biometra®  
Timer                                                                                     Roth 
0.2 ml Thermo-Strip PCR tubes and 
 caps DNA/RNA/RNase free ab-0266                                      
Thermo SCIENTIFIC  
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Vortex                Scientific Industries Genie-2 
Water Bath                                                                          GFL 1083, Amersham-Buchler 
Whatman paper                                                                       Hartenstein 
 
                                                                                     
3.2 Chemical Reagents  
Chemical  Manufacturer 
1kb DNA Ladder   Fermentas 
100 bp DNA Ladder                                                                    Fermentas
Acetone                                                                                       Applichem
Acrylamide (30%) /Bisacrylamide (0.8%)                                Roth
Agarose, ultra pure                                                                     Invitrogen
Ammoniumpersulphate (APS)                       Sigma 
Butylated Hydroxy toluene (BHT) Sigma 
Beta-Mercaptoethanol Roth 
Bovine serum albumin (BSA) Sigma 
Bromophenol blue   Sigma 
Beetle Luciferin, Potassium Salt                                               Promega 
Brain extract type II from bovine brain                                   Sigma
Bromodeoxyuridine (BrdU) Sigma 
Chloroform Roth 
Citric Acid    Roth 
Corn oil                           Mazola 
DAPI Sigma 
Diethyl pyrocarbonate (DEPC)  Merck 
Diaminobenzidine(DAB) Sigma 
Dimethyformide Roth 
Dimethysulfoxide (DMSO) Sigma 
Doxycycline Sigma 
dNTPs    Fermentas 
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EDTA       Sigma 
Entellan Merck 
Eosin Merck 
Ethanol Sigma Aldrich 
Ethidiumbromide   Applichem 
Fetal Calf Serum   Invitrogen 
Fetal Bovine Serum, charcoal stripped Sigma 
Formaldehyde Roth 
Formamide Roth 
Glacial acetic acid Roth 
Glucose   Sigma 
Glycerol 
Glutaraldehyde, 25% 
Sigma 
Alfa Aesar GmbH 
HCl Roth 
Heparin Roth 
HEPES Roth 
Hydrogen peroxide                                                                     Sigma 
Isopropanol        Merck 
Ketamin (10 %)                                                                                                      Bela-pharm     
Lipofectamine   Invitrogen 
Low melting agarose    
Mayers‘s Hematoxylin                                                             
Biozyme 
AppliChem
Methanol                  Hartenstein 
MgCl2      Sigma 
Mowiol Calbiochem 
Na2EDTA Sigma 
NaOH       Sigma 
n-butanol                                                                                  Roth 
Normal Goat Serum MILLIPORE 
Normal Donkey Serum MILLIPORE 
Paraformaldehye(PFA) Sigma 
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Paraffin wax Merck 
Phenol   Roth 
Phosphate.buffered saline (PBS)                                          Roth
Prestained protein ladder Fermentas 
Polybrene                                                                                Sigma 
Polyvinil Pyrolidine (PVP- 40)   Roth 
Ponceau S Sigma 
Ribose ATP Fermentas 
Rompun        Bayer 
Rabbit Serum Chemicon 
Sodium Chloride   Roth 
Sodiumdodecylsulphate (SDS) Roth 
TEMED   Sigma 
TissueTEK (OCT)                                                                   Chemicon
Tris Roth 
triSodium dehydrate                                                         Roth
Triton X-100                                                                        Sigma
Trizol Reagent Invitrogen 
Tween 20 Roth 
Potassium Ferrocyanide 99%  , P-9387   Sigma 
Potassium Ferricyanide  99%  P-8131                                                  Sigma
X- Gal 
Xylene, 0.25 % 
Xylol                          
 
                                                           
Fermentas 
Cyanole 
Fisher Scientific 
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3.3 Antibodies 
3.3.1 Primary antibodies 
 
Primary Antibody Firma 
Rabbit anti DsRed monoclonal Clonetech 
Mouse anti-beta-Galactosidase,purified 
monoclonal , Z3781 
Promega 
Anti-ki-67 Antigen, clone: MM1, Isotype Mouse 
IgG1 Cat.No IMG-80159 
IMGENEX 
CC10 (S-20) sc-9773 goat polyclonal IgG Santa Cruz 
Vimentin (C-20) sc-7557, goat polyclonal IgG Santa Cruz 
c-Myc (N-262) sc-764 rabbit polyclonal IgG Santa Cruz 
GATA-4 (C-20) sc-1237 goat polyclonal IgG Santacruz 
Rabbit Anti-Human Protein Gene Product 9.5 (50 
µl)  78-504 AbD 
Serotec 
DsRed (L-18) sc-33353 goat polyclonal IgG Santa Cruz 
Anti-TTF-1 Cat .No.IMG-80195 Clone: 8G7G3/ 
1Isotype: Mouse IgG1 
IMGENEX 
Actin (I-19) sc-1616-R rabbit polyclonal IgG Santacruz 
Purified anti-human PCNA Cat. No. 555566 Becton Dickinson Co. 
pro SPC , Rabbit Gift from J. Whitsett 
P-p44/42 MAPK (T202/Y204) (20G11)  # 4376S 
Rabbit monoclonal antibody   (Phospho Erk) 
Cell Signaling 
p44/42 MAPK (Erk 1/2) (137F5)  # 4695S Rabbit 
monoclonal antibody  (Total Erk) 
 
Cell Signaling 
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3.3.2 Secondary antibodies 
 
Secondary antibody Firma 
Polyclonal Rabbit Anti-Cow Cytokeratin Wide 
Spectrum Screening (WSS) , Ref Z0622 
DAKO North America , Inc. 6392 Via 
Real Carpinteria , CA  93013 USA 
 
Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/Biotinylated Ref. E0354 
DAKO Denmark A/S Produktionsvej 42 
DK-2600 Glostrup, Denmark 
 
Polyclonal Rabbit Anti-Goat 
Immunoglobulins/Biotinylated Ref. E0466 
DAKO Denmark A/S Produktionsvej 42 
DK-2600 Glostrup, Denmark 
 
Polyclonal Goat Anti-Rabbit  
Immunoglobulins/Biotinylated Ref. E0432 
DAKO Denmark A/S Produktionsvej 42 
DK-2600 Glostrup , Denmark 
 
Polyclonal Goat Anti-Mouse   
Immunoglobulins/Biotinylated Ref. E0433 
DAKO Denmark A/S Produktionsvej 42 
DK-2600 Glostrup, Denmark 
 
Biotinlyated Rabbit Anti-Rat IgG(H+L) Affinity 
Purified 
Vector Laboratories, Inc. Burlingame, 
CA 94010 
DyLight tm 488-conjugated AffiniPure Donkey 
Anti-Rat IgG (H+L) 
Jackson ImmunoResearch  Code No. 
712-485-150 
 
DyLight tm 488-conjugated AffiniPure Donkey 
Anti-Rabbit  IgG (H+L) 
Jackson ImmunoResearch  Code No. 
711-485-152 
DyLight tm 488-conjugated AffiniPure Donkey 
Anti-Goat IgG (H+L) 
Jackson ImmunoResearch  Code No. 
705-485-147 
 
Cy TM 5-conjugated AffiniPure Donkey Anti-Rat-
IgG (H+L) 
Jackson ImmunoResearch  Code No. 
712-175-153 
Cy TM 3-conjugated AffiniPure Donkey Anti-Rat- Jackson ImmunoResearch  Code No. 
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IgG (H+L) 712-165-153 
Cy TM 5-conjugated AffiniPure Donkey Anti-
Mouse -IgG (H+L) 
Jackson ImmunoResearch  Code No. 
715-175-113 
Cy TM 3-conjugated AffiniPure Donkey Anti-
Rabbit  -IgG (H+L) 
Jackson ImmunoResearch  Code No. 
711-165-152 
 
Cy TM 5-conjugated AffiniPure Donkey Anti-
Goat-IgG (H+L) 
Jackson ImmunoResearch  Code No. 
705-175-147 
 
Cy TM 3-conjugated AffiniPure Goat Anti-Mouse   
-IgG (H+L) 
Jackson ImmunoResearch  Code No. 
115-165-166 
 
Cy™ 5-conjugated AffiniPure Donkey Anti-Rabbit 
-IgG (H+L) 
Jackson ImmunoResearch  Code No. 
711-175-152 
 
3.3.3 Antibodies for immunoblotting  
 ECL™ Anti-Rat IgG, Horseradish Peroxidase-linked  F(ab‘)z fragment (from 
goat) NA9350V  : GE Healthcare UK Limited 
 ECL™ Anti-Rabbit IgG, Horseradish Peroxidase-linked  F(ab‘)z fragment 
(from donkey ) NA9340V : GE Healthcare UK Limited 
3.4 Enzymes 
Enzyme Firma 
Proteinase K (for Genotyping), 500 mg Art. 7528-
3 ROTH 
Proteinase K from Tritirachium album, P5568-1Ml 
> 500 units/Ml ie. 22.2mg protein/ml (Biuret); 974 
units/mL Sigma Alrich GmbH 
Dispase® from Bacillus Polymyxa 1.82 units/mg 
Cat.No.17105-041 GIBCO™ 
DNase I Ref: 11 284 932 001 100 mg from Roche Diagnostics GmbH 
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Bovine pancreas 
Collagenase, from Clostridium histolyticum 
C0130-100 mg 
Sigma-Aldrich Chemie GmbH 
 
Collagenase /Dispase (collagenase from Vibrio 
alginolyticus &Dispase from Bacillus polymyxa) 
Roche 
Restriction Endonucleases Fermentas 
Taq Polymerase 
Genecraft 
 
3.5 Kits 
Kit Firma 
BCA- Kit Thermo Scientific Pierce 
First Strand cDNA Synthesis Kit # K1612 (for 
100 Reactions) Fermentas Life Sciences 
Fast SYBR® Green Master Mix, Part No. 
4385612, Qty 5 mL Applied Biosystems 
AVIDIN/BIOTIN Blocking Kit SP-2001 
Vector Laboratories, Inc. Burlingame, 
CA 94010 
Elite® PK-6100 Standard VECTASTAIN 
ABC Kit BIOZOL Diagnostica Vertrieb GmbH 
Pierce ECL Western Blotting Substrate Prod 
32106 Thermo SCIENTIFIC 
QIAGEN DNeasy tissue kit Qiagen 
BEGM® Bronchiolar Epithelial Cell Growth 
Medium Bullet kit (CC -3171 & CC-4175) Lonza 
RT2 Profiler  PCR Arrays for  mouse Tumor 
Metastasis  , PAMM- 028C -2 Qiagen 
RED Taq®ReadyMix™ PCR Reaction Mix 
R2523-100RXN  080M6110 GmbH ; 
Components: Water,PCR Reagent W1754-1VL  
; ReadyMix™ redtaq™ PCR reaction mix with 
MgCl2  R2648- 20RXN 
 
Sigma Aldrich Chemie 
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3.6 Oligonucleotides  
 
Mouse Line 
 
Sequence 
 
PCR Conditions 
SPC rtTA (USA) 
400 bp 
 
5‘ gac aca tat aag acc ctg gtc 3‘ 
5‘ aaa atc ttg cca gct ttc ccc 3‘ 
 
 
 
95 °C for 3 minutes 
95 °C for 30 seconds 
58 °C for 30 seconds 
72 °C for 60 sec; 35cycles 
72 °C for 10 minutes 
4 °C hold 
 
Tet O Cre 
 
 
cre 3: tcg ctg cat tac cgg tcg atg c 
cre 4: cca tga gtg aac gaa cct ggt cg 
 
 
 
95 °C for 3 minutes 
94°C for 25 seconds 
63 °C for 30 seconds 
72 °C for 1minutes 15 
sec; 35  cycles 72 for 10 
minutes 
4 °C hold 
SPC c Myc (Mouse) 
500 bp 
 
 
spc-c myc   aag gac ttg gct ggc aga cag 
c myc   tgt tgg tga agt tca cgt tga gg 
 
 
 
94 °C for 3 minutes 
94 °C for 30 seconds 
60 °C for 30 seconds 
72 °C for 1minutes 15 
sec; 35 cycles 72 °C for 
10 minutes 
4 °C hold 
 
Tet O C Raf BXB 
 
tetonew :  tag aag aca ccg gga ccg atc 
cag 
bxb   : aca tct ccg tgc cat tta ccc 
 
 
95 °C for 3 minutes 
94 °C for 30 seconds 
62 °C for 30 seconds 
72 °C for 1minutes 35 
cycles 
72 °C for 10 minutes 
4 °C hold 
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SPC C Raf BXB 23 
400 bp 
 
 
 
 
SPC S1   gag gag agg aga gca tag cac 
c 
BXB         aca tct ccg tgc cat tta ccc 
 
 
 
 
94 °C for 3 minutes 
94 °C for 30 seconds 
60 °C for 30 seconds 
72 °C for 1minutes    35  
cycles 72 for 10 minutes 
4 °C hold 
DsRed  
208 bp 
 
IMR 3846   5‘ ccc cgt aat gca gaa gaa 
ga 
IMR 3847    5‘ ggt gat gtc cag ctt gga gt 
 
 
95 °C for 3 minutes 
95 °C for 30 seconds 
61 °C for 60 seconds 
72 °C for 1minutes  35 
cycle      72 for 10 minutes 
4 °C hold 
 
Lac Z 
410 bp 
 
Lac 7    5‘ ccc att acg gtc aat ccg ccg 
Lac 8    5‘ gcc tcc agt aca gcg cgg ctg 
 
95 °C for 3 minutes 
95°C for 30 seconds 
60°C for 30 seconds 
72 °C for 1minutes    35 
cycle 
72 °C for 10 minutes 
4 °C hold 
 
3.7 Oligos for expression analysis  
Primers used for expression analysis. All primers were designed using the program 
AIO (Karreman, 2002) 
 
Gene 
 
 
Sequence and Annealing temperature 
 
Axin 2 
5‘ccacttcaaggagcagctcagca 3′ and 5′- tacccaggctcctggagactga-3′. 55 °C 
 
 
CD 133 
 
5'-gga gct gac ttg aat tga gg-3' and  5'-acc aac acc aag aac aag gc-3'   51 °C 
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CD 24 
 
5'-gac aaa atg ggt ctc cat tcc gca c-3' and  5'-taa agg acg cgt gaa agg ttt ga-3'  
58 °C 
CD 34 
 
5'-ctg tcc tga tag atc aag tag -3' and  5'-atg cag gtc cac agg gac acg -3'  59 °C 
CD 44 
 
5'-cgc tgc tga cat cgt cat c-3' and  5'-aat tcc gag gat tca tcc ca-3'  53 °C 
Lef-1 
 
5'-tgg aca tgc ctt gct tgg agt t-3'and  5'-aca gcg acc cgt aca tgt caa a-3'  57 °C 
 
LGR 5 
 
5‘-cttccgaatcgtcgatcttc -3′ and 5- aacgatcgctctcaggctaa-3‘ 62 °C 
SYK 
 
5'-tcc atg gca aca tct cca g-3‘  and 5‘- gac atg gta ccg tga gga-3‘ 60 °C 
Sca 1 
5'-tca gag caa ggt ctg cag gag gac tg-3' and  5'-atg gac act tct cac act aca aag 
-3'  64 °C 
 
TCF -1 
5'-gtg gac tgc tga aat gtt cg-3'and  5'-agc aca ctt cgc aga gac ttt -3'  51 °C 
TERT 5'-ttc aac cgc aag acc gac ag-3' and  5'-atg gcg ttc ctg agt atg -3'  56 °C 
c Kit 5'-tgg ttt gag cat ctt cac gg-3' and  5'-gac gca act tcc tta tga tc-3'  53 °C 
Vimentin  5'-gtg cgc cag cag tat gaa ag-3' and 5'-gca tcg ttg ttc cgg ttg g-3' 58 °C 
TTF-1 5‗ ttg ctc acg tcc ccc agc g 3‗ and 5‘ cct tac cag gac acc atg gc 3‘  60 °C  
SpC 
 
5‘ gca gag ccc cta caa tca cc 3‘ and 5‘ gca aag agg tcc tga tgg ag 3‘ 61 °C 
DsRed 
 
5 ‗ctt cgc ctg gga cat cct g 3 ‗ and 5‘ tgg gtc acg gtc gcc acg cc 3‘ 62 °C  
Human 
C RAF BXB 
  5‘ ttt ccc cag atc ctg tct tcc at 3‘ and 5‘aca tgt gtt ctg cct ctg gaga 3‘ 61 °C 
 
CCSP 5‘gaa gat cgc cat cac aat cac t 3‘ and 5‘ cag ggt tga aag gct tca gg 3‘ 
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3.8 Solutions and buffers  
   1.  For RNA Isolation 
 BCP Phase separation reagent: cat. No. BP- 151 molecular biology grade 
from Roth 
 TRIzol® Reagent Cat. No. 15596-018 from  Invitrogen™ 
   2. For Protein Isolation 
 PhosSTOP Phosphatase Inhibitor Cocktail Tablets (10 tablets).04 906 845 
001 Roche Diagnostics GmbH Mannheim, Germany 
 Complete Mini, EDTA-free Protease inhibitor cocktail tablets (25 tablets) Ref 
11 836 170 001 Roche Diagnostics GmbH Mannheim, Germany 
Solutions/Buffers‗s formulations  
Nonidet P40 Lysis buffer                        3X Laemmli Buffer 
10 Mm Hepes, pH 7.4                                                                                                                                                                                        100 mM Tris/HCl pH 6.8                                                                                                                           
145 mM KCl                                                                                                                                                                                                             3% SDS                                                                                                                                                       
5 mM MgCl2                                                                                                                                                                                                       45% Glycerol
1 mM EGTA                                                                                                                                                                                                 0.01 % Bromophenol blue                                                                                                                                                         
0.2% IGEPAL( NP 40)                                                                                                                                                                                                7.5 % beta-Mercaptoethanol 
1 Mm Sodium Vanadate  
1x Net Gelatin SD-transblot buffer  
50mMTris/HCl pH 7.4                                                                                                                                                                 50 mM Tris/HCl pH 7.5
5mM EDTA                                                                                                                                                                             40mM Glycine                                                                                                                                                                                         
0.05% Triton X-100                                                                                                                                                                             20% Methanol                                                                                                       
150 mM NaCl                                                                                                                                                                                                   0.004 % SDS 
0.25% Gelatine  
Tail lysis buffer Stripping Buffer  
50 mM EDTA    62.5mM Tris/HCl  , pH 6.8 
50 mM Tris/HCl 2% SDS                                                                                                                                                                                                           
0.5% SDS 100 mM Beta-Mercaptoethanol   
pH 8.0 50 X TAE Buffer 
For 5 ml Anesthesia solution Tris-base: 242 g                                                                                                                                                                             
Ketamine   from Bela-pharma Glacial acetic acid, 57.1 ml                                                                                                                                                           
 Rompun ®2% Injektionslösung  from Bayer  0.5 M Na2EDTA (pH 8.0),100 ml                                                                                                                                                  
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HealthCare 
Ketamine: 500 μl + Rompun 250μl + Rest 
0.9%NaCl 
Distilled water,upto 100 ml 
10 X TBS  TBST 
0.5% SDS 1X TBS                                                                                                                                                                                                            
500 mM Tris- HCL  pH 7.4 000.05 % Tween-20 
 1.5 M NaCl Distilled water 
Distilled water Loading Buffer (6X)   
TE Buffer 30%Glyceral (make 25 ml with H2O) 
50  mM Tris Base (pH 8.0)                                                                                                                                                                                    0.25%Bromophenol blue
1 mM EDTA                                                                                                                                                                                                       Antigen Retrieval solution
0.5% Triton X-100  10 mM Citrate buffer (pH 6) 
4% PFA in PBS Stock solutions 
Weigh 37 g PFA in 850 ml of Water                                                                                                                                         Solution A= 0.1 M Citric Acid solution (21.01 
g Citric Acid monohydrate in 1 litre of water)  
Add 2 to 3 drops of 1 N NaOH Solution B= 0.1 M Sodium Citrate (29.49 g 
trisodium citrate dehydrate in 1 litre of water)  
  Heat to 60 °C and mix until the PFA is 
completely dissolved.                                                                                             
  Working solution (pH 6) 
Add 100 ml of 10X PBS and adjust the pH to 
7.4 
 18 ml of Solution A                                                                                                                                                                                               
 Bring the final volume to 1 litre with water.   82 ml of Solution B                                                                                                                                                                                      
 Make the volume till 1 litre with ddH2O  
 
18. FACS Buffer: 10% Fetal Bovine Serum in sterile cell culture grade PBS 
19. Proteinase K Buffer: 10 mM Tris-HCl (pH 8.0),   1 mM EDTA     and 1% Tween  
20. 1% Low Melting Point (LMP) Agarose: Weigh 1 g of LMP Agarose and dissolve 
in 100 ml of Millipore water using a microwave. Autoclave the solution. Warmify 
(Liquefy) before using by keeping the vial immersed in a water bath at 45 °C. 
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4 Methods 
4.1 Molecular Biology Methods 
4.1.1 Measurement of DNA concentration 
The concentration of DNA was determined by measuring the absorbance at 260 nm 
on a  NanoDrop ND 1000 spectrophotometer (Thermo Scientific). The DNA purity 
was controlled by the ratio of absorbance values at 260 nm and 280 nm 
(A260/A280) which should lie between 1.8 and 2. The ratio of A260/A280 lower than 
1.8 indicates protein contamination in the given sample. 
Isolation of DNA from tissue : For isolation of DNA  from murine tissue, the QIAGEN 
DNeasy tissue kit was used according to the included manual. 
4.1.2 Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction (PCR) is used for amplification of specific regions 
of a DNA-target. PCR was performed in a 30 µl reaction mix containing 3 µl of 10X 
Taq-Polymerase buffer, 1 µl of 2mM dNTP-mix, 0.5 µl of 20pmol forward and 
reverse primer and 0.3 µl Taq-Polymerase , filled up with Milli Q water. The PCR 
reaction typically consisted of 20 to 40 repeated temperature changes called  cycles. 
After an initiation step for 10 minutes at 95 degree centigrade  follows a cycling of 
the denaturation step (usually for 30 seconds at 95 degree centigrade), the 
annealing step (temperature for this stage depends on the type of primers that are 
used) and the elongation step (30 sec to 1 minute at 72 °C). Finally before cooling 
down the reaction mix, there is an additional elongation step at 72 °C for 10 minutes. 
All PCR reactions were performed as described above and the details of the 
individual PCR type has been already mentioned in the materials section. 
4.1.3 Agarose-gel electrophoresis of DNA molecules 
Double stranded DNA fragments with a length between 50 bp and 10kbp can be 
separated according to their length on an agarose gel. For this purpose a 
suspension of agarose (0.8-2%) in 1x TAE –buffer was cooked until the agarose was 
completely dissolved.  After cooling to about 50 °C, 0.5 µg/ml Ethidiumbrodium was 
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added before the solution was poured into the gel apparatus. When the gel was 
solidified, the DNA  mixed with loading dye was applied on the gel and 
electrophoresis was performed in 1X TAE buffer at 120 V for 30 min. The DNA 
bands then could be visualized under UV-light. 
4.1.4 Isolation of RNA 
RNA isolation from cells and tissue 
RNA isolation from cells or tissues was performed using TRIzol Reagent (Invitrogen) 
according to the manufacturer‘s instructions. Briefly approx. 100 mg frozen tissue 
was homogenized in 1 ml TRIzol solution with an Ultra-Turrax (IKA) in cold 
enviornment. Phase separation was carried out by adding either 100 µl of BCP 
reagent (MCP) or 200 µl of Chloroform. Subsequently, probes were vortexed for 15 
seconds, incubated at room temperature for 2 to 5 minutes and then centrifuged for 
5 minutes at full speed at 4 °C. RNA contained in the upper aqueous phase was 
precipitated by adding 500 µl isopropanol and centrifuged for 10 minutes at full 
speed at  4 °C. Pellet containing RNA was washed with 70% ethanol, air dried and 
dissolved in DEPC water and was stored at -80 °C. 
Quantification  and determination of the Quality of RNA (RNA yield) 
The concentration of the isolated RNA was determined by measuring the 
absorbance at 260 nm(A260) using a spectrophotometer. An absorbance of 1 unit at 
260 nm equals 44 µg of RNA per ml. The ratio between the absorbance values at 
260 nm and 280 nm , which should be between 1.7 and 2.1, gives an estimate of the 
RNA purity. 
4.1.5 cDNA synthesis 
Total RNA obtained from eukaryotic cells or tissue , was treated with RNase –free 
DNaseI to remove the genomic DNA contamination from the RNA sample. For this 
purpose 1 µg RNA was filled up to a volume of 9 µl with RNase free water and 1 µl 
DNaseI buffer was added to the reaction mix. After pipetting 1 µl of DNase I to the 
sample, the mix was incubated for 30 minutes at 37°C. The reaction was stopped by 
the addition of 1 µl of 25 mM EDTA and heated to 65 °C for 10 minutes. The first 
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strand synthesis was performed , using the sample directly from the DNaseI-
treatment with the fermentas first strand synthesis kit and random hexamer primers 
as described in the instruction manual. The cDNA was used  as a template for RT-
PCR and qPCR respectively. 
4.1.6 Real-time PCR  
Depending on the cDNA quality, 0.5 to 2 µl of cDNA obtained from cDNA-synthesis 
described above was used as a template for real time PCR analysis. 10 µl of 
Finnzymes SYBR Green master-mix, the template cDNA, 0.5 µM of the primers 
specific for the gene of interest or for the house  keeping gene, respectively, and 0.4 
µl of the dye ROX as an internal control were used in a 20 µl reaction. To calculate 
the relative amount of the transcript of the gene of interest , the amplification 
effeciency was raised to the power of the threshold cycle (Ct –value). This gives the 
number of cycles necessary for the product to be detectable. The resulting value 
was normalized to the level of the house keeping gene for all samples in the same 
experiment. Assays were performed in triplicates following the manufacturer‘s 
instructions in an Applied Biosystem set up. 
4.2 Biochemistry methods 
4.2.1 Preparation of whole protein lysates from cells and 
tissues 
Tissues were lysed in ice-cold NP40 buffer with protease and phosphatase inhibitor 
cocktails (Roche) using an Ultra-Turrax (IKA) homogenizer in a cold enviornment. 
After centrifugation for 10 minutes at full speed at 4 degress, supernatant containing 
proteins was transferred into a new eppendorf tube to measure the protein 
concentration. 
4.2.2 Measurement of protein concentration 
Protein concentration was measured by using the BCA protein assay kit ( 23225, 
Thermo Scientific) according to the supplier‘s instructions and using Bovine Serum 
Albumin (BSA) as standard control. 20 to 30 µg of proteins were denatured by 
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mixing with 3x laemmli buffer with beta-Mercaptoethnaol and heated for 10 minutes 
at 95 °C. Protein lysates were stored at -20 °C prior to SDS –PAGE and immunoblot 
analysis. 
4.2.3 SDS PAGE 
SDS PAGE was carried out using the Mini-PROTEAN Tetra Cell system from Bio-
Rad (Catalog number 165-8000). Glass cassettes and electrophoresis modules 
were assembled according to the manufacturer‘s instructions. A resolving gel of 8-15 
% acrylamide was prepared and poured between the two glass cassettes,leaving a 
gap of about 1cm for accomodating the stacking gel. Isopranol was added on top of 
the solution. After the gel was polymerized , isopropanol was removed off. A 
stacking  gel of 5 % acrylamide was prepared and poured over the resolving gel. 
Immediately, a comb with either 10 or 15 wells was inserted and the gel was allowed 
to polymerize. After polymerization the comb was removed and the wells were 
rinsed with water.The gel was placed in the electrophoresis module and the tank 
was filled with 1x SDS-PAGE running buffer. Protein samples were incubated at 95 
°C for 5 minutes and shortly centrifuged . Protein marker (6.5 µl /well) and protein 
samples (20-30 µl /well) were loaded on gel and the electrophoresis was run at 100 
V by using a power pack supply (Bio-Rad) for about 1.5 hour. After electrophoresis 
the gel was removed from the glass cassttes and subjected to western blotting. 
 
Resolving gel                                                                                                                           
Tris 1M pH 8.8 ………………………1.25 ml                                                                                                                                                                             
10 % SDS……………………………….50 µl                                                                                                                                                                                  
10% APS………………………………..50 µl                                                                                                                                                                                  
30% Acrylamide/Bisacrylamide..1.33-2.5 ml                                                                                                                  
Temed…………………………………….3 µl                                                                                                                                                                                      
Milipore water……………………….upto 5ml 
 
Stacking gel                                                                                                                         
Tris 1M pH 6.8 ……………………0.3125 ml                                                                                                                                                                          
10% SDS………………………………..25 µl                                                                                                                                                                          
10% APS…………………....…………..25 µl                                                                                                                                                                                       
30 % Acrylamide/Bisacrylamide…..0.425 ml                                                                                                                                                                     
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Temed…………………………………..2.5 µl                                                                                                                                                             
Milipore water…………………….upto 2.5ml 
4.2.4 Immunoblotting 
After SDS –Gelelectrophoresis , the proteins were transferred by electroblotting from 
the gel to a nitrocellulose membrane. This was carried out using the Mini Trans-Blot 
Electrophoretic Transfer Cell system from BIO-RAD (Catalog no. 170-3930) 
according to the manufacturer‘s instructions. The gel sandwich was prepared by 
placing the materials in the following order: Fiber pad, two to three Whattman filter 
paper , Gel, Nitrocellulose membrane , then  two to three Whattman filter paper and 
finally the Fiber pad again. All were soaked and rinsed with the SD Transblot buffer 
while carrying out this preparation. The sandwich gel was placed in the blotting 
cassette and subsequently submerged in the blotting tank filled with the SD 
Transblot buffer with a cold pack. SDS gels were transferred at 400mA in a blotting 
buffer for 1 hour. After the transfer, the membrane was incubated with blocking 
buffer containing 5% skimmed milk in 1X NET Gelatin for 1 hour at room 
temperature or overnight at 4 °C. To detect the protein of interest , after blocking , 
the membrane was incubated with the primary antibody diluted in 1X NET Gelatin 
(1:50 to 1:10000 concentration, depending on the type of antibody) for 2 hours at 
room temperature or overnight at 4 °C. Before applying the secondary antibody , the 
membrane was washed at least three times for 10 minutes each with 1X NET 
Gelatin. The appropriate peroxide –conjugated secondary antibody was diluted in 
PBS (1:100 to 1:10000 depending upon the type of antibody) and incubated with the 
membrane for 45 minutes at room temperature. An additional washing step was 
performed before the membrane was incubated for 1 minute at room temperature 
with a 1:1 mixture of the ECL-solutions I and II. The incubation of the peroxide 
bound to the secondary antibody with the ECL-solutions leads to the emission of 
light photons , which can be detected on an X Ray film. 
4.2.5  Membrane stripping 
To reprobe the same nitrocellulose membrane with the bound proteins with another 
antibody, it is possible to remove  the primary and secondary antibodies using 
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stripping buffer and incubating the membrane for 30 min at 54°C. Stripping was 
carried out by incubating the nitrocellulose membrane with stripping buffer in a 
shaking incubator. The menbrane was then washed 3x for 10 minutes with Net 
Gelatin, blocked with 5% milk in Net Gelatin for 1 hour at room temperature and 
subsequently re-probed with other primary antibody as described before. 
4.2.6  Eukaryotic cell culture technique 
All handling of cell cultures was performed using a clean and sterile bench and 
under a laminar air flow hood. To the media used for the cell lines used, 10 % Fetal 
calf serum was added and 1% Penicillin/Streptomycin was used to avoid the 
contamination. To passage the adherent cell lines, the cells were washed with PBS, 
treated with Trypsin-EDTA for 3 to 5 minutes, and then splitted in the desired ratio. 
The cultures were kept in an incubator at 37 °C in a humified atmosphere with 5 % 
CO2. Type II cells are cultured in a special medium  from clonetics® ie the BEGM 
medium supplemented with growth factors and other additives that includes Insulin, 
Hydrocortisone,Transferrin, Retinoic Acid, Epinephrine, and Triodothyronine. 
4.2.7  Freezing cell lines 
By addition of an anti-freezing compound like DMSO, eukaryotic cell lines can be 
stored in liquid nitrogen for several years. For this purpose, the trypsinized cells 
were spun down in a centrifuge (1000 rpm, 5 minutes, room temperature), the pellet 
was washed with PBS , counted using a Neubauer chamber and diluted in ice cold 
medium containing 20 % FCS and 10% DMSO to obtain at least 1-2x 106 cells per 
ml. 1 ml of this suspension was then transferred into a cryotube and stored at -80 °C 
for at least 24 hrs. For prolonged storage the cryotubes were then transferred to 
liquid nitrogen. 
For reculturing of the frozen cells, the cell suspension was defrosted at 37°C and 
immediately put into prewarmed medium.To remove the toxic DMSO, the cells were 
spun down (1000 rpm, 5 min, 37°C) and the pellet was resuspended in warm 
medium and cultured at 37 °C as described before. 
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4.2.8 Analysis of cultured cells via immunocytochemistry 
For immunocytochemical staining of cultured cells, the cells were grown on sterile 
coverslips, washed three times with PBS and fixed for 15 minutes at room 
temperature using 4% PFA-PBS. After fixation , the cells were washed three times 
for 5 minutes with PBS and permeabilized with 0.5% Triton X- 100 in PBS for 15 
minutes at room temperature and then washed two times with PBS. Thereafter the 
cells were blocked with blocking  solution containing the blocking reagent (consisting 
of 5% donkey serum, 0.2%Triton X-100 in PBS) for 2 hour at room temperature. The 
primary antibody (Goat polyclonal anti DsRed , Santacruz (1:50) and Rabbit 
polyclonal anti-human proSpC (1:500) was diluted in the blocking solution and the 
cells were incubated at 4°C overnight. Next day the cells were washed three times 
for 5 minutes each with PBS. Secondary antibody (Donkey anti-goat Cy 5 and 
Donkey anti-rabbit Cy 3) was diluted (1:200)  in the blocking solution and the cells 
were incubated for 2 hours at room temperature. After secondary antibody 
incubation, the cells were again washed with PBS , three times  for 5 minutes each. 
The cells were then counterstained with DAPI diluted to 1:200 in PBS at  room 
temperature for 15 minutes. After washing with millipore water, the cells were 
mounted with mowiol and stored at 4 °C until analysed under a Fluorescent 
Microscope. 
 
4.3 Histological methods 
4.3.1 Paraffin-embedding and sectioning of tissue 
Animals were sacrificed and lungs were fixed under 25 cm water pressure with 4 % 
buffered paraformaldehyde and paraffin embedded. Tissue was placed in proper 
embedding cassettes and paraffin embedding was carried out as follow. 
Paraffinization requires essentially three steps: dehydration, clearing and 
embedding. Dehydration process was achieved by passing the tissue through a 
series of increasing alcohol concentrations, the detailed steps were: 1 hour in 50% 
ethanol, 1 hour in 70% ethanol, 1 hour in 80% ethanol, 1 hour in 90% ethanol and 2 
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times for 1 hour in 100% ethanol. Clearing refers to the use of an intermediate fluid 
that is miscible with ethanol and paraffin since these two substances are immiscible. 
This step was carried out by passing the tissue, twice for 30 minutes, through a 1:1 
mixture of xylol and ethanol and subsequently 2 times for 30 minutes in xylol only. 
All these steps were performed at room temperature in an automated tissue 
processor (Shandon Citadel 2000). For embedding procedure the tissue was 
transferred into melted paraffin and incubated for 1 hour at 65°C and then in fresh 
paraffin for 2 hours or overnight at 65°C. Finally, the tissue was placed into an 
embedding mold and melted paraffin was poured into the mold to form a block. After 
cooling down the blocks were ready for sectioning. Tissue blocks were sectioned in 
6 µm sections by using a manual rotary microtome (Leica RM2235).  Embedding of 
mouse embryos was essentially carried out as already described except that 
chloroform was used instead of xylol and that the last step of paraffin incubation was 
prolonged to 5-7 days. Embryos tissue blocks were sectioned in 10 µm 
microsections.     
  4.3.2 Optimal cutting temperature (O.C.T.) - embedding 
and cryosectioning of tissue 
The fresh tissue was washed with PBS and fixed in 4% PFA in PBS at 4°C 
overnight. After washing with PBS, the tissue was transferred into 30% sucrose in 
PBS and incubated at 4°C until the tissue had fallen to the bottom of the tube owing 
to density. Before embedding on dry ice with OCT (Tissue-Tek), the tissue was 
washed with PBS. The blocks were sectioned into 6-10 µm micro-sections and used 
for further histological analysis. The blocks and the sections were stored at -80 °C 
until use. 
4.3.3 Haematoxylin and Eosin Staining 
For histological analysis of paraffin embedded sections, the tissue was stained with 
H&E. As indicated in first the paraffin has to be removed from the sections, then the 
tissue is stained with H&E, dehydrated and mounted with Entellan. 
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Reagent Incubation time 
Xylol 10 minues each two times 
100 % Ethanol 5 minutes  each three 
times 
70 % Ethanol 10 minutes 
Millipore water 5 minutes 
Hematoxylin 30 seconds 
Tap water 5 minutes 
Millipore water 5 minutes 
Eosin 20 seconds 
Millipore water 5 minutes 
70 % Ethanol 10 minutes 
100 % Ethanol 5 minutes each three times 
Xylol 10 minutes each two times 
4.3.4 Immunohistochemical stainings (Enzymatic based 
detection) 
After deparaffinization of the slides , apart from H&E staining , the paraffin sections 
can be stained immunohistochemically using a specific antibody inorder to detect an 
antigen/protein of interest. For this purpose, an antigen retrieval step was performed 
using 10mM Sodium citrate buffer, pH 6.0 and cooking the tissue in the microwave for 
few minutes ranging from 6 minutes to 30 minutes. After cooling down at room 
temperature for at least 30 to 45 minutes, the sections were washed with tap water 
and three times for five minutes each with PBS. Before incubation with the primary 
antibody , the sections were blocked for few hours ( from 30 minutes to 2 hours) at 
room temperature with the appropriate serums and Triton X-100 in PBS. The primary 
antibody is diluted in the blocking solution in appropriate concentrations and was 
incubated at 4°C overnight. Next day the sections were washed three times for five 
minutes each with PBS. The secondary antibody  (biotinylated) was diluted 1:200 in 
blocking solution and the sections were incubated for 1 to 2 hours. The A+B reagent 
was mixed at 1:1 ratio and 30 minutes later applied on the sections for 40 minutes at 
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room temperature. Before that the sections has been washed again three times with 
PBS. After incubation, the sections were washed again three times for five minutes 
each with PBS and incubated with DAB (1ml DAB + 0.8ul of 30% H2O2, Hydrogen 
peroxide) until the appearance of brown colour.The reaction was stopped with tap 
water for 5 minutes and afterwards the tissue was counterstained shortly with 
hematoxylin , washed with tap water, dehydrated and mounted with Entellan. The 
sections were then air dried until visualized under a Bright field Microscopy system. 
Antigen 
Antigen 
retrieval 
Blocking solution 
Primary 
antibody 
Secodary 
antibody 
DsRed 
Citrate 
buffer,15 
min. 
5% Rabbit  serum,                    
0.2% TritonX-100 in PBS 
Goat polyclonal 
anti-DsRed  
Santa Cruz 
(1:100) 
Rabbit anti 
goat 
biotinylated 
Cre 
Citrate 
buffer,15 
min. 
10% Goat serum, 
0.2%Tween 20 in PBS 
Rabbit anti Cre 
Novagen  
(1:5000) 
Goat anti 
rabbit 
biotinylated 
pro SpC 
Citrate 
buffer,10 
min. 
5% Goat serum,                 
0.2% Triton X-100 in PBS 
Rabbit anti-pro 
SpC  Whitsett 
(1:5000) 
Goat anti 
rabbit 
biotinylated 
c-Myc 
Citrate 
buffer,15 
min. 
4% Goat serum,                 
0.2% Triton X-100 in PBS 
Rabbit anti- c Myc 
(SC- 764) Santa 
Cruz  (1:100) 
Goat anti 
rabbit 
biotinylated 
pERK 
Citrate 
buffer, 
10min. 
5% Goat serum,                 
0.2% Triton X-100 in PBS 
Rabbit 
monoclonal anti-
pERK Cell 
signalling (1:100) 
Goat anti 
rabbit 
biotinylated 
C Raf 
Citrate 
buffer, 
10min. 
5% Rabbit serum,                 
0.2% Triton X-100 in PBS 
Mouse 
monoclonal anti-
Raf 1(E 10) Santa 
Cruz (1:100) 
Rabbit anti 
mouse 
biotinylated 
Aquaporin 5 
Citrate 
buffer,6 min. 
4% Goat serum,                 
0.2% Triton X-100 in PBS 
Rabbit polyclonal 
anti-Aquaporin 5  
Alomene Aqp-005 
(1:1000) 
Goat anti 
rabbit 
biotinylated 
Ki 67 
Citrate 
buffer,15 
min. 
5% Goat serum  in PBS 
Mouse anti-Ki67, 
MM1 Vector lab 
(1:50) 
Goat anti 
mouse 
biotinylated 
PGP 9.5 
Citrate 
buffer,12 
min. 
4% Goat serum,                 
0.2% Triton X-100 in PBS 
Rabbit anti-
human PGP  9.5  
Serotec (1:6000) 
Goat anti 
rabbit 
biotinylated 
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HA Tag 
Citrate 
buffer, 15 
min. 
5% Rabbit serum,       
0.2% Triton X -100 in  
PBS 
Rat monoclonal 
(clone 3F10) anti-
HA Roche  
(1:500) 
Rabbit anti-
Rat 
biotinylated 
TTF-1 
Tris EDTA 
Buffer, 20 
min. 
5% Rabbit serum, 0.1% 
Triton X-100 in PBS 
followed by 
Streptavidin/Biotin 
Blocking 
Mouse 
monoclonal anti-
rat TTF-1 (1:100) 
Goat anti 
mouse 
biotinylated 
Pecam-1 
Proteinase 
K buffer, 12 
min. 
2% Rabbit serum, 0.2% 
Triton X -100in PBS 
Rat anti-Pecam 1 
BD Pharmingen 
(1:200) 
Rabbit anti-
Rat 
biotinylated 
E Cadherin 
Citrate 
buffer, 15 
min. 
10% Goat serum in PBS 
Rabbit polyclonal 
E Cadherin Cell 
signalling (1:500) 
Goat anti 
rabbit 
biotinylated 
Cytokeratin 
Citrate 
buffer, 15 
min. 
5% Goat serum, 0.2% 
Triton X-100 in PBS 
Polyclonal rabbit 
anti-cow 
Cytokeratin 
(1:400) 
Goat anti 
rabbit 
biotinylated 
Cleaved 
Caspase 3 
Citrate 
buffer, 20 
min. 
5% Goat serum, 0.1% 
Tween-20 
Rabbit 
monoclonal anti-
Caspase 3 Cell 
Signaling (1:200) 
Goat anti 
rabbit 
biotinylated 
p53 
Citrate 
buffer, 12 
min. 
5% Goat serum in PBS 
Rabbit p53 (CM5) 
Vector (1:200) 
Goat anti 
rabbit 
biotinylated 
CCSP 
Citrate 
buffer, 12 
min. 
4% Rabbit serum, 0.1% 
Triton X-100 in PBS 
Goat anti-CCSP 
(sc-9773) Santa 
Cruz (1:2000) 
Rabbit anti 
goat 
biotinylated 
GATA4 
Citrate 
buffer, 
20min. 
4% Rabbit serum, 0.2% 
Triton X-100 in PBS 
Goat polyclonal 
GATA-4  (C-20) 
sc-1237  Santa 
Cruz (1:200) 
Rabbit anti 
goat 
biotinylated 
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4.3.5 Alcian Blue Staining                                                                                                                   
Reagents needed             
3% Acetic acid 
solution 
Alcian blue solution, pH 
2.5 
Acetic acid, 3 ml Alcian blue, 8GX, 1gram 
Distilled water, 97 ml 
Acetic acid, 3 % solution, 
100 ml 
Mix well and adjust the pH to 2.5 using Acetic acid. 
0.1%  Nuclear Fast Red 
solution 
Nuclear Fast , 0.1gram 
Aluminium sulphate, 5 gram 
Distilled water, 100 ml 
 
Dissolve aluminium sulphate in water. Add Nuclear Fast Red and slowly heat to boil 
and then cool.Filter Alcian blue and Nuclear Fast Red before use. 
Procedure:                                                                                                                                
Deparaffinization of the section was carried out like other staining procedures. The 
slides were then kept in millipore water.The slides were then incubated with Alcian 
Blue 2.5 solution for 30 minutes at room temperature. After that the slides were 
washed under tap water to get rid of the excess stain. The slides were then incubated 
with Nuclear Fast Red solution for 3 to 5 minutes. Again they were rinsed under tap 
water, subsequently dehydrated with a graded series of alcohols and xylol and then 
finally mounted with Entellan. 
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4.3.6  Immunofluorescence stainings  
Antigen/Stai
ning type 
Blocking 
solution 
Primary antibody Secodary antibody 
DsRed 
5% donkey serum, 
0.1%Triton X-100 in 
PBS 
Rabbit polyclonal anti 
DsRed, Clonetech, 
1:500 
Donkey anti Rabbit 
Cy5  
DsRed/SpC 
5% donkey serum, 
0.2%Triton-X 100 in 
PBS 
Goat polyclonal anti-
DsRed, Santa Cruz 
(1:50) 
Rabbit polyclonal anti 
human-Pro SpC 
(1:500) 
Donkey anti goat Cy5  
Donkey anti rabbit Cy3  
CCSP/DsRed 
4% donkey 
serum,0.1% Triton 
X-100 in PBS 
Rabbit polyclonal anti 
DsRed, Clonetech, 
1:500 
goat polyclonal CC10 
(S-20), Santa Cruz 
(1:500) 
Donkey anti rabbit Cy3 
Donkey anti goat Cy5 
SpC/CCSP 
4% donkey serum, 
0.2% Triton X-100 
in PBS 
Rabbit anti-pro SpC , 
Whitsett(1:4000) 
goat polyclonal CC10 
(S-20), Santa Cruz 
(1:2000) 
Donkey anti rabbit Cy3 
Donkey anti goat Cy5 
 
4.3.7  X Gal staining on frozen sections 
Reagents                                                                                                                                  
1.Fixation solution 
0.5% Glutaraldehyde                                                                                                                                                                            
100mM EGTA , pH7.3                                                                                                                                                                                             
1 M MgCl2                                                                                                                                                                                                                     
0.1M Sodium Phosphate buffer, pH 7.3 
 
2.Wash Buffer 
1M MgCl2                                                                                                                                                                                                        
1% Deoxycholate                                                                                                                                                                                        
2% NP40                                                                                                                                                                                                        
0.1M Sodium Phosphate buffer, pH 7.3 
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3.X Gal staining solution (to be freshly prepared and stored in dark) 
X Gal stock @ 1mg/ml                                                                                                                                                                      
Potassium Ferrocyanide                                                                                                                                                                      
Potassium Ferricyanide                                                                                                                                                                           
Wash buffer 
 
Procedure:                                                                                                                                                                                                  
Air dry the  frozen tissue section for about 30 minutes at room temperature. Incubate 
the slides with the fixative solution for 15 to 20 minutes in 4°C. Wash three times for 
five minutes each with the wash buffer. Incubate the slides in the staining solution at 
37°C /humidified chamber in dark for as long as 4 to 18 hours. Observe the 
appearance of blue colour in the tissue sections. Subsequently wash the sections 
three times with wash buffer. Counter-stain  with Nuclear Fast Red  staining solution 
for 30 seconds. Rinse with tap water to get rid off the excess stain. Dehydrate in a 
graded series of alcohol and then Xylol. Mount the sections with Entellan and store 
the sections at 4 °C for better retention of the signal. 
4.3.8  X Gal staining of FACS sorted DsRed cells  
The left over cells obtained after sorting for DsRed were stained with X Gal to detect 
the presence of the Lac Z transgene. The cells were cultured on a coverslip. Media 
was removed and the cells were gently washed with sterile PBS. The cells were then 
incubated with fixative solution for 10 minutes at 4 °C. After fixation the cells were 
rinsed gently with wash buffer. Subsequently the cells were incubated with the X Gal 
staining solution at 37 °C in a humified chamber in dark for about 4 hours to 18 
hours. Later the cells were washed with wash buffer for 10 minutes at room 
temperature , and then the coverslips were removed from the cell culture plate and 
were mounted with Entellan and  stored at 4 °C. 
4.3.9  X-Gal : Whole mount tissue preparation  
Reagents required: 
1.FIX Solution (for 50 ml) 
25% Glutaraldehyde...................................................0.4 ml                                                                                                                                                                                               
100 mM EGTA, pH 7.3…………………………………..2.5ml                                                                                                                                             
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1M MgCl2…………………………………………………..01ml                                                                                                                                                                                                           
0.1 M Sodium Phosphate buffer, pH 7.3……………....47 ml 
 
2.Wash buffer (for 200 ml) 
1 M MgCl2………………………………………………...0.4 ml                                                                                                                                                       
1%Deoxycholate……………………………………………2ml                                                                                                                                                                              
2%Nonidet-P 40…………………………………………….2ml                                                                                                                                                                                                        
0.1 M Sodium Phosphate buffer, pH 7.3……………195.6ml 
 
3.X Gal staining solution (for 50 ml) 
Potassium ferrocyanide………………………………..0.016g                                                                                                                                       
Potassium ferricyanide………………………………...0.082 g                                                                                                                                                               
Wash buffer………………………………………………...48ml                                                                                                                                                                                            
X Gal @ 1mg/ml…………..1.25 ml from a stock of 40mg/ml 
Prepare a 40 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-galactosidase stock in 
dimethylformamide. Dispense into 5-ml aliquots, and store at −20 °C. 
Procedure 
The organs were dissected and fixed in the fixative solution for 1 hour at 4 °C. After 
fixation, they were rinsed three times with the wash buffer by gentle shaking. Then 
the organs were incubated overnight with the X Gal staining solution at 37 °C in 
dark. Next day they were again post fixed with 4%PFA for 1 hour in dark. 
Subsequently tissues were washed with PBS, three times for 5 minutes each, 
transferred to 70 % Ethanol at 4 °C, and finally subjected to normal paraffin 
embedding procedures. 
4.3.10  FACS sorting of DsRed cells from triple transgenic 
reporter mice 
Procedure:         
Anesthesize the mice with Ketamin/Rompun formulation. The mice were sprayed 
with 70% alcohol. An incision was made over the rib cage. After that 10 ml of cold 
saline solution was injected through the right ventricle until the lungs were cleared 
off from blood. The trachea was exposed  using a forecep placing beneath it. Tip of 
the needle was inserted, all the way into the trachea and was tied securely with a 
thread to keep the trachea and the needle intact in the right position. 5 ml of Dispase 
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was injected via the trachea followed by warm 1% LMP Agarose (approx. 0.5 to 1 
ml). The animal was immediately  covered with ice for 2 minutes to let the agarose 
harden. The lung was dissected out  and placed in a 50 ml falcom tube containing 6 
ml of PBS (sterile cell culture grade) in cold. Enzymatic digestion of the lung was 
carried out by the addition of collagenase/dispase, agitated for 45 minutes  at 37 °C 
on a shaker. After the incubation, the lung was squeezed gently like a tea bag using 
a forcep until it was turned into a mass of suspension, leaving behind only 
connective tissue. At this stage , DNase I was added. The digested tissue was 
placed on ice for 5 minutes. Subsequently the digested  tissue suspension was 
filtered through 100 µm and then via 40 µm cell strainer to obtain a clear single cell 
suspension. The suspension was collected in a 50 ml falcom tube, centrifuged at 
800 rpm for 8 minutes in 4°C. A soft pellet was obtained. The supernatant was 
discarded. The pellet was resuspended in 2 ml of FACS buffer and was proceeded 
for FACS sorting (DsRed sorting was carried out in FLH-2 channel of the BD FACS , 
caliber). The sorted cells were collected in a special BEGM medium and cultured on 
matrigel coated plates.  
4.4 Animal Experiments   
4.4.1 Generation of reporter transgenic mouse lines for 
lineage tracing experiments 
To begin with the experiments; required the generation of transgenic mice with the 
reporter line (DsRed). This was carried out by breeding of single transgenic mice 
with several others in combination to obtain the final mice which can be utilized for 
the preliminary and future experiments. The details of the mating schemes has been 
described in the results section (5.1.2).  
4.4.2 Breeding of mice 
Mating was started when female and male mice were at least 4 and 6 weeks old, 
respectively. Often two females were bred together with one male. Matings were 
stopped by separating the males from the pregnant female after approx. 2 weeks. 
New born pups were weaned from the mother at the age of 3 to 4 weeks. At this 
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point of separation,  individual mouse was marked by an earmark (clip) and a tail 
biopsy was taken for genotyping. 
Animals 
All animal experiments were performed according to the regulations of the Bavarian 
State authorities. Mice were maintained as a specific pathogen-free in-house colony. 
Mice were allowed food and water ad libitum and maintained on a 12-hour/day 
light/dark cycle. Animals used in this study were from two to 24 months old. Animals 
were sacrificed via cervical dislocation unless described differently. 
Mice harboring the Lac Z floxed -DsRed recombination substrate (RS) transgene on 
a C57BL/6J background were purchased from The Jackson Laboratory and 
maintained by mating hemizygous individuals. Transgene positive mice were 
identified by PCR analysis of tail DNA using primers specific for the LacZ and the 
DsRed coding sequences. Bitransgenic SpCrtTA/ Tet O Cre mice were generated by 
breeding homozygous or hemizygous SpC rtTA with the Tet O Cre founder lines. 
Triple transgenic SpC rtTA/Tet O Cre/DsRed mice were generated by breeding 
hemizygous DsRed reporter transgenic mice with hemizygous bitrangenic 
SpCrtTA/Tet O Cre mice and the progeny were genotyped for the presence of 
individual transgenes. The details of the compound reporter transgenic animals 
generated are described in the results section. 
4.4.3 Genotyping of transgenic mice 
For obtaining DNA for genotyping, the mouse tails were cut (less than 1 cm)  during 
the age of 3 to 4 weeks and the mice were marked by earclips. The tails were lysed 
by the addition of 190 µl of tail lysis buffer and 12 µl of  0.4 mg/ml Proteinase K and 
incubated overnight at 54 °C. The resulting lysate was then centrifuged at 10000 
rpm for 15 minutes and the resulting supernatant was diluted 1:10  or 1:40 with 
distilled/autoclaved water. This was used as a template for a PCR reaction as 
described above  with primers for genotyping in the material section. In some cases 
a preliminary step of DNA isolation followed by PCR detection was necessary. DNA 
isolation was carried out by adding to tail lysates 250 µl lysis buffer and 250 µl of 
saturated NaCl (approx. 5 M NaCl). The mixture was mixed by inversion approx. 10 
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times, incubated for 5 minutes at room temperature and centrifuged at full speed for 
10 minutes. The supernatant was transferred into new 1.5 ml tube and DNA was 
precipitated by adding 600 µl of Isopropanol. The sample was throroughly mixed by 
inverting the tube several times, then incubated for 5 minutes at room temperature 
and centrifuged at full speed for 10 minutes. Supernatant was discarded and the 
pellet containing DNA was washed by adding 1 ml of 100% ethanol and 
centrifugation at full speed for 5 minutes. Finally, the pellet was air-dried for 10-15 
minutes at room temperature and resuspended with 50 -100 µl of sterile water. This 
DNA solution was diluted 1:10 or 1:40 with sterile water and used as a template for 
PCR reaction as decribed in materials section using the genotyping primers reported 
in section (3.1.6). 
4.4.4  Sacrification of mice 
Mice  were euthanized with a lethal intraperitoneal injection of Ketamin and Rompun 
in 0.9% NaCl. After the loss of righting reflex, mice were perfused by intra-cardiac 
injection of PBS  into the left ventricle of the beating heart to get rid off the excess 
blood, and the organs were then dissected out. For isolation of organs for RNA and 
protein purposes, the animals were not perfused and the organs were directly 
removed out and were immediately snap frozen in liquid nitrogen and stored at -80 
°C until use. 
4.4.5 Transplantation – experiments 
For subcutaneous injection of the DsRed tumor cells , the cells were washed two 
times with sterile PBS after trypsinization and were  counted. 106 cells were 
subcutaneously injected in 100 µl of sterile Matrigel solution into Rag-/- mice. The 
appearance of tumor and tumor size was measured weekly and the animals were 
sacrificed when the first tumors in the different groups were close to 2 cm of 
diameter. Under anaesthetic conditions the animals were perfused using 4 % PFA –
PBS  and the primary tumors, lungs, livers and lymph nodes  were collected for 
histology. 
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4.5 Statistical Analysis 
Statistical analysis of data sets were performed using the Graphpad Prism version 
4.0 software. Differences among the groups were compared with Students‘s t test. 
Results are presented as means +/- SE. All P values were two tailed. For all test, the 
statistical significance was considered to be at P<0.005. Survival graphs were 
generated by Kaplan-Meier method. The statistical significance between proportions 
was determined by the log rank test. 
 
Results 
73 
 
5 Results 
5.1 Transgenic reporter mice for lineage labeling studies in 
a murine NSCLC model 
The ability to introduce lineage tags within selective progenitor cell populations in 
vivo provides tools to unambiguously define the contribution that differential 
progenitor cell utilization makes toward altered epithelial cell function and its 
involvement in malignant progression. Towards this context, the goal of this project 
was to select a suitable tag that can be monitored easily in live cells, in tissues and 
which can be exploited for imaging purpose. Once such tag was confirmed for its 
feasible detection, we can utilize it for the generation of transgenic compound 
reporter mice for lineage tracing studies. For this purpose several reporter mice were 
tested for the suitability in the detection of the reporter molecule in the organs of the 
transgenic mice (data not shown). The preliminary results strongly indicated that 
DsRed would be the best choice to label cells, since it displays no signs of auto- 
fluorescence in the tissues observed and can be exploited for imaging studies. 
Hence, LacZ/DsRed reporter mice were decided to be utilized for all our future 
experiments.  
5.1.1 The Red Fluorescent protein (RFP) mice 
The Lac Z/Red transgenic mice express beta-galactosidase (lacZ) under the control 
of the chicken beta actin promoter coupled with the cytomegalovirus (CMV) 
immediate early enhancer. When crossed with a Cre recombinase-expressing strain, 
lacZ expression is replaced with red fluorescent protein (DsRed*MST) expression in 
tissues expressing Cre recombinase. 
5.1.2 Generation of compound transgenic reporter mice for 
lineage tracing experiments 
Once the reporter mice are validated; next begins the generation of compound 
transgenic mice with a combination of oncogenes under a DsRed reporter 
background for lineage tracing studies.  
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For lineage tracing of mouse alveolar type II cells we chose to use the Cre-loxP 
system, which is an effective method for expressing or deleting a target gene in Cre-
expressing cells. We introduced a mouse line in which a 37 kb human Surfactant 
Protein C (SpC) promoter drives the expression of Cre. We used this allele, in 
combination with the lacZ/DsRed reporter, to lineage trace type II cells in adult mice. 
With this strategy, we generated a series of compound mouse lines expressing Cre 
recombinase from specific lung alveolar epithelial type II cell promoter, SpC in 
combination with an inducible form of oncogenic C RAF (Tet O C RAF BXB) and a 
mouse line where SpC drives the expression of c Myc (Fig 8.1 and Fig 8.2). 
Beginning from one single transgenic mouse, via successive and continuous rounds 
of multiple breeding schemes, we were successful in obtaining more than 100 
compound reporter animals for our experiments in a span of 1 year. Once the 
compound animals were ready, Doxycycline was administered orally via food; 
(occasionally with water when the animals were being transported in a different 
animal facility) and targeted cells were identified by a series of experimental 
procedures that will be described in the following pages. 
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Fig 8.1 Mating scheme of the transgenic animals to obtain the basic lineage of 
compound mice with an integration of the reporter gene (1) and the oncogenes that 
includes c Myc (2a) and an inducible C RAF BXB (2b).The resulting progeny 
obtained is the triple transgenic compound mice that have a common backbone of 
the promoter/transactivator elements (SpC rtTA/Tet O Cre).  
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Fig 8.2 Mating schemes of the triple transgenic reporter mice to obtain a quadra transgenic 
reporter mice incorporating c Myc (3) and Tet O C RAF BXB (4). A final breeding was 
performed to obtain penta transgenic reporter mice with the intergration of both the 
oncogenes c Myc and Tet O C RAF BXB with a reporter line of DsRed (5). 
 
In the present study, we utilized transgenic mice in which the human SpC gene 
promoter is used to express the reverse tetracycline transactivator (rtTA) thus 
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placing the expression of Cre-recombinase (CRE) under conditional control of 
doxycycline. Expression of Cre was used to permanently label cells with Red 
fluorescent protein (DsRed) in subsets of respiratory epithelial cells in the conducting 
airways.  Distinct lines of transgenic mice that expresses rtTA under the control of 
the human SpC gene promoter were bred to Tet O Cre mice and reporter mice 
(LacZ/DsRed) creating triple transgenic mice as SpCrtTA/Tet O Cre /DsRed (here in 
designated as DsRed) in which respiratory alveolar epithelial cells permanently 
expressed DsRed after doxycycline induced recombination (Fig 9.1 and 9.2). Once 
we obtained triple transgenic reporter mice, multiple rounds of successive breeding 
with the oncogenic mice gave rise to Quadra  as SpCrtTA/Tet O Cre /SpC c Myc/ 
DsRed (Fig 8.2-3 here in designated as Myc-DsRed) and SpCrtTA/Tet O Cre /Tet O 
C RAF BXB/ DsRed (Fig 8.2-4 here in designated as C RAF BXB-DsRed)  and 
penta transgenic as SpCrtTA/Tet O Cre /Tet O C RAF BXB/SpC c Myc/ DsRed (Fig 
8.2-5 (here in designated  as Myc-BXB-DsRed)  were obtained. 
5.1.3 Testing of the compound reporter transgenic mice 
generated for the expression of the reporter gene  
To validate the specificity of our targeting strategy; we first began to analyze the 
triple transgenic reporter mice i.e. DsRed.  Adult mice lungs were harvested 2 weeks 
following Dox induction and were processed for paraffin embedding and Cryo 
fixation. Sections of lung tissue were stained for X Gal and DsRed was visualized via 
immunohistochemical and Immunofluorescence staining procedures. 
5.1.3.1 Lung targeted expression of the reporter gene in the DsRed mice.  
A Lac Z and DsRed expression in the lung   
Lungs from the DsRed mice were analysed for the expression of the reporter 
molecules that includes lac Z and DsRed.The X gal staining revealed the presence 
of Lac Z +ve cells in the bronchiolar region of the lung (where Clara cells are 
predominant) including areas that were devoid of type II cells. Whereas the lung 
section from the whole mount tissue processed for Lac Z activity, displayed those 
regions which were negative for the blue colour (Lac Z) in the form of a pink colour 
stain due to Nuclear fast Red stain. Rest region of the lung parenchyma is 
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completely blue (Fig 9.1). Subsequentl, DsRed staining was performed on an X Gal 
whole mount lung section. The lac Z negative cells are indeed DsRed cells as 
depicted from the staining results (Fig 9.1 lower panels). Histochemical detection for 
the DsRed was carried using an anti-DsRed antibody via standard 
immunohistochemical and Immunofluorescence staining procedures as described in 
the methods section. Lungs were harvested, processed for paraffin and cryo 
embedding; sections were stained and were visualized using bright field and 
fluorescent microscope. DsRed staining on frozen sections revealed many distinct 
cells positive for DsRed (Fig 9.2) whereas staining on a paraffin-embedded section 
also displayed the same pattern of DsRed expression, which morphologically 
resembles a type II cell. DsRed was exclusively observed in cells lining the alveolar 
epithelium (Fig 9.2).  
 
Fig 9.1 Lung targeted expression of the reporter gene (DsRed and Lac Z). X gal staining on 
frozen lung sections shows the bronchiolar Clara cells positive for Lac Z (in blue). Lung 
section derived from a whole mount tissue for X Gal shows the region that express lac Z (in 
blue colour; arrows indicated) and the cells negative for the lac Z expression (in pink). 
DsRed immunostaining depicts the DsRed positive cells (in arrows) in the alveolar 
distribution pattern. DsRed immunostaining on the X Gal mounted lung sections shows 
DsRed positive cells (in brown) on a lac Z background (in blue). Scale bar = 100 μm  
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Fig 9.2 DsRed expression in lungs of the induced DsRed transgenic mice. Formalin fixed 
lung sections depicting DsRed cells (brown). Frozen lung section depicting DsRed cells 
(red). Scale bar = 100 μm  
 
B DsRed and Lac Z co-immunofluorescence staining of the lung 
With the findings that many lineage tagged cells (DsRed +ve) were detected in the 
alveolar epithelium, there comes another interesting aspect of our labeling pattern. 
We were not able to detect any DsRed +ve cells in the bronchioles (Fig 9.3 A). This 
suggests that we are specifically able to mark only type II cells whereas the Clara 
cells are rendered negative for the lineage tag. Double immunofluorescence staining 
on the cryo-embedded lung sections with an antibody for beta Galactosidase and 
DsRed , revealed that those cells which are positive for DsRed  showed the absence 
of Lac Z and vice versa ( Fig 9.3 B).  
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Fig 9.3 Reporter gene is expressed in the type II cell specific fashion. Representative 
immunofluorescence staining images for DsRed (A) and DsRed/β-gal (B) on cryoembedded 
lung section from a non neo-plastic DsRed mouse shows the region displaying the 
bronchiolar epithelium. Note that the Clara cells in the bronchioles are negative for the 
DsRed expression (A) whereas expressed lac Z in the same (B). Scale bar = 100 μm  
 
C  Alveolar type II cells are selectively targeted by cell type-restricted Cre 
To confirm that the SpCrtTA/Tet O Cre/DsRed - switched cells are in fact type II 
cells, it becomes important to analyze for the Cre expression via induction. In 
addition, to be sure that the cells that we are targeting are type II, one has to 
evaluate the expression of SpC, a potent marker for type II cells of the lung. Lungs 
from induced and non-induced triple transgenic mice were viewed unstained for the 
detection of any DsRed positive cells, under a confocal laser-scanning microscope. 
As expected, the induced mice displayed many DsRed positive cells whereas the 
uninduced ones lacked the expression (Fig 10.1). This suggests that the Cre is not 
leaky in our transgenic system.  
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Fig 10.1 Unstained lung sections from the DsRed mice viewed under the RFP channel.The 
induced mice showed many DsRed +ve cell whereas the uninduced one lacks the 
expression. 
 
Furthermore to find out the tissue specificity for the expression of lineage marker; 
protein lysates from the different organs (Kidney, brain and liver) of the induced 
animals were analysed for the DsRed expression. As shown in the immunoblot, 
DsRed is expressed only in the lung whereas the rest organs were found to be 
negative for the expression (Fig 10.2). This data suggest that with our labeling 
strategy, we were able to target the pulmonary cells only, which says that the 
labeling system is tightly regulated. 
 
Fig 10.2 Lung targeted expression of the DsRed reporter. Immunoblot for DsRed protein 
expression in the tissue obtained from the induced DsRed mice 
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D   SPC and DsRed co-localization in the lung 
To further confirm that the SpC rtTA/Tet O Cre/DsRed switched cells are alveolar 
type II cells, we stained 10 mm thick cryosections with an anti-DsRed and a proSpC 
antibody. As expected, DsRed cells colocalized with SpC+ve cells in the airway 
epithelium (Fig 10.3 C). The same sections were stained with pro SpC, DsRed and 
with an anti-Cre antibody individually. The lung displayed abundant SpC (Fig 10.3 
A), and Cre (Fig 10.3 B) in almost similar fashion. Taken together these results 
confirm that Cre-mediated recombination is confined to a specific cell population as 
dictated by the promoter utilized. 
 
Fig 10.3 DsRed reporter gene is expressed in the alveolar type II cell compartment. 
Immunostaining for (A) SpC and (B) Cre on paraffin embedded lung sections. Double 
immunofluorescene staining for SpC and DsRed on cryo embedded lung sections display 
the colocalization of SpC cells with DsRed. Inset shows it in high magnification. Scale bar = 
100 μm 
5.1.3.2 FACS sorted DsRed cells cultured on matrigel  
One of the advantages of lineage tagging is that it provides an opportunity to obtain 
a purified population of cell enriched with the reporter tag. The cells obtained can be 
processed for vital experiments which can decipher their properties in detail, 
multilineage differentiation potential and transplantation experiments. Flow cytometry 
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has allowed to obtain pure cells based on the marker that is expressed by the 
desired cell of interest. Utilizing this strategy, we have sorted type II cells based on 
DsRed expression in the FLH 2 channel of the BD FACS Calibur. Lungs from the 
non-neoplastic DsRed mice were dissected, enzymatically digested and filtered to 
obtain a single cell suspension that was subjected for sorting via FACS.  
The DsRed+ve cells were cultured on a matrigel layer in a special BEGM medium. 
The cells appeared round in shape and were always found to retain the lineage 
marker, DsRed (Fig 11.1 A).  
 
Fig 11.1 (A) DsRed sorted cells from induced DsRed mice; cultured on matrigel. 
 
The DsRed-ve population obtained was also cultured under similar conditions. 
Initially they appeared round, but within one week, gained fibroblast like structures. 
They did not show any DsRed expression when observed under the RFP channel 
(Fig 11.2 B); but were stained positive for the Lac Z via an X Gal staining (Fig 11.2 
C). Finally, to make sure that the cells that we sorted were from alveolar type II 
lineage, cultured cells were cytospined and double immunofluorescence staining 
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was performed using a pro SpC and a DsRed antibody. The cells were found to be 
positive for both SpC and DsRed marker and visualized under high magnification 
confocal microscope (Fig 11.2 D) 
 
Fig 11.2 DsRed negative sorted population of cells from induced DsRed mice are negative 
for the DsRed expression (B) and are stained positive for the lac Z expression (C). Co-
immunofluorescence staining of the DsRed sorted cells with SpC and DsRed antibodies 
shows the co-localization of the indicated markers (D). Scale bar = 100μm  
 
Thus validating with a series of immunohistochemical staining, cell sorting and 
culturing the lineage tagged cells; we confirm that the strategy applied for lineage 
tracing by restricted Cre expression is technically sound which can be used to 
address the lineage specific and cell of origin in murine lung cancer (NSCLC) 
thereby elucidating the identity of putative cells contributing towards metastasis in 
our murine NSCLC model. 
5.1.4 Labeling tumor cells induced by oncogenic C RAF 
Once we were able to genetically tag the type II cells with DsRed in non-neoplastic 
cells, the next goal was to label the tumor cells with the lineage tag. For this 
purpose, Quadra C RAF BXB-DsRed transgenic reporter mice were generated The 
cell of origin of lung adenocarcinomas remains unknown, and candidates include 
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multipotent stem cells, Clara cells, and alveolar type II cells (Dermer, 1982). Oral 
administration of Doxycycline induces the expression of Cre that rapidly mediates 
excision of the transcriptional roadblock by catalyzing recombination across the 
fanking LoxP sites. With induction there occurs the expression of both the C RAF 
BXB oncogene and at the same time deletion of the stop cassette (lac Z) in front of 
the DsRed allele. The DsRed reporter gene is thereby activated in the SpC positive 
cells and subsequently transmitted to their progeny as they repopulate the tissue 
during normal homeostasis and in tumor formation.  
5.1.4.1 Lung tumor formation in C RAF BXB-DsRed induced mice exhibiting 
cuboidal tumor cell phenotype 
Quadra compound reporter animals were under doxycycline induction which gave 
rise to tumor nodules in the lung (Fig 12.1 A). Histological examination of the tumor 
nodules displayed the cellular structure of the tumor. The cuboidal shaped cells 
comprised the tumor mass as depicted by an H&E staining (Fig 12.1B).   
 
 
Fig 12.1 Lung tumor formation in C RAF BXB-DsRed transgenic mice. (A) Whole lung 
photographs of 9 to 12 months induced transgenic mice shows visible adenomas (in red 
circles). (B) Paraffin embedded H&E stained lung sections shows a tumor (in red circle, 
scale bar = 500 μm). A closer view of the adenoma shows the presence of cuboidal shaped 
tumor cells.Scale bar = 100 µm   
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5.1.4.2 Evaluation of the tumor for the expression of the lineage marker and 
the transgene 
Histological sections of the tumor bearing lungs were processed for immuno-staining 
to find out whether we were able to mark the tumor cells with the lineage tag of 
DsRed. The tumor cells were composed of type II cells as evident by the expression 
of SpC (Fig 12.2). The consecutive tumor sections were then stained for Ha tag, 
which serves as a read out for the Tet O C RAF BXB transgene. Lastly, the sections 
were stained for DsRed. To our surprise, all the cells comprising the tumor were 
found to be positive for DsRed (Fig 12.2). These results indicate that these tumor 
have been initiated by a population of cell type that expresses SpC and thus has an 
alveolar type II phenotype.  
 
 
 
Fig 12.2 Lung tumor generated from C RAF BXB-DsRed transgenic mice (9 month) are 
labeled with the lineage marker DsRed and are positive for the alveolar type II cell marke, 
SpC and the tumor driving transgene Ha tag, which is a read out for the Tet O C RAF BXB 
expression. Paraffin embedded lung sections were immunostained for the indicated 
markers. Tumor stained with DsRed, derived from a control mouse displayed the negative 
expression of DsRed. Scale bar = 100 μm  
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The lung tumor section was then processed for double-immunofluorescene staining 
to ascertain the identity of the tumor cells. The tumor cells exhibited double positive 
cells, claiming them to be derived from alveolar type II cells (Fig 12.3 A). Along with 
this the tumor were sustained by an active MAPKinase signaling as observed from 
the western blots for total ERK and phosho ERK. Actin served as a loading control 
(Fig 12.3B). 
 
 
Fig 12.3 Co-localization of SpC and DsRed cells in the tumors generated from C 
RAF BXB-DsRed transgenic mice.  (A) Double immunofluorescence staining for SpC 
and DsRed on the cryo embedded lung sections.Scale bar = 100 μm (B) Analysis of 
the mitogenic cascade in the tumors. Immuno-blot showing the expression of DsRed, 
total ERK and phospho ERK in the tumor.  
5.1.4.3 Labeling small cryptic lesions at earlier time points 
Analyzing lungs from induced C RAF BXB-DsRed mice at earlier time points 
(between 6 to 8 months) shows small cryptic tumor like lesions whose size varies 
from few cell clusters to many cells comprising a mass. This early tumor like lesions 
expressed DsRed (Fig 12.4). This indicates that the type II cells are in the process of 
tumor formation and these lesions would eventually progress to macroscopic visible 
adenoma in the lung at later stages. 
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Fig 12.4 Labeling adenoma like lesions with DsRed from C RAF BXB-DsRed transgenic 
mice harvested at earlier time points (6 to 8 months). Paraffin embedded lung sections 
stained with DsRed. Small tumor like lesions positive for DsRed is indicated within red 
circles. Scale bar = 100 μm  
5.1.4.4 C RAF BXB-DsRed transgenic mice exhibit proliferating bronchiolar 
hyperplasia  
Another striking feature observed in the compound reporter mice, was the presence 
of abundant bronchiolar hyperplasic regions. These hyperplasias were often 
continuous with the alveolar space adjacent to the respiratory bronchioles (Fig 12.5 
H&E). To investigate the histogenesis of the hyperplasias, immunohistochemistry 
was performed using antibodies against Clara cell antigen (CCSP) and the 
surfactant protein-C (SpC), commonly used markers that distinguish between Clara 
cells and alveolar type II cells, respectively. The isolated hyperplasic lesions were 
found to be positive for CCSP (Fig 12.5) suggesting that these lesions arose from 
Clara cells or their precursors but the adenomas were found to be positive for SpC, 
suggesting that they arise from type II cells. Few cells within the lesions were 
positive for SpC and were proliferating as depicted by the Ki67 positive cells within 
this zone (Fig 12.5).  
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Fig 12.5 C RAF BXB-DsRed lungs displayed abundant bronchiolar hyperplasias that are 
proliferating and express the markers of type II cell, SpC. Paraffin embedded lung sections 
stained with H&E, CCSP, SpC and Ki 67. Red circles indicate the hyperplasic regions. 
CCSP staining showing the massive expression of Clara cells in the hyperplasias (in red 
arrows). Scale bar = 100 μm  
 
Furthermore, double immunofluorescence staining was performed to determine 
whether individual cells in the hyperplasic structures were expressing both SpC and 
CCSP. Usually cells expressing both SpC and CCSP are observed at the junction of 
bronchiolar and alveolar epithelium in the respiratory bronchioles, called as 
bronchio-alveolar duct junction (BADJ) and in rare cases extended into the center of 
the adenoma. These cells are designated as bronchio-alveolar stem cells (BASCs). 
We did not find any double positive cells in these lesions (Fig 12.6). 
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Fig 12.6 Hyperplasias generated in the C RAF BXB-DsRed transgenic mice displayed the 
absence of BASCs. Co-Immunofluorescence staining for SpC and CCSP on the paraffin 
embedded lung sections showed no double positive cells. (BADJ = Bronchio-alveolar duct 
junction). Scale bar = 100 μm 
5.1.5 Labeling tumor cells generated in a reporter 
metastatic NSCLC model  
Since c Myc is known to be a metastatic gene for NSCLC and induced 
macrometastasis in liver (Rapp et al, 2009); we were interested to study the 
involvement of type II cells and its fate in malignant progression. For this purpose, 
Myc-DsRed and Myc-BXB-DsRed transgenic mice were generated. 
Transgenic mice were induced with doxycycline food and were harvested after a 
period of 1 year. Multiple macroscopic lung tumors were formed in Myc -DsRed mice 
(Fig 13.1 A) and Myc-BXB-DsRed (Fig 13.2 A). Whereas tumors derived from the 
Myc-DsRed mice exhibited columnar cell phenotype (Fig 13.1B); tumors obtained 
from the Myc-BXB-DsRed mice displayed a mixed phenotype comprising both 
cuboidal and columnar structure (Fig 13.2 C). This suggests that introduction of c 
Myc induces the tumor cells to gain a new phenotype-the columnar structure, which 
is thought to be more malignant and hence a signature for the appearance of 
papillary carcinomas in the advanced stages of tumor progression.  
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Fig 13.1 Macroscopic lung tumors are formed in Myc-DsRed transgenic mice and are made 
up of columnar cells. (A) Experimental strategy for conditional expression of DsRed in SpC c 
Myc mediated lung tumors. Whole lung photographs of 12 to 15 months induced transgenic 
mice shows visible tumor nodules (in yellow circles). (B) Paraffin embedded H&E stained 
lung sections show tumor (left panel, scale bar = 500 μm) which on closer examination 
depicts the presence of columnar cells (right panel). Scale bar = 100 μm 
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Fig 13.2 Macroscopic lung tumors are formed in Myc-BXB-DsRed transgenic mice and are 
composed of cuboidal and columnar tumor cells. (A) Experimental strategy for conditional 
expression of DsRed in SpC c Myc and C RAF BXB induced lung tumor. (B) Whole lung 
photograph of 12 months induced transgenic mice shows macroscopic tumor nodules. (C) 
Paraffin embedded H&E stained lung section shows tumor which consist of both cuboidal 
and columnar tumor cells. Right panel images (scale bar = 100 μm) are the higher 
magnifications of randomly selected regions from the tumor (left most panel, scale bar = 500 
μm) 
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5.1.6 Introduction of Myc induces a new phenotype: 
premalignant lesions 
Clusters of pleomorphic cells are detected in the lungs that are speculated to be the 
potential sources for metastasis initiating cells (MICs) (Fig 13.3 A H&E); (Rapp et al, 
2009) In order to characterize these potential premalignant lesions, and their 
lineage, expression of genes regulating proliferation and apoptosis were analyzed. 
Paraffin embedded lung sections from Myc-DsRed and Myc-BXB-DsRed transgenic 
mice (> 12 months) were immunostained with c Myc, Cleaved caspase 3, Ki 67 and 
DsRed antibodies. These pleomorphic clusters exhibited strong nuclear c-Myc (Fig 
13.3 A). Pleomorphic cells proliferate as seen by the Ki 67 staining (Fig 13.3 B) and 
simultaneously exhibit cells undergoing apoptosis as observed by the presence of 
cleaved-caspase 3 positive cells (Fig 13.3B). Lineage marker for type II 
pneumocytes are maintained in the c-Myc positive foci as depicted by the 
expression of DsRed (Fig 13.3 B).  
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A  
B  
Fig 13.3 Representative images from Myc-DsRed and Myc-BXB-DsRed transgenic 
lungs (>12 months) displayed the presence of unique premalignant lesions 
composed of pleomorphic cluster of cells that are labeled with DsRed and express 
c Myc which are in a constant status of proliferation and apoptosis. (A) Paraffin 
embedded lung sections stained with H&E shows the pleomorphic clusters (in red 
circles) which are immunopositive for c Myc (brown cells within red circles). (B) 
Immunostaining of the pleomorphic clusters for the indicated markers. Scale bar = 
100 μm 
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5.1.7 Evaluation and characterization of the primary tumor  
Adenocarcinoma of the lung is the most common form of lung cancer, but the cell of 
origin and the stages of progression of this tumor type are not well understood. 
Tumor might arise from Clara cells, alveolar type II cells, multipotent stem cell, or 
from derivative lineages from these cells (Beer & Malkinson, 1985; Jackson et al, 
2001; Magdaleno et al, 1998; Mason et al, 2000; Rehm et al, 1991; Thaete & 
Malkinson, 1991). In an attempt to get closer to identifying candidate precursors, 
tumor cells were analyzed by immunohistochemistry. Paraffin embedded tumor 
bearing lung sections from Myc-BXB-DsRed mice (>12 months) were analysed for 
the expresseion of the cell type specific markers. Heterogeneous expression of the 
lineage tag; DsRed persisted within the tumors in abundance (Fig 14.1A) which was 
subsequently confirmed by the similar SpC expression pattern observed (Fig 14.1A). 
Tumor also displayed a fair expression of the driving oncogenes. Membranous C 
RAF and Ha tag along with strong nuclear c Myc were detected in the tumor cells 
(Fig 14.1B). Marker of alveolar type I cell lineage, Aquaporin 5 was also expressed 
in these tumors (Fig 14.1B). In accordance with the immunoblot results, tumor cells 
displayed heterogenous expression of nuclear pERK (Fig14.1B). In addition novel 
marker like PGP 9.5 was expressed, which represents an endothelial cell lineage. 
Previously PGP 9.5 was known to be a marker for immature neuroendocrine cells 
(Rawlins, 2008) and as a candidate tumor marker for NSCLC (Hibi et al, 1999). 
 
 
Fig 14.1A Lung tumors from Myc-BXB-DsRed mice (>12 months) were labeled with the 
lineage tag DsRed and express alveolar type II cell marker, SpC. Immunohistochemical 
staining of the paraffin embedded lung sections displayed nucleo-cytoplasmic expression of 
DsRed and membranous localization of SpC. Right panel images display the higher 
magnification of the randomly selected regions of the left panel image. Scale bar = 100μm 
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Fig 14.1B Immunohistochemical analysis of the tumors obtained from Myc-BXB-
DsRed mice (>12 months) for lung differentiation markers. Paraffin embedded tumor-
bearing lungs were immunostained for the indicated markers. Haematoxylin was 
used as a counter-stain. Scale bar =100 μm  
5.1.8 Tumor progression concomitant with angiogenesis in 
the absence of EMT 
Angiogenesis is an important step in both tumor growth and metastasis (Onn et al, 
2003). Immunostaining of paraffin embedded lung tumor sections from Myc-BXB-
DsRed mice (> 12 months) displayed tumor vascularization with unusual vessels in a 
mosaic pattern expressing Pecam-1, a marker for blood vessels (Fig 14.2). 
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Fig 14.2 Angiogenic induction in tumor. Pecam-1 immunostaining of the paraffin embedded 
lung tumor sections from Myc-BXB-DsRed mice shows the presence of blood vessels within 
the tumor (in brown). Scale bar = 50 μm  
 
An important factor for maintaining normal tissue architecture is the E Cadherin-
catenin complex (Bremnes et al, 2002). Loss of E Cadherin expression is observed 
in local lung cancer invasion as well as in regional metastasis and is associated with 
poor prognosis (Hirata et al, 2001; Kalogeraki et al, 2003). Paraffin embedded lung 
tumor section from Myc-BXB-DsRed mice (> 12 months) was stained with the 
epithelial marker, E-Cadherin. Small tumor lesions strongly express E- Cadherin 
which shows that the E-Cadherin junctions of columnar cells in tumor remained 
intact (Fig 14.3 A). Immuno blot of the tumor showed high E-Cadherin and feebly 
detected Vimentin (Fig 14.3 B). Taken together these results indicate that the tumor 
cells were not undergoing typical epithelial mesenchymal transition. Interestingly, in 
massive papillary tumors, there were certain regions observed that appeared to lose 
E-Cadherin (Fig 14.3 C). This may be the beginning of the transition phase from 
epithelial to acquiring mesenchymal phenotype. But while addressing issues of EMT, 
one has to be careful enough since catching the right time window when a cell 
undergoes EMT is very a critical critreia in detecting the markers up or down 
regulated during this transition. 
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Fig 14.3 Analysis of Epithelial-Mesenchymal Transition (EMT) in lung tumor. Paraffin 
embedded tumor bearing lung sections were immunostained with the epithelial marker, E 
Cadherin.Tumor shows strong expression of E- Cadherin on the membranes of the tumor 
cells (A). Immunoblot of the lung tumor for E-Cadherin and Vimention shows strong E-
Cadherin and very feeble Vimentin (B). Some regions within the tumor are negative for the 
E-Cadherin expression (C). Scale bar = 100 μm 
5.1.9 Labeling efficiency in the transgenic compound 
reporter mice 
The number of cells targeted by Cre would give an estimate of the percentage of 
lineage tagged cells in our transgenic system. Lungs from the two groups of 
transgenic mice viz C RAF BXB-DsRed and Myc-DsRed were paraffin embedded, 
sectioned and stained with SpC and DsRed antibodies. Ten random animals were 
chosen from each group and the number of DsRed positive cells in the entire lung 
per animal was counted. Gross morphological examination of the lungs displayed 
the expression of SpC and DsRed (Fig 15 A) in an entirely normal alveolar type II 
cell pattern. Calculation of labeling efficiency revealed that 40 % of the total lung was 
labeled in C RAF BXB-DsRed mice whereas Myc-DsRed mice showed a tendency 
of 35% labeling of the entire lung (Fig 15 B).  
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Fig 15  (A) Paraffin embedded lung sections from the C RAF BXB-DsRed and Myc-    
DsRed reporter mice immunostained for SpC and DsRed shows fair expression of the 
lineage markers throughout the lung without any abnormal expression pattern otherwise 
Scale bar = 100 μm. (B) Quantification of the DsRed positive cells in the total lung 
determines the efficiency of labeling in the compound transgenic reporter animals 
harbouring c Myc and Tet O C RAF BXB oncogenes.   
5.1.10 Proliferation and apoptosis in the primary tumor  
A tumor is more or less a collection of cells that grow more rapidly than the 
surrounding normal tissue. Hence we were interested to know how actively the cells 
in tumor are growing compared to the surrounding tissue. The measurement of Ki67 
is one of the most common ways to measure the growth fraction of tumor cells. Ki-67 
is a molecule that is found in growing, dividing cells but is absent in the resting 
phase of cell. In order to understand the rate at which the cells within a tumor are 
growing; lung tumor sections were immuno-stained with a Ki 67 antibody. Strong 
nuclear Ki67 was detected in abundance within the tumor (Fig 16 A). In conjuction 
with analyzing tumors for their growing status, it is important to study the cells 
undergoing apoptosis. Apoptosis can occur when a cell becomes too damaged to 
survive but is still able to die in a controlled way (to prevent inflammation and the 
release of proteins that could damage other cells). One of the things that triggerers 
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apoptosis is genetic mutations. Since cells become cancerous due to multiple 
genetic mutations, it becomes necessary for them to be eliminated via apoptosis. In 
view of this, lung tumor sections were stained with cleaved Caspase 3 antibody to 
detect the cells undergoing apoptosis. Quantifying the number of cells in total lung 
derived from C RAF BXB-DsRed and Myc-DsRed animals; positive for Ki 67 and 
Cleaved Caspase 3; a graph is plotted which shows that the mice transgenic for 
Myc-DsRed scores high for Ki 67, and thus contain cells that are rapidly dividing and 
growing (Fig 16 B). 
 
Fig 16 Proliferation and apoptosis in the compound transgenic reporter mice. (A) Ki-67 
immunohistochemistry in paraffin embedded lung tumor sections. Right panel image is the 
magnified view of the randomly selected region of the tumor displayed in the left panel. 
Scale bar = 100μm (B) Quantification of proliferation and apoptosis, scored from the cells of 
the pulmonary epithelium in the compound transgenic reporter mice.  
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5.1.11 Status of p53 in the compound transgenic reporter 
animals  
p53 is a tumor suppressor gene that is frequently mutated in lung cancer with 
mutations in approx. 50% of Non–small cell lung cancer and 70% of small cell lung 
cancer (Harris, 1996; Rom et al, 2000). The p53 protein is a transcription factor that 
induces the expression of several genes, including p21, an inhibitor of the 
cyclin/cyclin-dependent kinase complex mediating G1 cell cycle arrest; bax, which 
promotes apoptosis; and GADD45, which is involved in cell cycle arrest and DNA 
nucleotide excision repair (Levine, 1997). Most missense mutations occur in the 
DNA-binding domain, resulting in defective contacts with DNA and loss of the ability 
of p53 to act as a transcription factor, thereby hampering the function of this potent 
tumor suppressor. Functional p53 is short-lived in the cell as it triggers its own 
degradation. Mutant p53 however can accumulate. This forms the basis for the 
detection of mutant p53 via standard immunohistochemical staining. In accordance 
with this, the goal of the present study was to carry out p53 assessment in the lung 
tumors obtained from three different groups of transgenic animals viz C RAF BXB-
DsRed, Myc-DsRed and Myc-BXB-DsRed respectively. Paraffin embedded lung 
tumor sections were immunostained with the p53 antibody. Pre-malignant lesions 
derived from the Myc-DsRed and Myc-BXB-DsRed exhibited p53 expression in the 
clusters of the pleomorphic cells, also a fraction of cells within the tumors showed 
strong p53 (Fig 17). In all cases, p53 was strongly confined to nucleus. Interestingly, 
we did not detect any p53 positive cells in the tumors generated from C RAF BXB-
DsRed animals (Fig 17). Finally, the number of tumor cells positive for p53 signal 
were counted, quantified and representated in the graph (Fig 17) which shows that 
the Myc-BXB-DsRed labeled tumor exhibit strong p53 upregulation compared to the 
tumor form Quadra transgenic reporter mice driven by c Myc alone. This is our 
preliminary observation about the p53 status in the labeled transgenic mice. And the 
molecular mechanisms underling this observed phenomena has yet to be 
investigated in detail. 
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Fig 17 Analysis of the p53 in the lungs of the compound transgenic reporter mice (with the 
indicated genotypes). Pleomorphic clusters and tumors of the Myc-DsRed and Myc-BXB-
DsRed mice displayed heterogenous, nuclear p53 expression whereas the tumors 
generated from C RAFBXB-DsRed mice showed the complete absence of p53 signal. 
Quantification of p53 positive cells were scored and a graph was plotted which shows that 
the tumors of the Myc-BXB-DsRed reporter mice have the maximum p53 expression when 
compared to others. Scale bar = 100 μm  
5.1.12 Screening for DsRed positive cells via Flow 
Cytometry  
One of the advantages of fluorescent labeling is to detect the presence of the 
labeling molecule under suitable filters utilizing flow cytometry. For that purpose, 
single cell suspension from total organs which includes lung, liver and kidney from 
three animals (Myc-DsRed, ~10 to14 months old) were subjected to FACS analysis 
for screening DsRed in the FLH-2 channel of the BD FACS caliber. Wild type organs 
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and tissue derived from non labeled mice (SpC c Myc/ BXB) served as control. 
Though no obvious visible metastasis and lung tumor were observed in these 
animals, but we detected fraction of cells from the total population; positive for the 
DsRed signal.This indicates that metastatic is an early event, yet it may require 
additional factors and time in-order to form a full fledged metastasis that can be 
readily detected via naked eyes. 
 
Fig 18 Quantification of DsRed positive cells in the parenchymal organs. Data represents 
the average of three animals. 
5.1.13 Loss of SpC and TTF-1 in the primary tumors: 
Hallmarks for metastatic progression     
NK2 homeobox 1 (NKX2-1), also known as thyroid transcription factor 1 (TTF-1), is a 
protein which in humans is encoded by the NKX2-1 gene (Guazzi et al, 1990). Also 
known as Thyroid transcription factor 1 (TTF-1), it  is the earliest known marker 
associated with commitment of endodermal cells to pulmonary and thyroid cell 
lineages; it appears before the definitive lung formation (Maeda et al, 2007). SpC is 
expressed in the distal epithelium during early lung development, and becomes 
restricted to alveolar type II cells late in gestation and postnatally. It is expressed in 
type II pneumocytes in the normal adult lung (Ikeda et al, 1995) and in approximately 
75% of non-mucinous lung adenocarcinomas (Kaufmann & Dietel, 2000). Currently, 
testing for TTF-1 expression by immunohistochemistry is commonly used to confirm 
the pulmonary origin of a carcinoma (Kaufmann & Dietel, 2000; Stenhouse et al, 
2004). Several studies have evaluated the prognostic significance of TTF-1 
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expression in NSCLC (Au et al, 2004; Berghmans et al, 2006) (Haque et al, 2002; 
Myong, 2003; Pelosi et al, 2001; Puglisi et al, 1999; Stenhouse et al, 2004). It has 
been shown that TTF-1 is a favorable prognostic factor for survival in patients with 
lung adenocarcinoma (Berghmans et al, 2006). Since the expression of TTF-1 is an 
early event during lung differentiation, the evaluation of TTF-1 expression in lung 
tumors would be of significant impact.  For this purpose, paraffin embedded lung 
tumor sections from Myc-DsRed and Myc-BXB-DsRed (>12 months) were 
immunoreacted with the SpC and TTF-1 antibodies and were analysed for the 
presence or absence of their immunoreactivity. Lung tumor expressed strong 
nuclear TTF-1 and SpC proteins (Fig 19). But interestingly, certain regions within the 
massive tumor lesions were found negative for the expression of SpC and TTF-1, 
which states that these tumor cells are losing these markers in their course of 
malignant progression. A recent report from Tyler Jacks laboratory showed that the  
loss of TTF-1 is a pre-requisite for metastatic progression in lung cancer (Winslow et 
al, 2011).In view of this our observation are in consistent with the already published 
phenomena in the case of malignant progression. 
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Fig 19 Lung tumors generated from the Myc-DsRed and Myc-BXB-DsRed reporter mice 
displayed abundant SpC and TTF-1 expression whereas certain tumor cells exhibited the 
loss of the indicated markers. Paraffin embedded lung tumor sections were immunostained 
with SpC and TTF-1 antibodies and shows membranous SpC and nuclear TTF-1 
expression. Scale bar = 100 μm  
5.1.14 Evidence of circulating Bronchioalveolar stem cells 
(BASCs) in the tumors 
Lung adenocarcinoma is the lethal form of lung cancer and has an overall poor 
prognosis with low 5-year survival due to late presentation, disease relapse and lack 
of curative systemic therapy. Recently, the cancer stem cells (CSC) theory proposes 
that cancers are maintained by subpopulations of tumor cells that possess stem or 
progenitor cell characteristics. These cells can initiate tumor formation, differentiate 
along multi-potent pathways and are relatively resistant to conventional 
chemotherapy (Lapidot et al, 1994). Bronchioalveolar stem cells (BASCs) were 
recently identified in adult mouse lung as a rare cell population located in the 
bronchoalveolar duct junction. (Kim et al, 2005; Mallick et al, 2009). BASCs were 
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characterized by its double positive staining characteristics for both the alveolar 
epithelial type II cell marker, Surfactant protein C (SpC), and the Clara cell marker, 
Clara cell secretary protein (CCSP). Viable BASCs were maintained through multiple 
passages in vitro under distinct culture conditions, and retained the ability to 
differentiate into either Clara cells or alveolar type II cells AT2 (Kim et al, 2005) and 
(Giangreco et al, 2002). In order to find the potential BASCs in the tumors generated 
from Myc-DsRed and Myc-BXB-DsRed mice, lung tumor sections were co-immuno-
stained with SpC and CCSP antibodies. Double immunofluorescence staining 
revealed the presence of few double positive cells inside the tumor and near the 
BADJ (Fig 20). These data suggest that the presence of rare circulating BASCs 
contribute as one of the potential candidate cell type that is capable of initiating and 
sustaining the tumor in these animals. Interestingly we have not detected a single 
BASC in the lung tumors derived from C RAF BXB-DsRed mice. A recent finding 
states that c-Myc regulates self renewal in Bronchoalveolar Stem Cells (Dong et al, 
2011) may shed some light on our findings. Nevertheless, this phenomena need to 
be explored in detail. 
 
Fig 20 Representative images of lung tumor generated from Myc-BXB-DsRed mice (>12 
months) showed the presence of BASCs. Paraffin embedded lung sections were co-
immunostained with SpC and CCSP. DAPI depicts the nucleus. Double positive cells are 
indicated with white arrows. Scale bar = 100μm 
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5.1.15 Detection of the tumor specific transcripts in 
compound transgenic reporter mice via gene expression 
analysis. 
 
Expression of lineage marker, DsRed was already determined in the primary lung 
tumors via Immuno histochemical stainings. In order to confirm our previous findings 
as well as to explore the presence of the lineage specific and type II cell marker in 
the primary tumors and their respective secondary organs, multigene real time PCR 
was carried out with the cDNA samples obtained from the lung, liver and kidney of 
the reporter transgenic animals viz. DsRed, Myc-DsRed and Myc-BXB-DsRed 
(metastatic animal). DsRed mice served as a control of this experiment. Probes 
were normalized with the HPRT (hypoxanthine-guanine phosphoribosyltransferase) 
as an internal control. Real time PCR detected the differential presence of the 
transcripts under study that comprises of DsRed, SpC, cMyc, C RAF-BXB, and TTF-
1 respectively. As expected metastastic mice displayed DsRed, SpC, c Myc and 
TTF-1 in both the primary lung tumor and in the liver metastasis. Whereas the liver 
metastasis displayed minimal levels of CCSP.   
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Fig 21 Relative mRNA levels expressed in the transgenic reporter mice screened for the 
presence/absence of the transcripts (DsRed, SpC, c Myc, C RAF-BXB, CCSP, and TTF-1) 
in the tissues (lung, liver and kidney) analysed. DsRed mice served as control. Genotypes of 
the derived tissue are indicated on the Y axis.  
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5.1.16 Gene expression profiling of the primary lung tumor 
The discovery of rare cells with stem cell-like properties in solid tumors is emerging 
as an important area of cancer research and may help explain the resistance of 
these tumors to current therapeutics. In view of this, we investigated the presence of 
cancer stem cells in our NSCLC mouse model. For this, a panel of cancer stem cell 
markers was screened at the gene expression level exclusively in the pure tumor 
nodules dissected from the lung lobes of Myc-BXB-DsRed mice. Among them 
includes the cluster of differentiation group of molecules namely CD 44, CD 24, CD 
34, and CD 133 along with Sca 1, c kit and TERT. Wild type lung served as a 
control. The expression of the CD 44, Sca 1 and TERT genes was significantly 
higher in tumor than compared to the normal lung tissue (Fig 22 A and B). LEF 1, 
CD 34, Axin 2, CD 24, LGR 5, CD 133, MMP 2, MMP 9 and SYK mRNA levels were 
not significantly different in the tumor relative to the normal healthy lung; whereas c 
kit, Vimentin and TCF 1 were found to be downregulated in the tumors (Fig 22 A). 
 
 
 
Fig 22 Gene expression profiling of the primary lung tumor obtained from Myc-BXB-DsRed 
transgenic reporter mice showed elevated expression of CD 44, Sca-1 and TERT. (A) Heat 
map generated from the fold expression values for the indicated genes. (B) Individual 
graphs depicting the genes up regulated in the tumor. Wildtype lungs were used as a 
control. 
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The establishment of metastasis requires that tumor cells acquire new adhesion and 
migration properties to emigrate from primary sites and colonize distant organs. The 
CD44 antigen is a cell-surface glycoprotein involved in cell-cell interactions, cell 
adhesion and migration. It participates in a wide variety of cellular functions including 
lymphocyte activation, recirculation and homing, hematopoiesis, and tumor 
metastasis. CD 44 may be involved in cloning selection of metastasis prone cells 
within early primary tumors. Since it is a cell membrane protein often over expressed 
on tumor cells and being both a cell–cell and cell–extracellular matrix adhesion 
protein, is well positioned to contribute to the early events of metastasis (Jothy, 
2003). Hence the high levels of CD 44 expression in our tumors is in accordance 
with the earlier findings which has demonstrated that many NSCLC cell lines are 
enriched with stem cell like properties thereby having elevated levels of CD 44 
expression (Leung et al, 2010). Stem cell antigen-1, Sca-1 is one of the important 
determinants of cell lineage which is expressed on hematopoietic stem cells which 
proliferate and differentiate into progenitors that then go on to become various cell 
lineages. Reports are available which states that aggressive breast cancer tumors 
express higher levels of this stem cell marker (Welm et al, 2002). Such elevated 
levels of Sca -1 in the tumors suggest its influential effect on the maintenance of rare 
cancer stem cells resulting in the prolonged diseased state. The TERT (telomerase 
reverse transcriptase) gene encodes the catalytic subunit of telomerase, which 
elongates the telomere ends using the RNA subunit TERC as a template (Gulmann 
et al, 2005). The stabilization of telomere size is a prerequisite for malignant cells to 
erase the senescence checkpoint and acquire the capacity to proliferate unlimitedly. 
Thus, telomerase reactivation is an obligatory event in carcinogenesis and, in fact, 
increased telomerase activity or TERT mRNA expression has been detected in up to 
90% of human cancers (Shay & Wright, 2005). Presence of high levels of TERT in 
the tumors explains the plausible reason as to why the cells within a tumor sustain 
themselves for a longer period until a fully-fledged metastasis happens succumbing 
the animal to death (Catarino R 2010). 
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5.1.17 Survival curve and tumor burden of the reporter 
transgenic animals 
To test whether the introduction of the reporter tag, DsRed interfered/affected the life 
span of the compound mice harbouring this allele; transgenic mice were observed 
for their mortality rate, general health and parameters regarding tumor incidence 
were studied. The animals under investigation consisted of C RAF-DsRed and Myc-
DsRed mice. Observation for a period of ≥2 years demonstrated accelerated death 
in the DsRed labeled (Myc-DsRed and C RAF-BXB-DsRed) reporter transgenic mice  
compared to their unlabeled counterpart animals (Fig 23.1 A and B, respectively). 
Compound reporter mice exhibited the percent survival that significantly differed 
from the control single SpC c MYC and Double SpCrtTA/Tet O C RAF BXB 
transgenic mice by log-rank analysis.   
This clearly demonstrates that labeling affects the overall life span of the labeled 
compound animals. The labeled animals start dying in a small interval of time after 
their birth compared to the non-labeled transgenic animals. These results indicate 
that DsRed influences the survival of labeled animals. For instance; though there is 
not much significant difference in the C RAF BXB- DsRed Quadro Vs SpC rtTA /Tet 
O C RAF BXB in terms of their median survival values but there is a tendency that 
prevails (Median survival C RAF BXB-DsRed = 54 and Tet O C RAF BXB = 56). In 
the case of Myc-DsRed Quadro Vs SpC c Myc animals analyzed there occurs a 
significant difference in their survival pattern due to labeling. The labeled mice die 
much earlier and have a vast difference in their median survival values (Median 
survival Myc-DsRed Quadro = 51 and SpC c Myc = 77.5).  
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Fig 23.1 Kaplan-Meier plot for (A) Myc-DsRed (n = 19), SpC c MYC (n = 52), and (B) C RAF 
BXB-DsRed (n=15), SpCrtTA/Tet O C RAF BXB (n= 23).  
Wild type (n = 28) littermate control mice. Log-rank analysis for percent survival for labeled 
compound mice Myc-DsRed vs SpC-c Myc = p>0.05; labeled C RAF BXB-DsRed Vs 
SpCrtTA/Tet O C RAF BXB = p<0.0001. n= number of animals.  
 
Another important observation that came to our knowldege is that the majority of the 
DsRed labeled animals (analysed ~8-12 months) indicated reduced incidence of 
tumor burden (Fig 23.2 A and B). More-over the size of the tumors generated from 
the labeled animals showed a marked decrease in its overall area occupying the 
lung; when compared with the tumor foci obtained from the non-labeled transgenic 
mice (Fig 23.2 C). H&E section of the lungs from the transgenic animals was 
analyzed for the presence of tumor and the tumor sizes were compared with the 
indicated animals for their specific genotype. The figure displays the representative 
examples of lung sections analysed from the animals that were generated for the 
project. 
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Fig 23.2 Labeling the lungs of the transgenic animals with DsRed decreases the tumor 
incidence and tumor size in the compound transgenic reporter mice. H&E stained lung 
sections (formalin fixed) were analysed for the presence of tumor foci (A and B). Most of the 
labeled lungs showed complete absence of tumor when compared to the age matched non-
labeled lungs. (C)Tumor size also decreased in the labeled lungs when compared to the 
unlabeled tumors of the age matched transgenic animals. (Age group ranging from 8 to 12 
months)  
 
 
Put together the existing data obtained from a cohort of animals clearly indicate that 
DsRed (First Generation DsRed, Clontech™) expression interferes with CRafBxB 
and c Myc induced tumorigenesis in the lung and influences the survival of labeled 
animals. 
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5.2 Analysis of liver metastases   
As we have previously determined the expression of DsRed in the primary tumor, 
our goal was to trace the fate of DsRed labeled cells and to identify their expression 
at the secondary sites elsewhere in the body as in the case of metastatic 
development in the compound reporter transgenic mice that were generated for this 
purpose. We examined mice for metastasis starting from the age of 12 to 15 months. 
None of the C RAF-BXB-DsRed mice developed metastasis. Consistent with the 
frequency of metastasis , in a cohort of 10 inducible Myc-BXB-DsRed compound 
reporter mice that were induced 12-18 months, one mouse developed multiple 
macroscopic liver metastastases (Fig 24.1). 
 
 
 
Fig 24.1 Macrometastases in the liver of a Myc-BXB-DsRed mouse (17 months). Whole liver 
photograph shows macroscopic tumor nodules on the liver (arrows with front and back view) 
5.2.1 Anatomical and morphological characterization of the 
metastatic lesions 
On histopathological examination of metastases via an H & E staining on paraffin 
embedded liver sections; we find three types of metastasis prevailing in the liver. 
Cystic, mixed-cystic papillary and papillary (Fig 24.2). On closer examination, we 
found that the central portion of the cysts contained empty vacuole like gaps and 
tumor cells were found predominantly outside the well-developed fibrous capsules in 
the liver. While the cystic metastases have an intact periphery, papillary projections 
were usually recognized within the cystic lesions of the mixed cystic papillary 
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metastases. Whereas papillary metastases have condensed cellular architecture 
with compact tumor cells composed of columnar cells resembling that of the primary 
tumor. Interestingly streaming single cells and clusters of cells were found scattered 
in the liver, indicative of initial seeds in metastatic colonization. Furthermore, to 
evaluate the presence of the lineage tag DsRed and the type II cell in the liver 
metastases, immunoblotting was performed using the protein lysates obtained from 
the primary lung tumor and the liver metastases. Actin served as the loading control. 
Interestingly both SpC and DsRed protein were detected in the primary tumor as 
well in its metastatic derivative (Fig 24.2). To facilitate tracking of both DsRed 
positive tumor cells and lineage tagged SpC derived cells in vivo, metastatic lesions 
were immunostained with the DsRed and SpC antibodies respectively. Subsequent 
results would focus on the expression pattern of SpC and DsRed in the different 
subtypes of liver metastases. 
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Fig 24.2 Histological analysis of the liver metastases from 17 months induced Myc-BXB-
DsRed mouse shows the presence of three types of metastatic lesions viz. cystic, mixed 
cystic papillary and papilary metatstases. Small clusters of foreign cells are also found 
streaming in the liver (yellow circles depicts the small clusters and cystic metastasis). Cystic 
lesions have a well defined periphery comprised of the tumor cells enclosing an empty 
space like structure. Cystic mixed papillary lesions have a less organized structure with 
small papillary like projections invading/protruding the adjacent/nearby liver. As the cysts 
advances to a papillary metastases; the space within the lesions becomes less empty and 
more condensed with the tumor cells making it appear like the primary tumor of the lung 
resembling the papillary structure composed of columnar cells. (T = tumor and L = liver). 
Scale bar = 100 μm. Immunoblot for SpC and DsRed of the primary tumor and its liver 
metatstases.  
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5.2.2 SpC expression is detected in cystic metastases  
Since the primary tumor cells were positive for SpC, we next examined the 
expression of SpC in the liver metastases. Small clusters of tumor cells were 
negative for the SpC and the first expression of few SpC positive cells were 
observed only in the cystic metastasis. Notably, in the stroma-rich border area of the 
cystic lesions, isolated clusters of tumor cells that were positive for SpC were 
observed (Figure 24.3) consistent with invasion by collective migration. The number 
of SpC expressing cells increased in the mixed cystic papillary metastases and 
advanced in the papillary metastases as abundant SpC positive cells were present 
in them. This result is consistent with the earlier observation of liver metastases in 
which few SPC positive cells occur only at the cystic stage (Rapp et al, 2009). 
 
Fig 24.3 SpC expressing type II cells (arrow) are detected only at the cystic metastatic 
lesions (very few in numbers) and are abundantly found in the papillary metastasis. Paraffin 
embedded liver metastases was immunostained with the SpC antibody. Small clusters are 
negative for the SpC expression (yellow circles). Scale bar=100 μm  
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5.2.3 DsRed is detected in the single cluster of cell 
including the cystic and the papillary lesions of metastatic 
colonization  
In-order to dissect the involment of SpC expressing alveolar type II cells, tagged with 
a DsRed reporter; paraffin embedded liver metastases sections were immunstained 
with anti-DsRed antibody. Strikingly interesting observations were made by 
analyzing the distinct pattern of DsRed expressing cells in the metastases. Small 
clusters comprising of few cells strongly expressed the lineage marker DsRed. Cells 
contributing to cystic metastases were all positive for DsRed. Individual DsRed 
positive cells were also observed in the liver other than the metastatic lesions. While 
cystic metastases were completely DsRed positive, cells comprising the mixed cystic 
papillary and papillary metastases were heterogenous for DsRed expression (Fig 
24.4). This specific pattern of DsRed expression clearly indicates that the cystic 
lesions are indeed metastases and are solely derived from type II cells. Earlier 
results for investigating the expression of SpC in metastases identified the cystic 
metastasis to be negative for SpC expression, yet retaining the DsRed lineage label, 
identifying them to be originated from type II cell precursors. To further confirm these 
findings, double immunofluorescence staining was performed on the consecutive 
metastatic sections with SpC and DsRed antibodies. Clusters of tumor cells and 
cystic metastases were found to be positive for the lineage label DsRed but haven‘t 
gained any SpC expression yet (Fig 24.5). This pattern of DsRed expression in small 
clusters of tumor cells and cysts in the liver symbolize the initial phase of metastatic 
colonization where the lineage tagged cells landed in the foreign tissue. 
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Fig 24.4 Lineage tracing of alveolar type II cells through histochemical analysis of the 
tagged marker (DsRed) expression in the liver metastases. DsRed is highly detectable in all 
the subtypes of metastases beginning from the single cluster of cells, including the cystic 
lesions and the mixed cystic papillaty lesions. DsRed acquires a heterogenous expression 
pattern only in the papillary metastases. Scale bar = 100 μm  
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Fig 24.5 Lineage marker DsRed is present in the small clusters and cysts which were still 
negative for the SpC expression. Cryo embedded liver metastases sections were co-stained 
with SpC and DsRed antibodies. No double positive cells were observed in the clusters and 
cysts which retained only DsRed expression, whereas one to two SpC positive cells (white 
arrow) appear near the papillary projections of a cystic metastasis which is strongly positive 
for DsRed. Scale bar =100 μm 
5.2.4 Evaluation of metastases for the expression of 
progenitor markers/lineage selectors 
We evaluated additional progenitor markers/lineage selectors for their expression in 
the metastases. Candidate markers were selected based on their role during lung 
development and expression in emerging lung foci from compound transgenic 
reporter mice. These included Transcription factor Gata4,  Thyroid transcription 
factor-1 (TTF-1) ; a tissue-specific transcription factor expressed in the epithelial 
cells of thyroid and lung (type II pneumocytes and Clara cells) , alveolar type I cell 
marker; Aquaporin 5, and Protein gene product 9.5 (PGP 9.5); marker for 
neuroendocrine cells. Liver metastases retained heterogeneous expression of pan-
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Cytokeratin, Aquaporin 5, GATA 4 and TTF-1. Pan-Cytokeratin and Aquaporin 5 
were expressed in all the subtypes of metastases including small clusters to cystic, 
mixed cystic papillary and papillary metastasis. Mucin, a target gene of Gata4 is also 
detected in the metastatic lesions. Finally PGP 9.5 which was identified as a novel 
marker for tumor vasculature in mouse NSCLC (Rapp et al, 2009) was highly 
expressed in the vasculature of liver metastases (Fig 24.6). Hence, these markers 
may therefore be suitable for early detection of metastases of NSCLC. 
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Fig 24.6 Liver metastases express the markers of pulmonary lineage. Lung differentiation 
markers are indicated. Pan-cytokeratin and Aquaporin 5 (marker for type I cells) are 
sustained in all the subtypes of metastases. TTF-1 and GATA 4 transcription factors are 
expressed in the small clusters as well as in the subsequent cystic and papillary metastasis. 
Mucin, a taget gene for GATA 4 is also expressed as Alcian blue positive cells which mark 
the mucin positive cells (blue). Neuro-endocrine marker PGP 9.5 was present in few cells of 
the metastases (Brown).  Scale bar =100 μm  
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5.2.5 Clara cell emerges at the mixed cystic papillary stage 
of liver metastases 
Since a fraction of primary tumors exhibit the columnar cell phenotype, displaying 
the participation of non-ciliated columnar Clara cells in tumor formation, it was 
obvious to screen the metastases for the appearance of Clara cell which is one 
among the cell type (s) responsible for initiating lung adenocarcinoma.  Hence, the 
liver metastases sections were immunostained with a Clara cell marker, CCSP 
(Clara Cell secretory protein). Small clusters and cystic metastasis were devoid of 
CCSP expression. Whereas few CCSP expressing cells were detected in the mixed 
cystic papillary metastases and the CCSP positive cells showed a pronounced 
increase in their number in the papillary metastases. This clearly indicates that the 
Clara cells appears late during the metastatic progression, since we have not 
detected any Clara cell in the initial clusters and cystic metastasis (Fig 24.7). Given 
the fact that Clara cells are abundantly present in the papillary metastases, we were 
interested in delineating its origin. Here we exploited the DsRed expression in type II 
cells, which would facilitate us to know whether the cell originated form alveolar 
lineage if at all we observe any double positive cell stained for CCSP and DsRed. 
Subsequently double immuno-fluorescence staining was performed on liver 
metastases sections for the DsRed and CCSP proteins. No double positive cell was 
detected indicating that Clara cell evolved from bronchiolar lineage rather than an 
alveolar one (Fig 24.8). 
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Fig  24.7 Clara cells appear only in the cystic mixed papillary metastases (yet few in 
number) and is abundantly present in the papillary metastases (red arrows). Small clusters 
and cystic metastasis are negative for the CCSP expression (green circle). Scale bar =100 
μm  
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Fig 24.8 Identification of the origin of Clara cell lineage in the liver metastases. Co-
immunofluorescene staining with the CCSP and DsRed revealed the absence of any double 
positive cells which indicates that Clara cells are derived from a bronchiolar lineage rather 
than from an alveolar one. Scale bar = 50 μm 
5.2.6 Presence of Bronchioalveolar stem cells (BASCs) in 
the metastases 
Above mentioned findings which indicate the presense of CCSP and SpC in liver 
metastases, gave us an opportunity to screen for the presence of BASCs. While few 
double positive BASC cells were detected in papillary metastases (Fig 24.9B); cystic 
metastases were found negative for BASCs (Fig 24.9B). More-over CCSP and 
DsRed double positive cells were detected in the papillary metastases, again 
confirming the presence of BASCs, with DsRed as readout for SPC positive cells 
(Fig 24.9 B). These results suggest that CCSP positive cells in the liver metastases 
might have been generated by multipotent cells with BASCs as intermediates. 
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Fig 24.9 No evidence of BASCs within the liver metastases (A) but few BASCs were 
observed near the periphery of the metastatic lesions (B) indicating the existence of 
circulating BASCs in the foreign tissue (in this case, liver). Paraffin embedded liver 
metastases section, co-immunostained with CCSP and SpC (A) and CCSP and DsRed (B). 
Scale bar = 100 μm 
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6 Discussion  
6.1 Novel transgenic murine model for lineage tracing of 
alveolar type II cells in NSCLC metastasis 
Lung cancer is the leading cause of cancer deaths worldwide (Jemal et al, 2004) 
and adenocarcinoma is currently the most common type of lung cancer. Unlike 
squamous cell carcinoma, the stages of progression have not been well described 
for adenocarcinoma, and little is known about the cell type of origin or the 
characteristics of precursor lesions of pulmonary adenocarcinoma. Mouse models 
are well suited to sample distinct cell populations for their propensity to give rise to 
specific tumors (Visvader, 2011). Such approach has been nicely demonstrated in 
pancreatic cancer models using cell type-specific Cre expression (Gidekel 
Friedlander et al, 2009; Wang et al, 2009). Here, we have addressed this question in 
lung focusing on the likely cell of origin of NSCLC via a genetic lineage tracing 
approach. 
Cell turnover in the adult lung is normally very low (Kauffman, 1980). However, 
epithelial injury elicits rapid proliferation of surviving cells, and the tissue is soon 
repaired. Several lines of evidence suggest that alveolar epithelium is repaired by 
the type II cells, hence serving as the progenitor cells (Kauffman, 1974). Despite the 
evidence that type II cells are the progenitor cells of the alveolar epithelium 
compartment; relatively little is known about their biology and the mechanisms 
regulating their behavior and participation in the metastatic progression in malignant 
tumors. To address this issue, we have generated a transgenic mouse line to more 
efficiently lineage trace and genetically manipulate alveolar type II pneumocytes. To 
target alveolar type II cells, we chose to use the Cre-loxP system, which is an 
effective method for expressing or deleting a target gene in Cre-expressing cells. We 
generated a series of compound mice lines expressing Cre recombinase from 
specific lung alveolar epithelial type II cell promoter, SpC. The attempt to study the 
metastatic potential of type II cells was determined through introduction of a geneic 
tag into SpC expressing cells of the alveolar epithelium. This model used the SpC 
Discussion 
128 
 
rtTA/Tet O Cre transgene in combination with the Lac Z floxed DsRed allele to 
generate tagged SpC expressing cells. Regulation of the recombined allele by the 
ubiquitous Chicken beta actin promoter allowed expression of the lineage tag in all 
cells derived from a SpC expressing progenitor cell. We introduced a new line in 
which a 37 kb human Surfactant Protein C (SpC) promoter drives Cre. We used this 
allele, in combination with the lacZ/DsRed reporter, to lineage trace alveolar type II 
cells in adult mice. Soon after the induction, most of the labeled cells (65%) were 
scored as type II cells (data not shown). This is the first report of genetic lineage 
tracing studies by doxycycline inducible expression of Cre in SpC expressing type II 
cells. 
We made bi-transgenic mice expressing SpCrtTA and Tet O Cre under the control of 
the same SpC promoter elements (Fig 8.1). Crossing the SPCrtTA/Tet O Cre mouse 
line to the Actin Lac Z/DsRed reporter strain and exposing the adult offspring to 
doxycycline gave widespread activation of the heritable reporter gene in alveolar 
epithelial type II cells throughout the airways (Fig 9.1 and 9.2 ) The DsRed tag was 
identified at the nucleo-cytoplasmic membrane of type II cells. Tagged type II cells 
displayed fair distribution throughout the lung. Sections were stained SpC which is 
expressed by type II cells and DsRed, which strongly labels type II cells; to confirm 
that recombination of the reporter gene was restricted to type II cells (Fig 10.3 C). 
The proportion of type II cells that were lineage-labeled varied from 65% to 70%. 
The lineage-labeled cells were visualized by using DsRed staining and colabeled 
with SpC (marker for type II cells). Within the non-neoplastic lungs, the tagging 
system is highly specific for type II cells. DsRed expression was not observed in the 
Clara cells of the bronchioles (Fig 9.3 A). 
 
Cellular heterogeneity is a common histopathologic feature in lung cancer. Cancer 
cells undertake progressive morphologic and behavioral changes during disease 
progression and metastasis. Because these changes are often correlated with the 
malignant state of the disease, investigating the morphologic and behavioral 
alterations may reveal clues to the mechanism by which tumor cells acquire more 
aggressive phenotype and metastatic potential. Subsequently with our transgenic 
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strategy, we tagged the cancer cells with red fluorescent protein to sensitively detect 
tumor cell metastasis in the mouse and to identify cancer cells that adopted 
significant morphologic changes. Fluorescence protein tagging is also a sensitive 
technique to track xenograft tumor cells metastasis. To identify, purify and track the 
fate of type II cell progenitors, this lineage tracing approach with a Cre/loxP system 
has enabled us to mark irreversibly SpC expressing type II cells and their 
differentiated progeny in the context of tumor progression and metastasis. Cre 
expression from the tet-o- locus mediates the excision of the floxed stop sequence 
on the chicken beta actin flox lac Z DsRed reporter compound transgenic  resulting 
in the irreversible expression of the DsRed MST (DsRed-MST is a variant DsRed 
protein) in type II  progenitors and their differentiated progeny. Immunostaining 
displayed co-expression of SpC and DsRed in the cells obtained from the induced 
triple transgenic mice (DsRed). To obtain purified populations of type II progenitors, 
we isolated DsRed cells by fluorescence-activated cell sorting (FACS) and were able 
to culture them under special regimes. 
Earlier results of lineage tracing in the developing lung, using a transgene driven by 
a regulatory region of the human SpC gene, are consistent with the presence of a 
multipotent epithelial population, but suggest that it does not include progenitors of 
NE (Neuro Endocrine) cells (Perl et al, 2002b).  
Current study provides an in vivo description of an adult proliferative differentiated 
cell compartment (ie. The alveolar epithelium) where we have observed a specific 
population, identified by DsRed expression in the liver metastasis that enables us to 
explore the contribution of type II cells in the metastatic colonization in NSCLC 
model.  
6.2 Alveolar type II cells in NSCLC tumor initiation; 
perspective and facts 
The cell of origin of pulmonary adenocarcinomas remains unknown and candidates 
include multipotent stem cells, Clara cells, and alveolar type II cells (Dermer, 1982). 
Human pulmonary adenocarcinomas are classified into six cytologic subtypes 
including both Clara cell type and alveolar type II cell type (Kobayashi et al, 1990), 
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suggesting different cells of origin. Tumors might arise from Clara cells, alveolar type 
II cells, multipotent stem cells, or from derivative lineages from these cells (Beer & 
Malkinson, 1985; Jackson et al, 2001; Magdaleno et al, 1998; Mason et al, 2000; 
Rehm et al, 1991; Thaete & Malkinson, 1991). Most often, the cell of origin of a lung 
tumor is determined by immunohistochemical staining with anti-SpC antibodies 
marking the alveolar type II cell lineage and anti-CC10 antibodies that identify cells 
from the Clara cell lineage. There is, however, increasing evidence that tumor cells 
can transdifferentiate or down regulate CC10 expression (Linnoila et al, 2000; 
Wikenheiser & Whitsett, 1997). The staining with these lineage markers might 
therefore not necessarily identify the cell of origin of the tumor. Solid tumors appear 
to originate from alveolar type II cells, but the origin of papillary tumors remains 
unclear (Malkinson, 1991). Papillary adenocarcinomas can express either SpC or 
Clara cell-specific markers (Thaete & Malkinson, 1990). Interestingly, both solid and 
papillary adenocarcinomas developed in CCSP, as well as in SpC Tag transgenic 
mice. This supports an argument in favor of a common multipotent precursor cell 
and/or transdifferentiation (Wikenheiser et al, 1992) for NSCLC. 
In an attempt to get closer to identifying candidate target genes in our mouse models 
generated, doxycycline administration to the transgenic mice (C RAF BXB-DsRed, 
Myc-DsRed and Myc-BXB-DsRed) marked SpC expressing type II cells in a mosaic 
fashion and led to the generation of labeled progeny. Compound transgenic reporter 
mice gave rise to lung tumors with cuboidal, papillary and mixed cuboidal-papillary 
tumor cells. Expression of DsRed in these tumors functioned as a readout for SpC 
expression. Immunohistochemical analysis of the tumor cells for the expression of 
cell type-specific and lineage marker revealed prominent results. Consistent with the 
DsRed expression in all the tumor types, SpC expression was also detected in 
cuboidal as well as in columnar cell tumors. Next, we examined expression of TTF-
1, a homeodomain transcription factor known to be involved in lung development 
and in SpC expression. TTF-1 nuclear staining was also detectable in the columnar 
cells of papillary tumors. Although type II cells appear the predominant cancer-
initiating population in NSCLC, our data also support the presence of a SpC positive 
progenitor cell population that can give rise to NSCLC following overexpression of c 
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Myc and C RAF switch albeit with a lower penetrance; as evidenced by the fact that 
we detected a fraction of tumor cells always positive for DsRed. This observation 
implies that there might be a population of SpC positive cells that, upon gain of C 
RAF activation and c Myc amplification, acquire the capacity to give rise to NSCLC. 
 
Another cell type that immediately comes to mind is the Bronchio-alveolar stem cell 
(BASC). BASCs have been proposed to be the cell of origin of K-ras-induced 
NSCLC (Kim et al, 2005). This rare cell type located at the Bronchio-alveolar duct 
junction (BADJ) expresses both CCSP and SpC, and thus would be targeted by our 
SpCrtTA/Tet O Cre system. 
The double immunofluorescence experiments in the current study clearly 
demonstrate the existence of SpC/CCSP double-positive cells within the tumors. 
These findings shed new light lead us to propose the existence of a pathway in the 
development of adenomas in which tumors arise from a cell type with characteristics 
of both Clara cells and type II cells. There are two possible models to describe this 
pathway. In the first model, oncogene activation induces hyperproliferation of Clara 
cells, which then undergo transdifferentiation as they move into the alveolar 
compartment. An alternative model is that may be these intermediate cells are the 
consequence of K-ras activation in a stem cell that has the potential to develop into 
either Clara cells or alveolar type II cells. Hyperplasia of such a cell type could give 
rise to adenomas in later time points. It is more likely that other cell types that 
express CCSP have the capacity to give rise to NSCLC. In this respect, it is 
noteworthy that a fraction of the NSCLC tumors also expresses CCSP, suggesting 
that CCSP is expressed in the lineage of the cell of origin of NSCLC. This indicates 
to the existence of an early progenitor that expresses low levels of CCSP and has 
the capacity to differentiate along the alveolar lineage. This could be a common 
progenitor residing in the lung or a committed progenitor that trans-differentiates 
under pressure of the concomitant expression of c Myc. In support of this 
hypothesis, it is interesting to note that there is evidence for a multipotent progenitor 
cell in the immature and developing lung (Rawlins et al, 2009a; Wuenschell et al, 
1996). One can also not underestimate the influence specific genetic mutations may 
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have on the target cell.  c Myc  is a critical controller of cell differentiation and is a 
reprogramming factor and induces a lineage switch in the cell fate determination 
process. Its overexpression loss could be a mechanism by which a progenitor-like 
AT2 cell could differentiate toward a more Neuro-epithelial and bronchiolar cell-like 
state. (Fig.20). A primary tumor‘s metastatic propensity may be dictated in large 
measure by transforming oncogenes that are active early in tumorigenesis (and 
regulate the expression of prognostic signatures) rather than solely by metastasis 
enabling mutations per se, which supposedly arise in rare metastatic precursors 
later in tumor progression (Ramaswamy et al, 2003). Most transforming oncogenes 
ultimately drive Myc expression either directly or indirectly thus assuring that de-
regulation of the Myc pathway is one of the most common features of human 
tumorigenesis. The Myc oncoprotein confers a selective advantage on cancer cells 
in differing contexts by promoting proliferation, cell survival, differentiation blockade, 
epithelial to mesenchymal transition and genetic instability, all of which can 
contribute to metastasis indirectly. (Grandori et al, 2000). Myc is also a powerful 
reprogramming factor that can determine normal and cancer cell differentiation 
(Takahashi & Yamanaka, 2006). Cancer cells in an undifferentiated, more stem-like 
state might more easily migrate to and seed distant sites therefore promoting 
metastasis. 
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Fig 25 (A) The proposed model which demonstrate the existence of a common 
multipotent progenitor cell exhibiting the phenotype that expresses both SpC and 
CCSP and finally differentiates into Clara cells and type II cells during the 
development of the pulmonary epithelium. In the case of tumorigenesis with the 
introduction of c Myc in particular, interferes with the normal cell fate determination 
process and reprograms the progenitor cell  contained in the neoplasias to aquire a 
columnar phenotype,yet producing SPC (Fig 25 B) 
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It should be noted that it is unlikely that every SpC positive cell has the 
capacity to develop a tumor with alveolar features following the 
overexpression of c Myc and C RAF. Instead, the susceptibility of a subset of 
SpC positive cells to tumor development might be a consequence of intrinsic 
capabilities inherent to progenitor cells.  
6.3 Contribution of alveolar type II cells in the metastases; 
an insight 
Although SpC positive type II cells were abundantly found in the lung tumors 
generated from the inducible expression of oncogenic  C RAF and 
consititutive expression of c Myc; it was  unknown whether these cells 
represent a specialzed population in the metastasis and at what stages of 
metastatic progression, one can detect type II cells in them. We asked 
whether DsRed positive progeny of the type II cells, persisted in the 
metastases. After 17 months of induction, macrometastasis in the liver was 
observed comprising of multiple tumor nodules visualized by the naked eyes 
(Fig 24.1). Although DsRed protein was readily detected in the liver 
metastases (Fig 24.2) we wanted to explore its localization and distribution 
pattern in the metastases via further experimental approach. 
On histopathological examination of the liver metastases, three predominant 
subtypes were observed; cystic, mixed cystic papillary and papillary forms 
(Fig 24.2). Commonly all the three forms coexist in the same target organ. 
Whether these forms can interconvert or whether cysts are early precursor 
forms of mixed cystic-papillary metastasis was so far unknown. 
Micrometastatic clusters of DsRed positive cells attached to each other were 
also observed (Fig 24.4, initial seedings) demonstrating that single emboli 
could have invaded from the primary tumor site and reached the liver as a 
cluster. The presence of DsRed positive cluster of cells in the cystic 
metastasis suggests that these have been originated from the SpC producing 
type II cells. This shows that the resulting metastases were clonal at this 
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stage of cystic appearance which suggests that these cystic metastases 
might have resulted from the proliferation of a single viable DsRed positive 
cell (type II) within a circulating tumor embolus which is likely to be 
homogenous for DsRed expression, because it might have been originated 
from a clonal zone of a DsRed positive primary neoplasm. However the fact 
that we found many purely cystic liver metastases which shows DsRed 
positive cells in the lining epithelium (Fig 24.4) argues that cysts may be a 
transitional state to development of frank malignancy. Hence with our lineage 
tracing results in metastases, we propose that cysts are the precursors of 
advanced liver metastases. 
Of the metastatic lesions observed, only cystic lesions uniformly expressed 
DsRed in all the cells comprising the lesions and small clusters indicative of 
type II cells origin. Papillary lesions displayed heterogenous distribution of 
DsRed among the cells, which states the fact that cell types of other lineage 
have participated in the tumor formation that might include endothelial cells, 
macrophages, stromal cells and other cells types of the lung.  These lesions 
express SpC and TTF-1, characteristics of early progenitor markers. GATA4 
transcription factor is also expressed and its direct target gene mucin as 
evident by the Alcian blue positive cells in the metastatic lesions.The 
expression of these early progenitor markers within the metastases strongly 
supports the existence of cells; characteristics of early cancer precursors.  
The presence of up to 5 to 10 cells in clusters of DsRed positive cells in some 
regions within the liver indicates that the originally labeled cells are going 
through multiple rounds of duplication and self-renewal. Moreover we noticed 
that few SpC cells emerge late at a stage in a cystic lesion and advanced in 
the mixed cystic papillary metastases; whereas DsRed positive cells were 
fully prevalent right from the single cell seedings to the small clusters and 
cystic metastases (Fig 24.4). However, in the papillary metastasis, 
heterogeneity in the DsRed expression has been observed (Fig 24.4). 
Analysis of metastases for the expression the Clara cell marker CCSP 
revealed that the small clusters and cystic metastases which were all found to 
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be positive for the lineage label DsRed; were negative for the CCSP 
expression. Few Clara cells appeared only in the mixed cystic papillary 
metastases and subsequently their number increased in the papillary 
metastases. This shows that the occurance of bronchiolar lineage in the liver 
metastases is not an early event and Clara cells populate the metastases, 
once a full-fledged metastatic colonization has been established. 
        
 
Fig 26 Lineage tracing of metastasis reveals the contribution of lineage tagged 
DsRed positive alveolar type II cells. type II cells of the lung were labeled with DsRed 
which are expressed in the pleomorphic clusters of the premalignant lesions (2) 
which are in a constant state of proliferation and dying, unless hitted by a mutation (K 
Ras or loss of LKB 1B) which with c Myc as a driver forms a primary tumor in the 
lung expressing DsRed (3). Upon long term sustainance of the oncogene, finally 
results in metastasis in the liver (4) and displays differential expression of the early 
progenitor and lineage markers (5 and 6) and finally culminating to a papillary 
metastases with the lesions exactly resembling the primary tumor (7). Red stars = 
DsRed positive type II cells. 
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The fact that liver metastasis and primary tumours share markers of alveolar 
lineage, DsRed, and others which include, TTF-1 and Aquaporin 5, suggests 
that aggressive malignant cell progenies are derived from a parental primary 
tumour.This is in accordance with the fact that metastatic and primary 
tumours share somatic mutations. In view of this the assumption that primary 
and metastatic tumours have common ancestory is inherent in the design of 
systemic treatment strategies for advanced cancers. Important examples 
include HER2 amplification in breast cancers and their subsequent lymph 
node or distant organ metastasis (Strien et al, 2010). Hence our findings that 
has been focused on characterizing the cell type(s) contributing to metastasis 
demonstrate that alveolar type II cells are one among the other unknown cell 
types, which harbours the potential in context to metastatic colonization, since 
we have identified single DsRed positive cells streaming in the liver, and 
abundant and strong DsRed expression in several small clusters including the 
cystic metastases. 
6.4 Putative metastatic initiating cells; contribution of 
the alveolar lineage  
With our lineage tracing approach we were able to show that the oral 
administration of doxycycline induces the expression of Cre that rapidly 
mediates excision of the transcriptional roadblock by catalyzing recombination 
across the flanking LoxP sites. The DsRed reporter gene is thereby activated 
in the SPC producing type II cells and subsequently transmitted to their 
progeny as they repopulate the tissue during normal homoestasis (in non 
neoplastic, DsRed animals) and in tumor formation. Because the DsRed 
labeled, SPC positive type II cells are progenitors of the alveolar epithelium, 
they would continuously generate DsRed progeny, which contributes to tissue 
renewal over the entire lifetime of the mouse and would also exhibit its 
expression in the very late stages of abnormamities as in the case of 
metastasis formation. However it is not possible to rule out the existence of 
undifferentiated progenitor compartment existing and such a pool does 
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contribute to the metastasis at late stages once the tumor cell has been 
recruited at a foreign site. 
In view of this our data support the existence of three progenitor cell pool in 
pulmonary epithelium of the lung which acts as a putative metastatic initiating 
cell. First is an actively proliferating stem cell compartment responsible for the 
daily maintenance of the alveolar and the bronchiolar epithelium that is 
characterized by the expression of SpC and CCSP; preferably termed as 
BASCs. (Fig 27 A) 
In accordance with this, it would be highly justifiable to rely on the notion that 
the cancer stem cells may be the source of metastasis based on the 
assumption that these cells are rare, resistant to therapy and therefore 
responsible for cancer recurrences (Reya et al, 2001). It is also presumed 
that the capacity to self-renew is required not only during primary 
tumorigenesis but also for the re-initiation of growth by disseminated cancer 
cells. In line of these assumptions, we were able detect few BASCs in the 
primary tumor as well as in the papillary metastasis. Second is the SPC 
expressing cuboidal type II cells that later aquire a columnar phenotype (Fig 
27 B). Once the cells attain a bronchiolar like columnar structure, it starts 
producing CCSP, to sustain it throughout. The negative expression of CCSP 
in the columnar tumor cells that are still positive for SpC (Fig 25 B) proves this 
hypothesis that tumor cell acquires a more aggressive phenotype, (the 
columnar cells which forms a major cell mass of the papillary tumors in 
advanced cancers) during later stages of malignancy. Third is the SpC 
expressing columnar type II cells that later aquire a cuboidal phenotype and 
gain some neuroendocrine feature (Fig 27C). 
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Fig 27 Proposed identity of the cell types responsible for metastasis in the NSCLC 
model.  
 
Nevertheless, metastases formed from a primary tumor most probably as the 
result of a complex interplay of several factors: the initial transforming 
mutation and additional mutations in subpopulations of the primary tumor, the 
genetic background of the organism and the cell type from which the tumor 
develops and the response of the host to the tumor in terms of innate tumor 
immunity and inflammation as well as the constitution of the stroma.The 
crucial point is that in most cases none of these factors alone is sufficient to 
determine whether a metastasis actually forms or not. 
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7 Critical parameters, troubleshooting and time 
considerations 
 In the compound transgenic reporter lungs, (Myc-BXB-DsRed, C RAF BXB-DsRed 
and Myc-DsRed) there are certain region in the primary tumors where the 
expression of Cre is silenced (i.e. there occurred a silence of the knock-in allele in a 
region-dependent fashion). Hence there prevails a population of cells that are Cre 
escapers. Even the transgenes are not 100 % activated in all the type II cells. Such 
variegated expression of transgenes is commonly observed in the lungs derived 
from the compound reporter mice. 
The Myc-BXB-DsRed, C RAF BXB-DsRed and Myc-DsRed mice are only viable as 
heterozygotes. Apart from that, DsRed bred to homozygosity leads to the death of 
the littermates (prenatal as well as post natal). In vivo lineage tracing is therefore 
always performed with DsRed-het mice. Nevertheless, in principle, in vivo lineage 
tracing can be performed using SpCrtTA/Tet O Cre/Tet O C RAF BXB/SpCc 
Myc/DsRed    mice in combination with any inducible reporter mouse strain that is 
activated using standard Cre/loxP technology. 
The dose of doxycycline used to induce adult transgenic reporter mice (500 mg/kg 
body weight via DOX food) is shown to achieve stochastic activation of the 
DsRed/Lac Z reporter gene within the SPC positive population of the lung. Higher 
doses of doxycycline may be used to increase the frequency of lineage tracing if 
desired (But not tested in the current study). 
Advantage of labeling  
Given that the SPC positive cells belong to a progenitor cell compartment, the 
frequency of DsRed positive alveolar epithelial type II units present will remain 
constant even after the alveolar epithelium has undergone multiple rounds of 
complete renewal. Thus, we expect to see multiple tracing units even 24 months 
after induction. (As in the case of metastases development which takes approx. 
more than 12 months) 
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Time considerations and Animal numbers  
Generation of Triple, Quadra and Penta Transgenic mice via multiple rounds of inter 
breeding takes more than a year to get statistically justifiable number of animals for 
the experiments. Induction of the transgenic reporter mice for tumor development 
takes 9 to 13 months and metastasis being a late event is usually observed between 
15 to 24 months. Hence the current project with animal generation and their analysis 
takes more than 3 years to conclude something reproducible about the outcome of 
the present study. 
 
Due to shifting of the complete animal facility twice in two different years (from MSZ, 
Wurzburg) to Charles River laboratories and from Charles River labs to Max-Planck-
Institut für Herz- und Lungenforschung, Bad Nauheim; it was very difficult to control 
the number of animals available to me for carrying out the experiments, in a 
statistically justifiable number at regular time points. Hence the data presented are 
the reprersentative analysis and findings that I observed in a small group of animals 
analyzed during this time period. Additionally, a severe contamination/infection in the 
Animal Facility (year 2011) prohibited us to get access to more number of animals 
(cessation of breeding and harvesting) to reproduce the results including large 
number of animals that was initially generated for the project.  
 
Here I describe the number of animals that were incorporated for studies that 
represent the results section. 
Total compound transgenic reporter animals generated for the project includes 49 
Quadra Myc-DsRed mice (20 dead), 62 Quadra C RAF-DsRed (15 dead) and 11 
Penta Myc-BXB-DsRed (1 dead). 
 Induction of the transgenic animals lead us to the following number of animals that 
were ready to be analysed after they reached the required age for being harvested. 
29 Myc-DsRed, 47 C RAF-DsRed and 10 Myc-BXB-DsRed animals. 15 animals 
were analysed from the two groups i.e. Myc-DsRed and C RAF-DsRed that reached 
the age of ≥ 12 months and between 9 to 12 months, respectively. 2 animals 
developed tumors in Myc-DsRed mice (13%), 5 animals developed tumors in C 
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RAF-DsRed (33%) and 2 animals developed tumors and 1 of them developed macro 
liver metastasis in Myc-BXB-DsRed mice from 10 animals. 
The results described are the representative data from the tumor bearing animals as 
well as the lungs of the transgenic compound reporter mice; that were processed for 
experimental procedures.   
    
1. Section 5.1.3: representative data from a group of 5 animals. 
2. Section 5.1.4: representative data from a group of 3 tumor bearing animals. 
analyzed, whereas, fig 12.4 and fig 12.5 are the results from 10 animals.  
3. Section 5.1.5 which includes, fig 13.1 and fig 13.2 are the representative for 2 
animals. 
4. Section 5.1.6: representative data from 5 animals (fig 13.3). 
5. Section 5.1.7: representative data from 2 animals. 
6. Section 5.1.8: representative data from 2 animals. 
7. Section 5.1.9: representative data from 10 animals. 
8. Section 5.10: representative data from 5 animals. 
9. Section 5.1.11: representative data from 2 animals per genotype.   
10. Section 5.1.12: representative data from 3 animals. 
11. Section 5.1.13 representative data from 2 animals. 
12. Section 5.1.14: representative data from 2 animals. 
13. Section 5.1.15: representative data from 3 animals. 
14. Section 5.1.16: representative data from 1 tumor bearing animal (repeated 
thrice to confirm the results). 
15. Section 5.2: Data shown from one animal that was detected for metastases 
development. 
 
Nevertheless, the purpose for lineage tracing has been depicted well. Although it 
would have been much easier and more informative if we could have analyzed all 
the animals, which was somehow not feasible due to animal deaths occurring during 
the time period and unexpected delays in experiments caused from certain factors 
which includes, animals transport from different animal facilities, and inability to 
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monitor the animals regularly and frequently for analysis. It is plausible that if the 
transgenic animals were analysed at a later time point including more mice, we 
would have been readily detected more metastases and tumors. Still the observation 
that we made would have not been changed in terms of the data reflecting the 
lineage tracing strategy that worked well. We were able to mark the primary tumors 
(cells) with DsRed and were successful in monitoring the different stages of 
metatstasis in context to DsRed and SpC expression which has broadened our 
knowledge regarding the cystic liver lesions. This is the first report which tends to 
declare that hepatic cysts occurring in the NSCLC metastatic animals (readily 
detected at earlier time points by the previous investigators of Rapp‘s lab) are not 
simply any pathological liver condition, but are indeed a metastasis. However future 
work needs to be done in this area which will help us in finding the identity of the cell 
type solely responsible for metastasis/metatstatic potential.  
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8 Appendix  
Abbreviations 
Abbreviation Full name 
APS Ammoniumpersulfate 
ATP Adenosine-5‘-triphosphate 
BCP 1-Bromo-3-Chloropropane (C3H6BrCl) 
BASCs Bronchioalveolar stem cells 
BADJ Bronchioalveolar duct junction 
BSA Bovine Serum Albumin 
°C Degree Celsius 
CCSP Clara cell secretory protein 
cDNA Complementary DNA 
CMV Cytomegalovirus 
CO2 Carbon dioxide 
DPCs Double positive cells 
DAPI 4‘,6-Diamidino-2-phenylindol 
DMEM Dulbecco‘s Modified Eagle Medium 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
DOX Doxycycline 
dNTP (Di)Desoxynucleotide triphosphate 
DOX Doxycycline 
ECL Enhanced Chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
et al. Et alii 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
Fig Figure 
Floxed Flanked by loxP site 
g Gram 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFP Green Flourescent Protein 
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HCl Hydrochloric acid 
H&E Hematoxylin/eosin staining 
hm Hyper methylation 
HPRT 
Hypoxanthine guanine phosphoribosyl 
transferase 
Kb Kilo basepair 
het heterozygotes 
kDa Kilo dalton 
ko Knock-out 
L Liter 
LOH Loss of heterozygosity 
M Month 
mA Milliampere 
mg Milligram 
min Minutes 
mM Millimolar 
ml Millilitre 
NaOH Sodium hydroxide 
NEBs Neuro-epithelial bodies 
NP40 
Nonidet P-40  
(octyl phenoxypolyethoxylethanol) 
NSCLC Non-Small-Cell Lung Cancer 
N  Normal 
OCT Optimal cutting temperature 
OD Optical density 
PAGE Polyacrylamide Gel Electrophoresis 
PCR Polymerase Chain Reaction 
PBS Phosphate Buffered Saline 
PFA Paraformaldehyde 
rpm Rounds per minute 
RT Room temperature 
RTK  Receptor tyrosine kinase 
RT-PCR Reverse transcriptase polymerase chain reaction 
RFP Red Flourescent Protein 
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rtTA Reverse tetracycline transactivator 
SCLC Small-Cell Lung Cancer 
sq.m Square meter 
SDS Sodium dodecylsulfate 
SP-C Surfactant Protein C 
sq.m Square meter 
TAE Tris-Acetate-EDTA 
TEMED N,N,N‘,N‘-Tetramethylethylenediamine 
tet tetracycline-regulated 
Tet-O tetracycline operator 
Tris Tris(hydroxymethyl)aminomethane 
TRE  Tetracycline responsive elements 
TRITC Tetramethylrhodamine isothiocyanate 
TTF-1/Nkx2.1 Thyroid transcription factor 1 
V Volt 
wt Wild type 
µg Microgram 
µl Microlitre 
% Percentage 
+ve positive 
-ve  negative 
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